D-ribose - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	D-ribose	go back to main search page
Accession:	CHEBI:16988	browse the term
Definition:	A ribose in which the chiral carbon atom furthest away from the aldehyde group (C4') has the same configuration as in D-glyceraldehyde.
Synonyms:	exact_synonym:	D-ribo-pentose
	related_synonym:	D-Rib; Formula=C5H10O5
	alt_id:	CHEBI:13011; CHEBI:21078
	xref:	DrugBank:DB01936; PMID:24404872; PMID:24752650
	cyclic_relationship:	is_enantiomer_of CHEBI:46997

show annotations for term's descendants Sort by:
Rat (772 ) Mouse (774 ) Human (802 ) Chinchilla (0 ) Bonobo (0 ) Dog (0 ) Squirrel (0 ) Pig (5 ) Green Monkey (0) Naked Mole-rat (0 ) All
Genes (772)

2'-deoxyguanosine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

caspase 3

multiple interactions

ISO

[9-deaza-9-(3-thienylmethyl)guanine co-treated with Deoxyguanosine] results in increased activity of CASP3 protein; Deoxycytidine inhibits the reaction [[9-deaza-9-(3-thienylmethyl)guanine co-treated with Deoxyguanosine] results in increased activity of CASP3 protein]

PMID:9297556 PMID:9403342

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

ISO

CYP1A1 protein promotes the reaction [Aflatoxin B1 binds to Deoxyguanosine]

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

ISO

CYP1A2 protein promotes the reaction [Aflatoxin B1 binds to Deoxyguanosine]; CYP1A2 protein promotes the reaction [Estrone binds to Deoxyguanosine]

NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149

G

cytochrome P450, family 1, subfamily b, polypeptide 1

multiple interactions

ISO

CYP1B1 protein promotes the reaction [Aflatoxin B1 binds to Deoxyguanosine]

NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions

ISO

CYP3A4 protein promotes the reaction [Aflatoxin B1 binds to Deoxyguanosine]; CYP3A4 protein promotes the reaction [Estrone binds to Deoxyguanosine]

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

O-6-methylguanine-DNA methyltransferase

decreases activity

ISO

Deoxyguanosine analog results in decreased activity of MGMT protein

NCBI chr 1:201,140,832...201,367,481
Ensembl chr 1:201,140,661...201,367,482

2-deoxy-alpha-D-ribose 1-phosphate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

thymidine phosphorylase

increases abundance

ISO

TYMP protein results in increased abundance of 2-deoxyribose 1-phosphate

NCBI chr 7:122,318,396...122,323,716
Ensembl chr 7:122,316,520...122,324,003

2-deoxy-D-ribofuranose 1-phosphate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

thymidine phosphorylase

increases abundance

ISO

TYMP protein results in increased abundance of 2-deoxyribose 1-phosphate

NCBI chr 7:122,318,396...122,323,716
Ensembl chr 7:122,316,520...122,324,003

3'-phospho-5'-adenylyl sulfate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

multiple interactions

ISO

[NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of diosbulbin B] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A analog] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]

NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581

G

N-acetyltransferase 2

multiple interactions

ISO

[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[SULT1A2 protein co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]

NCBI chr16:26,974,874...27,005,191
Ensembl chr16:26,974,601...26,976,304

G

NAD(P)H quinone dehydrogenase 1

multiple interactions

ISO

[NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone

NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260

G

purinergic receptor P2Y1

decreases activity

ISO

Phosphoadenosine Phosphosulfate results in decreased activity of P2RY1 protein

NCBI chr 2:147,391,661...147,397,870
Ensembl chr 2:147,390,681...147,398,027

G

sulfotransferase family 1A member 1

multiple interactions
increases sulfation

ISO

2,2',3,4,4',5',6-heptabromodiphenyl ether inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; 2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; [NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; Halogenated Diphenyl Ethers analog inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; pentabrominated diphenyl ether 100 inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; Pentachlorophenol inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; tetrabromobisphenol A inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; tribromodiphenyl ether 28 inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]
SULT1A1 protein results in increased sulfation of Phosphoadenosine Phosphosulfate

PMID:11425650 PMID:16601080 PMID:20545351

NCBI chr 1:190,702,592...190,706,112
Ensembl chr 1:190,702,592...190,706,131

G

sulfotransferase family 2A member 1

multiple interactions

ISO

[Phosphoadenosine Phosphosulfate co-treated with SULT2A1 protein] affects the sulfation of Ethinyl Estradiol; Celecoxib affects the reaction [[Phosphoadenosine Phosphosulfate co-treated with SULT2A1 protein] affects the sulfation of Ethinyl Estradiol]; SULT2A1 protein affects the metabolism of [Phosphoadenosine Phosphosulfate co-treated with Ethinyl Estradiol]

NCBI chr 1:84,582,011...84,639,001

3-iodobenzyl-5'-N-methylcarboxamidoadenosine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adenosine A3 receptor

multiple interactions

EXP
ISO

2,3-diethyl-4,5-dipropyl-6-phenylpyridine-3-thiocarboxylate-5-carboxylate inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA3 mRNA]]; 2,3-diethyl-4,5-dipropyl-6-phenylpyridine-3-thiocarboxylate-5-carboxylate inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA3 protein]]; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine binds to and results in increased activity of ADORA3 protein; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA3 mRNA]; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA3 protein]
[N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine binds to and results in increased activity of ADORA3 protein] which results in decreased susceptibility to Dizocilpine Maleate; [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine binds to and results in increased activity of ADORA3 protein] which results in decreased susceptibility to Scopolamine; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine binds to and results in increased activity of ADORA3 protein

PMID:12672554 PMID:15452191 PMID:19966059

NCBI chr 2:196,077,042...196,080,686
Ensembl chr 2:196,077,042...196,080,686

G

AKT serine/threonine kinase 1

multiple interactions

ISO

Pertussis Toxin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in increased phosphorylation of AKT1 protein]; wortmannin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in increased phosphorylation of AKT1 protein]

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

baculoviral IAP repeat-containing 3

decreases expression
decreases response to substance

ISO

N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of BIRC3 mRNA
BIRC3 protein results in decreased susceptibility to N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine

NCBI chr 8:13,285,702...13,313,329
Ensembl chr 8:13,285,703...13,298,590

G

baculoviral IAP repeat-containing 5

decreases response to substance

ISO

BIRC5 protein results in decreased susceptibility to N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine

NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,572,080...103,582,155

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

EXP

N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of FOS mRNA]

NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598

G

interleukin 12A

multiple interactions

ISO

N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]; Pertussis Toxin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]]; wortmannin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]]

NCBI chr 2:155,275,734...155,282,997
Ensembl chr 2:155,275,625...155,282,997

G

interleukin 12B

multiple interactions

ISO

N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]; Pertussis Toxin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]]; Wortmannin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]]

NCBI chr10:29,390,300...29,405,194
Ensembl chr10:29,389,905...29,405,194

G

NLR family, apoptosis inhibitory protein 6

decreases response to substance
decreases expression

ISO

NAIP protein results in decreased susceptibility to N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine
N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of NAIP mRNA

NCBI chr 2:33,241,520...33,293,184
Ensembl chr 2:33,241,521...33,276,859

G

natriuretic peptide A

multiple interactions

EXP

2,3-diethyl-4,5-dipropyl-6-phenylpyridine-3-thiocarboxylate-5-carboxylate inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]]; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]

PMID:15452191 PMID:19966059

NCBI chr 5:163,712,184...163,713,493
Ensembl chr 5:163,712,184...163,713,493

G

regulator of G-protein signaling 2

multiple interactions

EXP

N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of RGS2 mRNA]

NCBI chr13:58,350,063...58,352,666
Ensembl chr13:58,349,163...58,352,697

G

solute carrier family 9 member A1

multiple interactions

EXP

N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of SLC9A1 protein]

NCBI chr 5:150,859,412...150,913,525
Ensembl chr 5:150,860,228...150,913,517

5'-S-methyl-5'-thioadenosine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

actin alpha 2, smooth muscle

decreases expression

ISO

5'-S-methyl-5'-thioadenosine decreases expression of Acta2 mRNA in Mdr2-/- mouse liver and liver myofibroblasts

RGD

NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503

G

adenosine A2B receptor

multiple interactions

ISO

5'-S-methyl-5'-thioadenosine enhances the reaction [lipopolysaccharide increases expression of Adora2b mRNA in mouse liver myofibroblasts]

RGD

NCBI chr10:47,439,712...47,456,092
Ensembl chr10:47,439,701...47,456,091

G

AKT serine/threonine kinase 1

decreases phosphorylation
multiple interactions

ISO

5'-methylthioadenosine results in decreased phosphorylation of AKT1 protein
IL7 protein inhibits the reaction [5'-methylthioadenosine results in decreased phosphorylation of AKT1 protein]

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

C-C motif chemokine ligand 2

decreases expression

ISO

5'-S-methyl-5'-thioadenosine decreases expression of Ccl2 mRNA in Mdr2-/- mouse liver and myofibroblasts

RGD

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875

G

cyclin D1

decreases expression

ISO

5'-S-methyl-5'-thioadenosine decreases expression of cyclin-D1 mRNA in Mdr2-/- mouse liver myofibroblasts

RGD

NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810

G

collagen type I alpha 1 chain

decreases expression

ISO

5'-methylthioadenosine results in decreased expression of COL1A1 mRNA
5'-S-methyl-5'-thioadenosine decreases expression of Col1a1 mRNA in Mdr2-/- mouse liver and liver myofibroblasts

CTD
RGD

PMID:15983038 PMID:21209952

NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460

G

collagen type I alpha 2 chain

decreases expression

ISO

5'-methylthioadenosine results in decreased expression of COL1A2 mRNA

NCBI chr 4:33,518,557...33,553,484
Ensembl chr 4:33,518,420...33,553,995

G

isocitrate dehydrogenase (NADP(+)) 2

increases abundance
multiple interactions

ISO

IDH2 protein mutant form results in increased abundance of 5'-methylthioadenosine
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of 5'-methylthioadenosine]

NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:143,439,323...143,467,248

G

interferon gamma

multiple interactions
decreases secretion

ISO

5'-methylthioadenosine inhibits the reaction [fumonisin B1 results in increased expression of IFNG mRNA]
5'-methylthioadenosine results in decreased secretion of IFNG protein

PMID:17080400 PMID:31712395

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216

G

interferon, lambda 1

multiple interactions

ISO

5'-methylthioadenosine inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of IFNL1 mRNA]

NCBI chr 1:92,926,184...92,927,830

G

interleukin 1 beta

multiple interactions

ISO

5'-methylthioadenosine inhibits the reaction [fumonisin B1 results in increased expression of IL1B mRNA]

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 2

multiple interactions
decreases secretion

ISO

5'-methylthioadenosine inhibits the reaction [fumonisin B1 results in increased expression of IL2 mRNA]
5'-methylthioadenosine results in decreased secretion of IL2 protein

PMID:17080400 PMID:31712395

NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:121,932,968...121,937,672

G

interleukin 33

multiple interactions

ISO

5'-methylthioadenosine inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of IL33 mRNA]

NCBI chr 1:237,115,478...237,149,897
Ensembl chr 1:237,115,572...237,150,901

G

interleukin 6

multiple interactions
decreases expression

ISO

5'-methylthioadenosine inhibits the reaction [fumonisin B1 results in increased expression of IL6 mRNA]
5'-S-methyl-5'-thioadenosine decreases expression of Il6 mRNA in Mdr2-/- mouse liver

CTD
RGD

PMID:17080400 PMID:21209952

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

interleukin 7

multiple interactions

ISO

IL7 protein inhibits the reaction [5'-methylthioadenosine results in decreased phosphorylation of AKT1 protein]

NCBI chr 2:96,142,523...96,186,282
Ensembl chr 2:96,142,092...96,187,389

G

JunD proto-oncogene, AP-1 transcription factor subunit

decreases expression

ISO

5'-S-methyl-5'-thioadenosine decreases expression of JunD protein in Mdr2-/- mouse liver myofibroblasts

RGD

NCBI chr16:18,768,093...18,769,771
Ensembl chr16:18,764,985...18,782,148

G

lymphotoxin beta

multiple interactions

ISO

5'-methylthioadenosine inhibits the reaction [fumonisin B1 results in increased expression of LTB mRNA]

NCBI chr20:3,632,209...3,634,054
Ensembl chr20:3,632,210...3,634,054

G

MDM4 regulator of p53

multiple interactions

ISO

5'-methylthioadenosine affects the splicing of and affects the expression of MDM4 mRNA alternative form

NCBI chr13:46,922,236...47,068,241
Ensembl chr13:46,958,298...47,026,372

G

marker of proliferation Ki-67

decreases expression

ISO

5'-S-methyl-5'-thioadenosine decreases expression of Ki-67 protein in Mdr2-/- mouse liver

RGD

NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:199,926,150...199,952,593

G

matrix metallopeptidase 13

decreases expression

ISO

5'-S-methyl-5'-thioadenosine decreases expression of MMP13 mRNA in Mdr2-/- mouse liver

RGD

NCBI chr 8:12,782,829...12,793,108
Ensembl chr 8:12,782,813...12,793,105

G

mechanistic target of rapamycin kinase

decreases phosphorylation

ISO

5'-methylthioadenosine results in decreased phosphorylation of MTOR protein

NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435

G

nitric oxide synthase 2

decreases expression

ISO

5'-S-methyl-5'-thioadenosine decreases expression of iNOS mRNA in Mdr2-/- mouse liver

RGD

NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880

G

ribosomal protein S6

decreases phosphorylation

ISO

5'-methylthioadenosine results in decreased phosphorylation of RPS6 protein

NCBI chr 5:106,417,680...106,420,540
Ensembl chr 5:106,417,680...106,420,566

G

transforming growth factor, beta 1

decreases expression

ISO

5'-S-methyl-5'-thioadenosine decreases expression of Tgfb1 mRNA in Mdr2-/- mouse liver myofibroblasts

RGD

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899

G

transforming growth factor, beta 2

decreases expression

ISO

5'-S-methyl-5'-thioadenosine decreases expression of Tgfb2 mRNA in Mdr2-/- mouse liver and myofibroblasts

RGD

NCBI chr13:100,691,540...100,793,227
Ensembl chr13:100,692,953...100,792,856

G

tenascin C

decreases expression

ISO

5'-S-methyl-5'-thioadenosine decreases expression of tenascin-C mRNA in Mdr2-/- mouse liver

RGD

NCBI chr 5:82,391,340...82,476,197
Ensembl chr 5:82,391,340...82,476,131

G

tumor necrosis factor

multiple interactions

ISO

5'-S-methyl-5'-thioadenosine inhibits the reaction [lipopolysaccharide increases expression of Tnf-alpha mRNA and protein in mouse liver myofibroblasts]

RGD

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

tumor protein p53

increases expression

ISO

5'-methylthioadenosine results in increased expression of TP53 protein

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aggrecan

decreases expression

ISO

Azacitidine results in decreased expression of ACAN mRNA

NCBI chr 1:142,390,951...142,453,779
Ensembl chr 1:142,390,951...142,453,779

G

actin alpha 2, smooth muscle

multiple interactions

ISO

Azacitidine inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]

NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503

G

ADAM metallopeptidase with thrombospondin type 1 motif, 1

decreases expression

ISO

Azacitidine results in decreased expression of ADAMTS1 mRNA

NCBI chr11:38,418,565...38,427,384
Ensembl chr11:38,418,101...38,427,390

G

adrenoceptor beta 1

affects expression

ISO

Azacitidine affects the expression of ADRB1 mRNA

NCBI chr 1:265,777,103...265,780,114
Ensembl chr 1:265,766,079...265,849,237

G

adrenoceptor beta 2

affects expression
multiple interactions

ISO

Azacitidine affects the expression of ADRB2 mRNA
Azacitidine inhibits the reaction [Particulate Matter results in decreased expression of ADRB2 mRNA]

PMID:19002953 PMID:30986742

NCBI chr18:57,912,760...57,914,802
Ensembl chr18:57,911,348...57,914,803

G

alpha-fetoprotein

increases expression

ISO

Azacitidine results in increased expression of AFP mRNA

NCBI chr14:17,857,584...17,875,645
Ensembl chr14:17,857,584...17,875,649

G

angiogenic factor with G patch and FHA domains 1

increases expression

ISO

Azacitidine results in increased expression of AGGF1 mRNA

NCBI chr 2:28,354,073...28,380,794
Ensembl chr 2:28,354,073...28,380,759

G

aryl hydrocarbon receptor

increases expression
multiple interactions

ISO

Azacitidine results in increased expression of AHR mRNA
[Azacitidine co-treated with Butyrates] inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene promotes the reaction [AHR protein binds to CYP1A1 promoter]]]; Azacitidine inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene promotes the reaction [AHR protein binds to CYP1A1 promoter]]]

PMID:12927368 PMID:17682057

NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901

G

adenylate kinase 5

increases expression

ISO

Azacitidine results in increased expression of AK5 mRNA

NCBI chr 2:244,057,240...244,241,372
Ensembl chr 2:244,057,240...244,241,366

G

AKT serine/threonine kinase 1

multiple interactions

ISO

Azacitidine inhibits the reaction [TGFB1 protein results in increased phosphorylation of AKT1 protein]

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

aminolevulinate dehydratase

decreases expression

ISO

Azacitidine results in decreased expression of ALAD mRNA

NCBI chr 5:80,977,562...80,987,901
Ensembl chr 5:80,977,562...80,988,041

G

albumin

decreases expression
increases expression

ISO

Azacitidine results in decreased expression of ALB protein
Azacitidine results in increased expression of ALB mRNA

NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,891,582...17,911,865

G

aldehyde dehydrogenase 3 family, member A1

multiple interactions

ISO

[Azacitidine co-treated with Butyrates] inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene results in increased expression of ALDH3A1 mRNA]]; Azacitidine inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene results in increased expression of ALDH3A1 mRNA]]

NCBI chr10:46,392,464...46,402,151
Ensembl chr10:46,392,411...46,402,151

G

androgen regulated protein

increases expression

ISO

Azacitidine results in increased expression of CST4 mRNA

NCBI chr 3:157,171,739...157,178,262
Ensembl chr 3:157,171,740...157,178,104

G

annexin A1

decreases expression

EXP

Azacitidine results in decreased expression of ANXA1 protein

NCBI chr 1:227,287,713...227,306,739
Ensembl chr 1:227,287,717...227,306,831

G

amyloid beta precursor protein

decreases methylation
multiple interactions

ISO

Azacitidine results in decreased methylation of APP promoter
Azacitidine results in increased expression of and results in increased cleavage of APP protein; Betaine inhibits the reaction [Azacitidine results in decreased methylation of APP promoter]; Betaine inhibits the reaction [Azacitidine results in increased expression of and results in increased cleavage of APP protein]

NCBI chr11:37,506,207...37,724,351
Ensembl chr11:37,506,408...37,722,971

G

aquaporin 5

decreases methylation
increases expression
multiple interactions

ISO

Azacitidine results in decreased methylation of AQP5 promoter
Azacitidine results in increased expression of AQP5 protein
[Azacitidine results in decreased methylation of AQP5 promoter] which results in increased expression of AQP5 mRNA; Azacitidine promotes the reaction [SP1 protein binds to AQP5 promoter]

NCBI chr 7:132,601,528...132,605,060
Ensembl chr 7:132,601,059...132,605,062

G

aquaporin 9

multiple interactions
increases expression

ISO

[Azacitidine results in increased expression of AQP9 mRNA] which results in increased uptake of arsenic trioxide; HNF1A mutant form inhibits the reaction [Azacitidine results in increased expression of AQP9 mRNA]

NCBI chr 8:80,678,027...80,718,273
Ensembl chr 8:80,678,030...80,717,240

G

androgen receptor

multiple interactions
increases expression

ISO

[Azacitidine analog results in increased expression of AR protein] which results in increased susceptibility to bicalutamide; [Azacitidine analog results in increased expression of AR protein] which results in increased susceptibility to Dihydrotestosterone

NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467

G

Rho GTPase activating protein 35

increases expression

ISO

Azacitidine results in increased expression of ARHGAP35 mRNA

NCBI chr 1:86,330,566...86,447,414
Ensembl chr 1:86,330,566...86,447,414

G

Rho/Rac guanine nucleotide exchange factor 2

decreases expression

ISO

Azacitidine results in decreased expression of ARHGEF2 mRNA

NCBI chr 2:176,358,909...176,416,178
Ensembl chr 2:176,358,904...176,417,646

G

ADP-ribosyltransferase 1

increases expression

ISO

Azacitidine results in increased expression of ART1 mRNA

NCBI chr 1:165,890,032...165,899,154
Ensembl chr 1:165,890,086...165,899,146

G

ankyrin repeat and SOCS box-containing 2

increases expression

ISO

Azacitidine results in increased expression of ASB2 mRNA

NCBI chr 6:128,239,550...128,275,833
Ensembl chr 6:128,239,552...128,266,321

G

ATPase plasma membrane Ca2+ transporting 1

decreases expression

ISO

Azacitidine results in decreased expression of ATP2B1 mRNA

NCBI chr 7:35,622,267...35,731,904
Ensembl chr 7:35,622,461...35,731,904

G

ATPase H+ transporting V0 subunit C

increases expression

ISO

Azacitidine results in increased expression of ATP6V0C mRNA

NCBI chr10:13,700,764...13,707,147
Ensembl chr10:13,700,764...13,706,245

G

aurora kinase A

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of AURKA mRNA

NCBI chr 3:181,546,742...181,562,890
Ensembl chr 3:181,546,742...181,562,771

G

BCL2-associated agonist of cell death

increases expression
multiple interactions

EXP

Azacitidine results in increased expression of BAD mRNA
[Azacitidine co-treated with entinostat] results in increased expression of BAD mRNA

NCBI chr 1:213,562,719...213,572,034
Ensembl chr 1:213,562,187...213,572,034

G

BCL2-antagonist/killer 1

multiple interactions
increases expression

EXP

[Azacitidine co-treated with entinostat] results in increased expression of BAK1 mRNA
Azacitidine results in increased expression of BAK1 mRNA

NCBI chr20:5,102,334...5,111,615
Ensembl chr20:5,102,335...5,110,974

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases expression

ISO

Bleomycin inhibits the reaction [Azacitidine results in increased expression of BAX mRNA]

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

branched chain amino acid transaminase 1

decreases expression

ISO

Azacitidine results in decreased expression of BCAT1 mRNA

NCBI chr 4:179,695,662...179,777,973
Ensembl chr 4:179,695,662...179,777,288

G

BCL2, apoptosis regulator

multiple interactions
decreases expression

ISO

Bleomycin inhibits the reaction [Azacitidine results in decreased expression of BCL2 mRNA]; Bleomycin inhibits the reaction [Azacitidine results in decreased expression of BCL2 protein]
Azacitidine results in decreased expression of BCL2 mRNA; Azacitidine results in decreased expression of BCL2 protein

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

Bcl2-like 1

multiple interactions
affects expression

ISO

[metacept-1 co-treated with Azacitidine] results in decreased expression of BCL2L1
[Azacitidine affects the expression of IL6R protein] which affects the expression of BCL2L1 protein

PMID:18443271 PMID:19148494

NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907
Ensembl chr 1:161,745,540...161,764,907

G

Bcl2-like 13

increases expression

ISO

Azacitidine results in increased expression of BCL2L13 mRNA

NCBI chr 4:155,728,284...155,785,058
Ensembl chr 4:155,728,284...155,781,158

G

brain-derived neurotrophic factor

increases expression
decreases methylation
multiple interactions

ISO

Azacitidine results in increased expression of BDNF mRNA
Azacitidine results in decreased methylation of BDNF promoter
Tetrodotoxin inhibits the reaction [Azacitidine results in decreased methylation of BDNF promoter]; Tetrodotoxin inhibits the reaction [Azacitidine results in increased expression of BDNF mRNA]

NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:116,619,633...116,670,657

G

bone gamma-carboxyglutamate protein

decreases expression
increases expression

EXP
ISO

Azacitidine results in decreased expression of BGLAP protein
Azacitidine results in increased expression of OCN mRNA

PMID:18037191 PMID:39531065

NCBI chr 2:176,136,341...176,137,318
Ensembl chr 2:176,136,341...176,137,318

G

BICD cargo adaptor 1

decreases expression

ISO

Azacitidine results in decreased expression of BICD1 mRNA

NCBI chr 4:184,208,891...184,362,840
Ensembl chr 4:184,210,363...184,357,391

G

BCL2-interacting killer

multiple interactions
increases expression

EXP

[Azacitidine co-treated with entinostat] results in increased expression of BIK mRNA
Azacitidine results in increased expression of BIK mRNA

NCBI chr 7:116,552,303...116,571,317
Ensembl chr 7:116,552,303...116,571,317

G

bone morphogenetic protein 15

increases expression

ISO

Azacitidine results in increased expression of BMP15 mRNA

NCBI chr X:18,840,943...18,846,006
Ensembl chr X:18,840,829...18,847,438

G

BCL2 interacting protein 3

increases expression

ISO

Azacitidine results in increased expression of BNIP3 mRNA

NCBI chr 1:203,137,778...203,154,962
Ensembl chr 1:203,137,778...203,154,962

G

BCL2 family apoptosis regulator BOK

multiple interactions
increases expression

EXP

[Azacitidine co-treated with entinostat] results in increased expression of BOK mRNA
Azacitidine results in increased expression of BOK mRNA

NCBI chr 9:101,670,729...101,681,834
Ensembl chr 9:101,670,625...101,681,833

G

BUB1 mitotic checkpoint serine/threonine kinase B

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of BUB1B mRNA

NCBI chr 3:126,017,019...126,069,470
Ensembl chr 3:126,017,045...126,069,796

G

similar to human chromosome 6 open reading frame 62

increases expression

ISO

Azacitidine results in increased expression of C6ORF62 mRNA

NCBI chr17:40,684,236...40,695,874
Ensembl chr17:40,684,236...40,704,043

G

complement C3a receptor 1

increases expression

ISO

Azacitidine results in increased expression of C3AR1 mRNA

NCBI chr 4:157,747,419...157,756,609
Ensembl chr 4:157,746,089...157,776,323

G

calcitonin-related polypeptide alpha

decreases methylation

ISO

Azacitidine results in decreased methylation of CALCA promoter

NCBI chr 1:178,312,636...178,317,588
Ensembl chr 1:178,312,638...178,317,529

G

caldesmon 1

increases expression

ISO

Azacitidine results in increased expression of CALD1 mRNA

NCBI chr 4:64,232,906...64,414,085
Ensembl chr 4:64,233,171...64,414,085

G

calcium homeostasis modulator family member 2

increases expression
multiple interactions

ISO

Azacitidine results in increased expression of CALHM2 mRNA
Cisplatin affects the reaction [Azacitidine results in increased expression of CALHM2 mRNA]

NCBI chr 1:255,963,661...255,969,387
Ensembl chr 1:255,963,663...255,969,387

G

caspase 3

affects expression
increases activity
increases expression
multiple interactions

ISO

Azacitidine affects the expression of CASP3 protein
5-azacytidine co-treated with doxorubicin increases activity of CASP3 protein in lung cancer cells
Azacitidine results in increased expression of CASP3 mRNA
[metacept-1 co-treated with Azacitidine] results in increased expression of CASP3

CTD
RGD

PMID:18443271 PMID:19148494 PMID:23395740 PMID:24356455

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caspase 8

increases expression

ISO

Azacitidine results in increased expression of CASP8 mRNA

PMID:18082045 PMID:23395740

NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699

G

caspase 9

increases expression

ISO

Azacitidine results in increased expression of CASP9 mRNA

Ensembl chr 5:159,391,188...159,409,648

G

cyclin A1

multiple interactions
decreases expression

ISO

Azacitidine inhibits the reaction [MECP2 protein binds to CCNA1 promoter]; Azacitidine promotes the reaction [H3-4 protein modified form binds to CCNA1 promoter]; Azacitidine promotes the reaction [H4C16 protein modified form binds to CCNA1 promoter]
Azacitidine results in decreased expression of CCNA1 mRNA

NCBI chr 2:141,383,352...141,428,205
Ensembl chr 2:141,382,468...141,393,300

G

cyclin A2

multiple interactions
decreases expression

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of CCNA2 mRNA
Azacitidine results in decreased expression of CCNA2 mRNA

PMID:18720364 PMID:20823114

NCBI chr 2:121,355,363...121,361,762
Ensembl chr 2:121,355,363...121,361,701

G

cyclin B1

multiple interactions
increases expression

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of CCNB1 mRNA
Azacitidine results in increased expression of CCNB1 protein

PMID:18720364 PMID:20607034

NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:33,646,252...33,655,225

G

cyclin D1

increases expression

ISO

Azacitidine results in increased expression of CCND1 mRNA

NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810

G

cyclin D2

affects methylation
multiple interactions

ISO

Azacitidine affects the methylation of CCND2 promoter
[Azacitidine affects the methylation of CCND2 promoter] which affects the expression of CCND2 mRNA

NCBI chr 4:161,653,048...161,675,422
Ensembl chr 4:161,653,048...161,680,301
Ensembl chr 4:161,653,048...161,680,301

G

cyclin G2

decreases expression

ISO

Azacitidine results in decreased expression of CCNG2 mRNA

NCBI chr14:15,088,694...15,097,190
Ensembl chr14:15,088,695...15,096,206

G

CD274 molecule

multiple interactions

ISO

Azacitidine inhibits the reaction [Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 mRNA]]; Azacitidine inhibits the reaction [Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 protein]]

NCBI chr 1:236,526,215...236,549,956
Ensembl chr 1:236,496,463...236,549,951

G

cell division cycle 20

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of CDC20 mRNA

NCBI chr 5:137,251,596...137,255,799
Ensembl chr 5:137,251,596...137,255,799

G

CDC42 binding protein kinase alpha

decreases expression

ISO

Azacitidine results in decreased expression of CDC42BPA mRNA

NCBI chr13:94,215,359...94,435,681
Ensembl chr13:94,215,959...94,435,681

G

cadherin 1

decreases methylation
increases expression

ISO

Azacitidine results in decreased methylation of CDH1 promoter
Azacitidine results in increased expression of CDH1 mRNA

NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565

G

cadherin 2

increases expression

EXP

Azacitidine results in increased expression of CDH2 mRNA

NCBI chr18:8,051,097...8,265,288
Ensembl chr18:8,051,097...8,265,288

G

cyclin-dependent kinase 1

multiple interactions
increases expression

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of CDK1 mRNA
Azacitidine analog results in increased expression of CDK1 protein

PMID:18324645 PMID:18720364

NCBI chr20:19,265,252...19,280,456
Ensembl chr20:19,265,289...19,280,455

G

cyclin dependent kinase 2

decreases expression

ISO

Azacitidine analog results in decreased expression of CDK2 protein

NCBI chr 7:1,714,392...1,721,964
Ensembl chr 7:1,714,392...1,721,878

G

cyclin-dependent kinase 4

decreases expression

ISO

Azacitidine analog results in decreased expression of CDK4 protein

NCBI chr 7:64,771,453...64,774,891
Ensembl chr 7:64,771,147...64,775,163

G

cyclin-dependent kinase inhibitor 1A

increases expression
multiple interactions

ISO
EXP

Azacitidine analog results in increased expression of CDKN1A protein; Azacitidine results in increased expression of CDKN1A mRNA
[Azacitidine co-treated with entinostat] results in increased expression of CDKN1A mRNA; Azacitidine inhibits the reaction [potassium bromate results in increased expression of CDKN1A protein]
[metacept-1 co-treated with Azacitidine] results in increased expression of CDKN1A

PMID:18324645 PMID:19148494 PMID:20823114 PMID:21224363 PMID:25015661

NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969

G

cyclin-dependent kinase inhibitor 1C

increases expression

ISO

Azacitidine results in increased expression of CDKN1C mRNA

NCBI chr 1:208,084,801...208,087,680
Ensembl chr 1:208,084,787...208,087,498

G

cyclin-dependent kinase inhibitor 2A

multiple interactions
decreases methylation
affects methylation
increases expression

EXP
ISO

[Azacitidine co-treated with entinostat] results in decreased methylation of CDKN2A gene; [Azacitidine co-treated with entinostat] results in increased expression of CDKN2A mRNA
Azacitidine inhibits the reaction [Particulate Matter results in increased methylation of CDKN2A promoter]
Hydroxyurea inhibits the reaction [Azacitidine results in decreased methylation of CDKN2A gene]
Azacitidine affects the methylation of CDKN2A gene
Azacitidine results in increased expression of CDKN2A mRNA

PMID:17686055 PMID:18443271 PMID:21224363 PMID:22355787

NCBI chr 5:109,100,763...109,114,448
Ensembl chr 5:109,100,772...109,119,248

G

cyclin-dependent kinase inhibitor 2B

decreases methylation
multiple interactions
affects response to substance

ISO

Azacitidine results in decreased methylation of CDKN2B promoter
[metacept-1 co-treated with Azacitidine] results in increased expression of CDKN2B
CDKN2B promoter modified form affects the susceptibility to Azacitidine

PMID:17611569 PMID:19148494 PMID:19194470

NCBI chr 5:109,123,308...109,134,906
Ensembl chr 5:109,114,322...109,134,855

G

CCAAT/enhancer binding protein alpha

decreases methylation
increases expression

ISO

Azacitidine results in decreased methylation of CEBPA promoter
Azacitidine results in increased expression of CEBPA mRNA

PMID:19194470 PMID:27590069

NCBI chr 1:96,896,584...96,899,256
Ensembl chr 1:96,896,171...96,899,309

G

centromere protein A

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of CENPA mRNA

NCBI chr 6:31,420,062...31,431,703

G

centromere protein F

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of CENPF mRNA

NCBI chr13:103,715,344...103,760,931
Ensembl chr13:103,715,344...103,760,886

G

centromere protein O

increases expression

ISO

Azacitidine results in increased expression of CENPO mRNA

NCBI chr 6:32,923,127...32,937,879
Ensembl chr 6:32,908,025...32,937,853

G

choline O-acetyltransferase

increases expression

ISO

Azacitidine results in increased expression of CHAT mRNA; Azacitidine results in increased expression of CHAT protein

NCBI chr16:7,663,665...7,723,416
Ensembl chr16:7,663,665...7,723,416

G

chromogranin A

decreases expression

ISO

Azacitidine results in decreased expression of CHGA protein

NCBI chr 6:127,460,895...127,472,238
Ensembl chr 6:127,460,854...127,472,237

G

chitinase 1

increases expression

ISO

Azacitidine results in increased expression of CHIT1 mRNA

NCBI chr13:48,117,886...48,165,645
Ensembl chr13:48,145,893...48,165,639

G

cholinergic receptor, muscarinic 1

affects expression

ISO

Azacitidine affects the expression of CHRM1 mRNA

NCBI chr 1:214,996,180...215,012,136
Ensembl chr 1:214,995,872...215,020,602

G

cholinergic receptor, muscarinic 2

affects expression

ISO

Azacitidine affects the expression of CHRM2 mRNA

NCBI chr 4:65,981,136...66,116,128
Ensembl chr 4:65,981,006...66,126,464

G

carbohydrate sulfotransferase 14

increases expression

EXP

Azacitidine results in increased expression of CHST14 mRNA

NCBI chr 3:126,370,348...126,372,405
Ensembl chr 3:126,370,348...126,372,777

G

class II, major histocompatibility complex, transactivator

multiple interactions
increases expression

ISO

[Azacitidine promotes the reaction [IFNG protein results in increased expression of CIITA mRNA]] which results in increased expression of HLA-DRA protein; [Azacitidine results in decreased methylation of CIITA promoter] promotes the reaction [IFNG protein results in increased expression of CIITA mRNA]
Azacitidine results in increased expression of CIITA mRNA

PMID:18829986 PMID:20823114

NCBI chr10:5,646,854...5,694,393
Ensembl chr10:5,647,085...5,694,342

G

claudin 10

decreases expression

ISO

Azacitidine results in decreased expression of CLDN10 mRNA

NCBI chr15:102,269,858...102,361,589
Ensembl chr15:102,269,858...102,361,589

G

claudin 6

increases expression
decreases methylation
multiple interactions

ISO

Azacitidine results in increased expression of CLDN6 mRNA
Azacitidine results in decreased methylation of CLDN6 promoter
[trichostatin A co-treated with Azacitidine] results in decreased methylation of CLDN6 promoter

NCBI chr10:13,213,837...13,218,578
Ensembl chr10:13,213,956...13,218,581

G

claudin 7

multiple interactions
decreases expression

ISO

Cisplatin affects the reaction [Azacitidine results in decreased expression of CLDN7 mRNA]

NCBI chr10:55,188,670...55,190,871
Ensembl chr10:55,188,684...55,190,905

G

claudin 8

increases expression

ISO

Azacitidine results in increased expression of CLDN8 mRNA

NCBI chr11:41,362,081...41,364,330

G

claudin 9

decreases methylation
multiple interactions
increases expression

ISO

Azacitidine results in decreased methylation of CLDN9 promoter
[trichostatin A co-treated with Azacitidine] results in decreased methylation of CLDN9 promoter
Azacitidine results in increased expression of CLDN9 mRNA

NCBI chr10:13,218,728...13,220,159
Ensembl chr10:13,218,729...13,220,178

G

cyclin and CBS domain divalent metal cation transport mediator 2

decreases expression

ISO

Azacitidine results in decreased expression of CNNM2 mRNA

NCBI chr 1:255,585,063...255,709,455
Ensembl chr 1:255,585,095...255,704,849

G

collagen type XIV alpha 1 chain

increases expression

ISO

Azacitidine results in increased expression of COL14A1 mRNA

NCBI chr 7:88,611,827...88,826,939
Ensembl chr 7:88,611,828...88,826,938

G

collagen type I alpha 1 chain

multiple interactions

ISO

Azacitidine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]; Azacitidine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein]

NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460

G

collagen type VI alpha 3 chain

decreases expression

ISO

Azacitidine results in decreased expression of COL6A3 mRNA

NCBI chr 9:98,809,171...98,887,060
Ensembl chr 9:98,809,171...98,886,990

G

collagen type IX alpha 3 chain

decreases expression

ISO

Azacitidine results in decreased expression of COL9A3 mRNA

NCBI chr 3:188,089,337...188,112,034
Ensembl chr 3:188,089,403...188,112,270

G

cytochrome c oxidase subunit 6A2

increases expression

ISO

Azacitidine results in increased expression of COX6A2 mRNA

NCBI chr 1:192,218,970...192,221,188
Ensembl chr 1:192,218,970...192,219,716

G

carboxypeptidase E

increases expression

ISO

Azacitidine results in increased expression of CPE mRNA

NCBI chr16:29,796,707...29,908,647
Ensembl chr16:29,796,689...29,909,524

G

complexin 1

increases expression

ISO

Azacitidine results in increased expression of CPLX1 mRNA

NCBI chr14:1,329,073...1,360,781
Ensembl chr14:1,329,032...1,360,769

G

cAMP responsive element binding protein 1

multiple interactions

ISO

Azacitidine promotes the reaction [CREB1 protein modified form binds to PPP2CA promoter]

NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:73,397,306...73,466,339

G

cAMP responsive element binding protein 3-like 4

increases expression

EXP

Azacitidine results in increased expression of CREB3L4 mRNA

NCBI chr 2:177,987,981...177,994,568
Ensembl chr 2:177,987,981...177,993,485

G

cAMP responsive element modulator

decreases expression

ISO

Azacitidine results in decreased expression of CREM mRNA

NCBI chr17:58,932,011...59,001,160
Ensembl chr17:58,934,147...59,001,160

G

crystallin, alpha A

increases expression

EXP

Azacitidine results in increased expression of CRYAA protein

NCBI chr20:9,784,872...9,788,656
Ensembl chr20:9,784,857...9,788,654

G

crystallin, alpha B

increases expression

EXP

Azacitidine results in increased expression of CRYAB protein

NCBI chr 8:59,989,885...59,995,532
Ensembl chr 8:59,989,814...59,995,528

G

colony stimulating factor 1

increases expression

EXP

Azacitidine results in increased expression of CSF1 mRNA

NCBI chr 2:198,065,400...198,084,774
Ensembl chr 2:198,065,405...198,084,468

G

casein alpha s1

increases expression

ISO

Azacitidine results in increased expression of CSN1S1 mRNA

NCBI chr14:20,622,858...20,638,849

G

cystatin C

increases expression

ISO

Azacitidine results in increased expression of CST3 mRNA

NCBI chr 3:156,790,061...156,794,116
Ensembl chr 3:156,790,079...156,793,937

G

C-X-C motif chemokine ligand 12

decreases methylation
increases expression

ISO

Azacitidine results in decreased methylation of CXCL12 promoter
Azacitidine results in increased expression of CXCL12 mRNA; Azacitidine results in increased expression of CXCL12 protein

NCBI chr 4:152,060,781...152,073,628
Ensembl chr 4:152,060,780...152,073,627

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
increases expression

ISO

Azacitidine promotes the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; Azacitidine promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]
[Azacitidine co-treated with Butyrates] inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene promotes the reaction [AHR protein binds to CYP1A1 promoter]]]; [Azacitidine co-treated with Butyrates] inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]]; Azacitidine inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene promotes the reaction [AHR protein binds to CYP1A1 promoter]]]; Azacitidine inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]]
Azacitidine results in increased expression of CYP1A1 mRNA

PMID:11281733 PMID:12927368 PMID:17682057 PMID:27590069

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions
increases expression

ISO

Azacitidine promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A2 mRNA]
Azacitidine results in increased expression of CYP1A2 mRNA

NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149

G

cytochrome P450, family 1, subfamily b, polypeptide 1

multiple interactions
increases expression

ISO

Azacitidine promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA]
Azacitidine results in increased expression of CYP1B1 mRNA

PMID:12927368 PMID:27590069

NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases expression

ISO

Azacitidine results in increased expression of CYP3A4 mRNA

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

cytohesin 1

increases expression

ISO

Azacitidine results in increased expression of CYTH1 mRNA

NCBI chr10:103,901,376...103,984,496
Ensembl chr10:103,864,804...103,984,383

G

death associated protein kinase 1

affects methylation

ISO

Azacitidine affects the methylation of DAPK1 promoter

NCBI chr17:3,935,826...4,096,858
Ensembl chr17:3,935,625...4,096,581

G

decorin

multiple interactions
decreases expression

ISO

Azacitidine promotes the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of DCN protein]
Azacitidine results in decreased expression of DCN mRNA

NCBI chr 7:34,167,973...34,208,004
Ensembl chr 7:34,163,011...34,218,926

G

desmin

increases expression
multiple interactions

EXP
ISO

Azacitidine results in increased expression of DES mRNA; Azacitidine results in increased expression of DES protein
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of DES mRNA

PMID:18037191 PMID:20823114

NCBI chr 9:84,299,626...84,307,344
Ensembl chr 9:84,298,447...84,307,347

G

DExH-box helicase 9

decreases expression

ISO

Azacitidine results in decreased expression of DHX9 mRNA

NCBI chr13:68,152,813...68,189,580
Ensembl chr13:68,152,813...68,189,546

G

iodothyronine deiodinase 2

decreases expression

ISO

Azacitidine results in decreased expression of DIO2 mRNA

NCBI chr 6:115,396,308...115,410,594
Ensembl chr 6:115,396,308...115,410,594

G

delta like non-canonical Notch ligand 1

decreases methylation

ISO

Azacitidine results in decreased methylation of DLK1 promoter

NCBI chr 6:134,192,491...134,199,779
Ensembl chr 6:134,192,518...134,200,529

G

distal-less homeobox 5

increases expression

ISO

Azacitidine results in increased expression of DLX5 mRNA

NCBI chr 4:35,965,579...35,969,973
Ensembl chr 4:35,965,579...35,969,845

G

distal-less homeobox 6

increases expression

ISO

Azacitidine results in increased expression of DLX6 mRNA

NCBI chr 4:35,951,005...35,956,354
Ensembl chr 4:35,951,005...35,956,354

G

DNA methyltransferase 1

multiple interactions
decreases expression

ISO
EXP

[SLC28A1 protein results in increased uptake of Azacitidine] which results in decreased expression of DNMT1 protein; Arsenic Trioxide promotes the reaction [Azacitidine results in decreased expression of DNMT1 protein]; Azacitidine inhibits the reaction [DNMT1 protein binds to MIR497 promoter]
Azacitidine results in decreased expression of DNMT1 mRNA
[Azacitidine co-treated with entinostat] results in decreased expression of DNMT1 protein; [Cisplatin co-treated with Azacitidine] results in decreased expression of DNMT1 protein

PMID:19139132 PMID:19723570 PMID:21224363 PMID:28901456 PMID:35066776 More...

NCBI chr 8:27,716,797...27,763,405
Ensembl chr 8:27,716,797...27,763,119

G

DNA methyltransferase 3 alpha

multiple interactions
decreases expression

ISO

Azacitidine inhibits the reaction [DNMT3A protein binds to MIR497 promoter]
Azacitidine results in decreased expression of DNMT3A mRNA

PMID:35066776 PMID:39331569

NCBI chr 6:32,507,316...32,621,678
Ensembl chr 6:32,512,070...32,614,970

G

DNA methyltransferase 3 beta

multiple interactions
decreases expression

ISO

Azacitidine inhibits the reaction [DNMT3B protein binds to MIR497 promoter]
Azacitidine results in decreased expression of DNMT3B mRNA

PMID:35066776 PMID:39331569

NCBI chr 3:162,590,777...162,629,313
Ensembl chr 3:162,604,037...162,629,313

G

dihydropyrimidine dehydrogenase

decreases methylation
multiple interactions
decreases response to substance

ISO

Azacitidine results in decreased methylation of DPYD promoter
[Azacitidine results in decreased methylation of DPYD promoter] which results in increased expression of DPYD mRNA
DPYD protein results in decreased susceptibility to Azacitidine

NCBI chr 2:209,293,902...210,159,777
Ensembl chr 2:209,293,929...210,159,778

G

dual specificity phosphatase 1

increases expression

ISO

Azacitidine results in increased expression of DUSP1 mRNA

NCBI chr10:17,184,853...17,187,646
Ensembl chr10:17,184,823...17,187,644

G

dual specificity phosphatase 6

increases expression

ISO

Azacitidine results in increased expression of DUSP6 mRNA

NCBI chr 7:35,979,502...35,983,834
Ensembl chr 7:35,977,921...35,983,833

G

E2F transcription factor 1

multiple interactions

ISO

E2F1 protein affects the reaction [Azacitidine results in decreased activity of TERT protein]; E2F1 protein affects the reaction [Azacitidine results in decreased expression of TERT mRNA]

NCBI chr 3:163,524,739...163,535,563
Ensembl chr 3:163,524,739...163,535,563

G

eukaryotic translation elongation factor 1 alpha 1

decreases expression

ISO

Azacitidine results in decreased expression of EEF1A1 mRNA

NCBI chr 8:88,221,839...88,225,688
Ensembl chr 8:88,221,843...88,225,072

G

ephrin A3

increases expression

ISO

Azacitidine results in increased expression of EFNA3 mRNA

NCBI chr 2:177,026,928...177,035,838
Ensembl chr 2:177,026,933...177,044,843

G

early growth response 2

increases expression

ISO

Azacitidine results in increased expression of EGR2 mRNA

NCBI chr20:21,050,149...21,055,201
Ensembl chr20:21,050,149...21,057,748

G

enolase 2

decreases expression

ISO

Azacitidine results in decreased expression of ENO2 protein

NCBI chr 4:159,258,371...159,267,220
Ensembl chr 4:159,258,371...159,267,220

G

ectonucleoside triphosphate diphosphohydrolase 1

increases expression

ISO

Azacitidine results in increased expression of ENTPD1 mRNA

NCBI chr 1:249,374,810...249,502,310
Ensembl chr 1:249,374,836...249,502,317

G

estrogen receptor 1

increases expression

ISO

Azacitidine results in increased expression of ESR1 protein

NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354

G

ETS proto-oncogene 1, transcription factor

multiple interactions

ISO

Azacitidine promotes the reaction [ETS1 protein binds to KIR2DL2 promoter]; Azacitidine promotes the reaction [ETS1 protein binds to KIR2DL4 promoter]

NCBI chr 8:39,303,936...39,426,022
Ensembl chr 8:39,303,925...39,426,021

G

EYA transcriptional coactivator and phosphatase 1

decreases expression

ISO

Azacitidine results in decreased expression of EYA1 mRNA

NCBI chr 5:9,646,599...9,884,609
Ensembl chr 5:9,646,591...9,884,614

G

fatty acid desaturase 2

decreases expression

ISO

Azacitidine results in decreased expression of FADS2 mRNA

NCBI chr 1:216,132,277...216,172,190
Ensembl chr 1:216,133,676...216,172,066

G

family with sequence similarity 8, member A1

increases expression

ISO

Azacitidine results in increased expression of FAM8A1 mRNA

NCBI chr17:18,232,834...18,241,736
Ensembl chr17:18,232,834...18,241,703

G

Fas ligand

increases response to substance

ISO

Azacitidine results in increased susceptibility to FASLG protein

NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503

G

fibulin 1

increases expression

ISO

Azacitidine results in increased expression of FBLN1 mRNA

NCBI chr 7:118,190,347...118,269,965
Ensembl chr 7:118,190,478...118,269,965

G

flap structure-specific endonuclease 1

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of FEN1 mRNA

NCBI chr 1:216,270,016...216,274,873
Ensembl chr 1:216,269,163...216,275,016

G

fibroblast growth factor 7

decreases expression

ISO

Azacitidine results in decreased expression of FGF7 mRNA

NCBI chr 3:133,734,557...133,786,678
Ensembl chr 3:133,734,673...133,786,328

G

filamin A interacting protein 1-like

decreases expression

ISO

Azacitidine results in decreased expression of FILIP1L mRNA

NCBI chr11:56,403,467...56,646,422
Ensembl chr11:56,410,582...56,646,402

G

forkhead box O1

multiple interactions

ISO

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of FOXO1 mRNA

NCBI chr 2:138,462,974...138,541,420
Ensembl chr 2:138,462,697...138,541,419

G

forkhead box P3

multiple interactions

ISO

[Azacitidine co-treated with TGFB1 protein] results in increased expression of FOXP3 protein; [Azacitidine results in decreased methylation of FOXP3 gene] which results in increased expression of FOXP3 protein

NCBI chr X:17,580,380...17,601,181
Ensembl chr X:17,580,380...17,595,894

G

ferritin light chain 1

decreases expression

EXP

Azacitidine results in decreased expression of FTL1 protein

NCBI chr 1:105,072,858...105,074,705
Ensembl chr X:45,399,355...45,399,915
Ensembl chr 2:45,399,355...45,399,915
Ensembl chr 1:45,399,355...45,399,915

G

FYN proto-oncogene, Src family tyrosine kinase

increases expression

ISO

Azacitidine results in increased expression of FYN mRNA

NCBI chr20:44,322,635...44,514,498
Ensembl chr20:44,322,361...44,515,479

G

gamma-aminobutyric acid type A receptor subunit beta1

increases expression

ISO

Azacitidine results in increased expression of GABRB1 mRNA

NCBI chr14:36,434,339...36,917,920
Ensembl chr14:36,434,352...36,902,893

G

growth arrest and DNA-damage-inducible, alpha

decreases methylation
multiple interactions
increases expression

ISO

Azacitidine results in decreased methylation of GADD45A promoter
[Azacitidine results in increased expression of GADD45A protein] which results in increased susceptibility to docetaxel
Azacitidine results in increased expression of GADD45A mRNA; Azacitidine results in increased expression of GADD45A protein

NCBI chr 4:97,484,497...97,486,799
Ensembl chr 4:97,484,502...97,486,807

G

growth arrest and DNA-damage-inducible, beta

multiple interactions

ISO

Azacitidine promotes the reaction [Depsipeptides results in increased expression of GADD45B]

NCBI chr 7:9,428,689...9,430,991
Ensembl chr 7:9,428,689...9,430,718

G

GATA binding protein 4

increases expression

EXP

Azacitidine results in increased expression of GATA4 mRNA; Azacitidine results in increased expression of GATA4 protein

NCBI chr15:41,635,572...41,707,252
Ensembl chr15:41,635,572...41,681,609

G

guanylate binding protein 2

decreases expression

ISO

Azacitidine results in decreased expression of GBP2 mRNA

NCBI chr 2:234,005,727...234,021,812
Ensembl chr 2:234,008,590...234,021,810

G

glucosaminyl (N-acetyl) transferase 2

decreases expression

ISO

Azacitidine results in decreased expression of GCNT2 mRNA

NCBI chr17:24,002,592...24,107,339
Ensembl chr17:24,002,597...24,106,989

G

growth differentiation factor 9

increases expression

ISO

Azacitidine results in increased expression of GDF9 mRNA

NCBI chr10:38,090,021...38,100,801
Ensembl chr10:38,089,878...38,100,797

G

gap junction protein, alpha 1

increases expression
decreases expression

EXP
ISO

Azacitidine results in increased expression of GJA1 protein
Azacitidine results in decreased expression of GJA1 mRNA

PMID:18037191 PMID:20823114

NCBI chr20:36,302,490...36,315,010
Ensembl chr20:36,302,352...36,319,689

G

galactosidase, beta 1

increases expression

ISO

Azacitidine results in increased expression of GLB1 protein

NCBI chr 8:122,963,718...123,036,326
Ensembl chr 8:122,963,718...123,036,326

G

G protein subunit gamma 7

affects methylation

ISO

Azacitidine affects the methylation of GNG7 promoter

NCBI chr 7:9,348,148...9,411,924
Ensembl chr 7:9,348,218...9,411,923

G

G patch domain and KOW motifs

increases expression

ISO

Azacitidine results in increased expression of GPKOW mRNA

NCBI chr X:17,463,521...17,478,298
Ensembl chr X:17,463,525...17,478,298

G

glycoprotein nmb

decreases expression

ISO

Azacitidine results in decreased expression of GPNMB mRNA

NCBI chr 4:79,341,128...79,362,366
Ensembl chr 4:79,341,021...79,380,240

G

glutathione peroxidase 3

increases expression

ISO

5-azacytidine increases expression of GPX3 mRNA in epithelial cells of stomach

RGD

NCBI chr10:39,529,335...39,537,406
Ensembl chr10:39,529,448...39,537,405

G

glutamate ionotropic receptor NMDA type subunit 2B

decreases methylation

ISO

Azacitidine results in decreased methylation of GRIN2B gene

NCBI chr 4:170,297,811...170,775,420
Ensembl chr 4:170,322,617...170,773,570

G

guanylate kinase 1

increases expression

ISO

Azacitidine results in increased expression of GUK1 mRNA

NCBI chr10:44,471,075...44,488,332
Ensembl chr10:44,471,085...44,479,355

G

granzyme B

multiple interactions

ISO

Azacitidine inhibits the reaction [IL2 protein results in increased secretion of GZMB protein]

NCBI chr15:34,459,007...34,462,469
Ensembl chr15:34,459,007...34,462,469

G

H1.0 linker histone

increases expression

ISO

Azacitidine results in increased expression of H1-0 protein

NCBI chr 7:112,473,280...112,475,140
Ensembl chr 7:112,473,222...112,475,006

G

H2A.X variant histone

increases expression
multiple interactions

ISO
EXP

Azacitidine results in increased expression of H2AX protein
Azacitidine inhibits the reaction [potassium bromate results in increased phosphorylation of H2AX protein]

PMID:17991895 PMID:25015661

NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079

G

H3.4 histone, cluster member

multiple interactions

ISO

Azacitidine promotes the reaction [H3-4 protein modified form binds to CCNA1 promoter]

NCBI chr10:44,240,282...44,240,842

G

homogentisate 1, 2-dioxygenase

increases expression

ISO

Azacitidine results in increased expression of HGD mRNA

NCBI chr11:76,592,202...76,643,776
Ensembl chr11:76,592,204...76,643,767

G

hepatocyte growth factor

increases expression

ISO

Azacitidine results in increased expression of HGF mRNA

NCBI chr 4:19,628,902...19,700,467
Ensembl chr 4:19,632,267...19,700,851

G

hematopoietically expressed homeobox

increases expression

ISO

Azacitidine results in increased expression of HHEX mRNA

NCBI chr 1:244,602,945...244,608,532
Ensembl chr 1:244,602,825...244,608,604

G

high mobility group AT-hook 1

increases expression

ISO

Azacitidine results in increased expression of HMGA1 mRNA

NCBI chr20:5,612,902...5,620,596
Ensembl chr20:5,613,471...5,620,593

G

high mobility group AT-hook 2

increases expression
multiple interactions

ISO

Azacitidine results in increased expression of HMGA2 mRNA
TP73 protein promotes the reaction [Azacitidine results in increased expression of HMGA2 mRNA]

NCBI chr 7:57,762,710...57,884,555
Ensembl chr 7:57,765,675...57,880,341

G

high mobility group box 1

decreases expression
multiple interactions

ISO

Azacitidine results in decreased expression of HMGB1 mRNA
Azacitidine results in decreased expression of and results in increased secretion of HMGB1 protein; Bleomycin inhibits the reaction [Azacitidine results in decreased expression of and results in increased secretion of HMGB1 protein]; Bleomycin inhibits the reaction [Azacitidine results in decreased expression of HMGB1 mRNA]

NCBI chr12:11,009,236...11,015,941
Ensembl chr16:39,039,050...39,041,327
Ensembl chr12:39,039,050...39,041,327

G

HNF1 homeobox A

decreases methylation
multiple interactions
increases expression

ISO

Azacitidine results in decreased methylation of HNF1A promoter
HNF1A mutant form inhibits the reaction [Azacitidine results in increased expression of AQP9 mRNA]
Azacitidine results in increased expression of HNF1A mRNA; Azacitidine results in increased expression of HNF1A protein

NCBI chr12:47,299,171...47,333,457
Ensembl chr12:47,306,245...47,332,755

G

hepatocyte nuclear factor 4, alpha

increases expression

ISO

Azacitidine results in increased expression of HNF4A mRNA

NCBI chr 3:172,606,220...172,667,758
Ensembl chr 3:172,606,220...172,667,758

G

homeobox A1

multiple interactions
increases expression

ISO

Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of HOXA1 mRNA]
Azacitidine results in increased expression of HOXA1 mRNA

NCBI chr 4:82,586,505...82,589,209
Ensembl chr 4:82,586,505...82,589,209

G

15-hydroxyprostaglandin dehydrogenase

decreases methylation
multiple interactions
increases expression

ISO

Azacitidine results in decreased methylation of HPGD gene
trichostatin A promotes the reaction [Azacitidine results in increased expression of HPGD mRNA]

NCBI chr16:38,996,876...39,034,831
Ensembl chr16:38,996,876...39,034,831

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1

affects expression

ISO

Azacitidine affects the expression of HSD3B1 mRNA

NCBI chr 2:188,858,574...188,864,694

G

heat shock transcription factor 1

decreases activity

ISO

Azacitidine results in decreased activity of HSF1 protein

NCBI chr 7:110,076,710...110,103,665
Ensembl chr 7:110,076,710...110,103,665

G

heat shock protein family A (Hsp70) member 6 like, pseudogene 1

increases expression

ISO

Azacitidine results in increased expression of HSPA6 mRNA

NCBI chr13:85,805,911...85,807,052

G

inhibitor of DNA binding 1

increases expression

ISO

Azacitidine results in increased expression of ID1 mRNA

NCBI chr 3:161,671,525...161,672,691
Ensembl chr 3:161,671,538...161,672,685

G

inhibitor of DNA binding 3

increases expression

ISO

Azacitidine results in increased expression of ID3 mRNA

NCBI chr 5:153,656,253...153,657,860
Ensembl chr 5:153,630,498...153,657,856

G

interferon gamma

multiple interactions

ISO

[Azacitidine promotes the reaction [IFNG protein results in increased expression of CIITA mRNA]] which results in increased expression of HLA-DRA protein; [Azacitidine results in decreased methylation of CIITA promoter] promotes the reaction [IFNG protein results in increased expression of CIITA mRNA]; [Azacitidine results in increased expression of KIR2DL4 protein] which results in increased secretion of IFNG protein

PMID:18829986 PMID:18945643

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216

G

insulin-like growth factor binding protein 1

multiple interactions
increases expression

ISO

Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA]; Azacitidine promotes the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 protein]
Azacitidine results in increased expression of IGFBP1 mRNA

NCBI chr14:86,261,277...86,266,344
Ensembl chr14:86,261,277...86,266,344

G

insulin-like growth factor binding protein 4

increases expression

ISO

Azacitidine results in increased expression of IGFBP4 mRNA

NCBI chr10:84,491,471...84,503,487
Ensembl chr10:84,485,775...84,503,473

G

interleukin 12B

increases expression

ISO

Azacitidine results in increased expression of IL12B mRNA

NCBI chr10:29,390,300...29,405,194
Ensembl chr10:29,389,905...29,405,194

G

interleukin 1 beta

increases expression
multiple interactions

EXP
ISO

Azacitidine results in increased expression of IL1B mRNA
Azacitidine inhibits the reaction [Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 mRNA]]; Azacitidine inhibits the reaction [Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 protein]]

PMID:17156202 PMID:32894642

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 2

multiple interactions

ISO

Azacitidine inhibits the reaction [IL2 protein results in increased secretion of GZMB protein]; Azacitidine inhibits the reaction [IL2 protein results in increased secretion of PRF1 protein]

NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:121,932,968...121,937,672

G

interleukin 4

affects methylation

ISO

Azacitidine affects the methylation of IL4 promoter

NCBI chr10:38,272,003...38,277,549
Ensembl chr10:38,272,003...38,277,549

G

interleukin 6

affects secretion
affects methylation

ISO

Azacitidine affects the secretion of IL6 protein
Azacitidine affects the methylation of IL6 promoter

PMID:18158872 PMID:18443271

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

interleukin 6 receptor

affects expression
multiple interactions

ISO

[Azacitidine affects the expression of IL6R protein] which affects the expression of BCL2L1 protein; Azacitidine affects the expression of IL6R mRNA
[Azacitidine affects the expression of IL6R protein] which affects the phosphorylation of STAT3 protein

NCBI chr 2:177,582,020...177,646,705
Ensembl chr 2:177,582,164...177,645,221

G

iron-sulfur cluster assembly 1

increases expression

ISO

Azacitidine results in increased expression of ISCA1 mRNA

NCBI chr17:4,910,816...4,923,478
Ensembl chr17:4,910,795...4,923,476

G

integrin subunit beta 1

decreases expression

ISO

Azacitidine results in decreased expression of ITGB1 mRNA

NCBI chr19:73,602,277...73,650,271
Ensembl chr19:73,602,126...73,650,269

G

integrin subunit beta 2

decreases expression

ISO

Azacitidine results in decreased expression of ITGB2 mRNA

NCBI chr20:11,061,009...11,097,242
Ensembl chr20:11,058,492...11,097,182

G

ITPR interacting domain containing 2

increases expression

ISO

Azacitidine results in increased expression of ITPRID2 mRNA

NCBI chr 3:84,943,572...84,980,993
Ensembl chr 3:84,939,808...84,980,899

G

kinase insert domain receptor

increases expression

EXP

Azacitidine results in increased expression of KDR mRNA

NCBI chr14:32,572,031...32,615,204
Ensembl chr14:32,572,049...32,615,192

G

kinesin family member 2C

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of KIF2C mRNA

NCBI chr 5:135,873,925...135,899,267
Ensembl chr 5:135,873,925...135,899,212

G

killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1

increases expression
decreases methylation

ISO

Azacitidine results in increased expression of KIR3DL1 mRNA; Azacitidine results in increased expression of KIR3DL1 protein
Azacitidine results in decreased methylation of KIR3DL1 promoter

PMID:18945643 PMID:19394699

NCBI chr 1:78,756,035...78,796,961
Ensembl chr 1:78,757,394...78,796,715

G

KLF transcription factor 6

increases expression
multiple interactions

ISO

Azacitidine results in increased expression of KLF6 mRNA
TP73 protein promotes the reaction [Azacitidine results in increased expression of KLF6 mRNA]

NCBI chr17:69,449,483...69,458,478
Ensembl chr17:69,441,493...69,498,601

G

kallikrein 1-related peptidase C10

increases expression

ISO

Azacitidine analog results in increased expression of KLK3 protein

NCBI chr 1:103,539,527...103,543,586
Ensembl chr 1:103,539,527...103,543,586

G

keratin 19

increases expression

ISO

Azacitidine results in increased expression of KRT19 mRNA

NCBI chr10:85,576,235...85,580,952
Ensembl chr10:85,576,235...85,580,952

G

keratin 32

increases expression

ISO

Azacitidine results in increased expression of KRT32 mRNA

NCBI chr10:85,513,951...85,520,978
Ensembl chr10:85,513,951...85,520,978

G

keratin 8

multiple interactions
increases expression

ISO

Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of KRT8 mRNA]
Azacitidine results in increased expression of KRT8 mRNA

NCBI chr 7:135,002,886...135,010,339
Ensembl chr 7:135,002,894...135,010,403

G

laminin subunit alpha 1

affects localization

ISO

Azacitidine affects the localization of LAMA1 protein

NCBI chr 9:115,139,548...115,263,620
Ensembl chr 9:115,139,548...115,264,251

G

laminin subunit beta 2

increases expression

ISO

Azacitidine results in increased expression of LAMB2 mRNA

NCBI chr 8:118,056,899...118,069,090
Ensembl chr 8:118,056,935...118,069,090

G

lactate dehydrogenase B

increases expression

ISO

Azacitidine results in increased expression of LDHB mRNA

NCBI chr 4:177,159,389...177,177,408
Ensembl chr 4:177,159,392...177,177,408

G

LIM zinc finger domain containing 1

increases expression

ISO

Azacitidine results in increased expression of LIMS1 mRNA

NCBI chr20:26,851,364...26,961,607
Ensembl chr20:26,852,996...26,961,606

G

lipopolysaccharide-induced TNF factor

decreases expression

ISO

Azacitidine results in decreased expression of LITAF mRNA

NCBI chr10:5,163,258...5,199,930
Ensembl chr10:5,163,242...5,199,930

G

leukotriene B4 receptor

decreases expression

ISO

Azacitidine results in decreased expression of LTB4R mRNA

NCBI chr15:33,233,120...33,235,636
Ensembl chr15:33,232,820...33,235,637

G

lysozyme 2

increases expression

ISO

Azacitidine results in increased expression of LYZ mRNA

NCBI chr 7:54,792,715...54,798,060
Ensembl chr 7:54,792,716...54,798,011

G

mitotic arrest deficient 1 like 1

decreases expression

ISO

Azacitidine results in decreased expression of MAD1L1 mRNA

NCBI chr12:19,434,782...19,744,574
Ensembl chr12:19,434,746...19,744,567

G

MAF bZIP transcription factor B

increases expression
multiple interactions

ISO

Azacitidine results in increased expression of MAFB mRNA
Cisplatin affects the reaction [Azacitidine results in increased expression of MAFB mRNA]

NCBI chr 3:169,417,890...169,419,810
Ensembl chr 3:169,416,945...169,419,975

G

microtubule-associated protein 1A

decreases expression

ISO

Azacitidine results in decreased expression of MAP1A mRNA

NCBI chr 3:128,716,907...128,736,638
Ensembl chr 3:128,716,940...128,740,159

G

mitogen activated protein kinase kinase 5

decreases expression

ISO

Azacitidine results in decreased expression of MAP2K5 mRNA

NCBI chr 8:72,520,616...72,748,395
Ensembl chr 8:72,520,617...72,747,373

G

microtubule-associated protein tau

decreases expression

ISO

Azacitidine results in decreased expression of MAPT protein

NCBI chr10:89,638,618...89,736,108
Ensembl chr10:89,638,599...89,736,108

G

MCL1 apoptosis regulator, BCL2 family member

decreases expression

ISO

5-azacytidine decreases expression of MCL1 protein in lung cancer cells

RGD

NCBI chr 2:185,884,840...185,912,532
Ensembl chr 2:185,908,168...185,938,782

G

minichromosome maintenance complex component 5

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of MCM5 mRNA

NCBI chr19:13,488,813...13,510,131
Ensembl chr19:13,488,813...13,517,758

G

mediator of DNA damage checkpoint 1

increases expression

ISO

Azacitidine results in increased expression of MDC1 mRNA

NCBI chr20:2,898,496...2,914,960
Ensembl chr20:2,900,308...2,914,960

G

MDM2 proto-oncogene

increases expression

ISO

Azacitidine results in increased expression of MDM2 mRNA

NCBI chr 7:55,176,558...55,201,757
Ensembl chr 7:55,176,560...55,200,791

G

methyl CpG binding protein 2

multiple interactions

ISO

Azacitidine inhibits the reaction [MECP2 protein binds to CCNA1 promoter]

NCBI chr X:156,932,481...156,995,981
Ensembl chr X:156,941,234...156,943,560

G

myocyte enhancer factor 2a

increases expression
affects expression

ISO

Azacitidine results in increased expression of MEF2A
Azacitidine affects the expression of MEF2A protein

PMID:12094073 PMID:19002953

NCBI chr 1:130,258,083...130,392,819
Ensembl chr 1:130,260,339...130,392,162

G

myocyte enhancer factor 2D

affects expression
increases expression

ISO

Azacitidine affects the expression of MEF2D protein
Azacitidine results in increased expression of MEF2D

PMID:12094073 PMID:19002953

NCBI chr 2:175,904,332...175,933,451
Ensembl chr 2:175,903,959...175,930,760

G

multiple EGF-like-domains 6

decreases expression

ISO

Azacitidine results in decreased expression of MEGF6 mRNA

NCBI chr 5:170,020,699...170,121,557
Ensembl chr 5:170,020,778...170,121,554

G

mesoderm development LRP chaperone

decreases expression

EXP

Azacitidine results in decreased expression of MESD protein

NCBI chr 1:147,275,904...147,289,134
Ensembl chr 1:147,275,396...147,289,134

G

microfibril associated protein 2

decreases expression

ISO

Azacitidine results in decreased expression of MFAP2 mRNA

NCBI chr 5:158,595,121...158,603,283
Ensembl chr 5:158,597,512...158,610,656

G

milk fat globule EGF and factor V/VIII domain containing

affects expression

ISO

Azacitidine affects the expression of MFGE8 mRNA

NCBI chr 1:142,474,027...142,489,431
Ensembl chr 1:142,474,028...142,489,431

G

O-6-methylguanine-DNA methyltransferase

increases expression
decreases methylation

ISO

Azacitidine results in increased expression of MGMT mRNA
Azacitidine results in decreased methylation of MGMT protein

PMID:7511991 PMID:12807730

NCBI chr 1:201,140,832...201,367,481
Ensembl chr 1:201,140,661...201,367,482

G

microRNA 193a

increases expression

ISO

5-azacytidine increases expression of MIR193A in liver cells
5-azacytidine increases expression of MIR193a RNA in lung cancer cells

RGD

PMID:28036298 PMID:24356455

RGD:153344564, RGD:153344603

NCBI chr10:65,170,306...65,170,417

G

microRNA 23b

increases expression

ISO

5-azacytidine increases expression of MIR23B miRNA in liver cells

RGD

NCBI chr17:1,819,386...1,819,482

G

microRNA 497

increases expression
multiple interactions
decreases methylation

ISO

Azacitidine results in increased expression of MIR497 mRNA
Azacitidine inhibits the reaction [DNMT1 protein binds to MIR497 promoter]; Azacitidine inhibits the reaction [DNMT3A protein binds to MIR497 promoter]; Azacitidine inhibits the reaction [DNMT3B protein binds to MIR497 promoter]
Azacitidine results in decreased methylation of MIR497 promoter

NCBI chr10:55,450,171...55,450,239
Ensembl chr10:55,450,162...55,450,241

G

microRNA 9-3

increases expression

ISO

5-azacytidine increases expression of MIR9-3 in lung cancer cells

RGD

NCBI chr 1:142,849,400...142,849,489

G

marker of proliferation Ki-67

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of MKI67 mRNA

NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:199,926,150...199,952,593

G

matrix metallopeptidase 1

increases expression

ISO

Azacitidine results in increased expression of MMP1 mRNA

NCBI chr 8:12,943,453...12,963,966
Ensembl chr 8:12,943,453...12,963,964

G

matrix metallopeptidase 9

multiple interactions

ISO

metacept-1 inhibits the reaction [Azacitidine results in increased expression of MMP9]

NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442

G

mortality factor 4 like 2

decreases expression

ISO

Azacitidine results in decreased expression of MORF4L2 mRNA

NCBI chr X:104,874,850...104,885,946
Ensembl chr X:104,852,693...104,892,855

G

Mov10 like RNA helicase 1

increases expression

ISO

Azacitidine results in increased expression of MOV10L1 mRNA

NCBI chr 7:121,949,743...122,015,042
Ensembl chr 7:121,949,822...122,015,042

G

methionine sulfoxide reductase B2

increases expression

ISO

Azacitidine results in increased expression of MSRB2 mRNA

NCBI chr17:86,882,750...86,908,392
Ensembl chr17:86,882,394...86,908,391

G

methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase

decreases expression

ISO

Azacitidine results in decreased expression of MTHFD2 mRNA

NCBI chr 4:117,368,833...117,380,350
Ensembl chr 4:117,368,835...117,380,350

G

Mtr4 exosome RNA helicase

increases expression

ISO

Azacitidine results in increased expression of MTREX mRNA

NCBI chr 2:46,233,528...46,293,827
Ensembl chr 2:46,194,647...46,293,827

G

MYC proto-oncogene, bHLH transcription factor

decreases expression
multiple interactions

ISO

Azacitidine analog results in decreased expression of MYC mRNA
MYC protein affects the reaction [Azacitidine results in decreased activity of TERT protein]; MYC protein affects the reaction [Azacitidine results in decreased expression of TERT mRNA]

PMID:18045574 PMID:19451745

NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028

G

myogenic factor 5

increases expression

ISO

Azacitidine results in increased expression of MYF5 mRNA

NCBI chr 7:44,689,407...44,692,638
Ensembl chr 7:44,689,407...44,692,638

G

myosin heavy chain 7

increases expression

EXP

Azacitidine results in increased expression of MYH7 mRNA; Azacitidine results in increased expression of MYH7 protein

NCBI chr15:32,416,525...32,439,851
Ensembl chr15:32,416,527...32,438,194

G

myosin light chain 2

increases expression

EXP

Azacitidine results in increased expression of MYL2 mRNA

NCBI chr12:40,114,964...40,126,236
Ensembl chr12:40,114,958...40,129,149

G

myogenic differentiation 1

increases expression

EXP
ISO

Azacitidine results in increased expression of MYOD1 mRNA

PMID:18037191 PMID:18938140

NCBI chr 1:106,021,161...106,023,871
Ensembl chr 1:106,021,161...106,023,871

G

myogenin

increases expression

ISO

Azacitidine results in increased expression of MYOG mRNA

NCBI chr13:48,297,476...48,300,065
Ensembl chr13:48,297,235...48,300,065

G

neural cell adhesion molecule 1

increases expression

EXP

Azacitidine results in increased expression of NCAM1 mRNA

NCBI chr 8:58,762,088...59,062,131
Ensembl chr 8:58,762,116...59,061,971

G

neurofilament light chain

increases expression

ISO

Azacitidine results in increased expression of NEFL mRNA

NCBI chr15:46,477,330...46,481,203
Ensembl chr15:46,458,204...46,482,515

G

nuclear factor of activated T-cells 1

increases expression

ISO

Azacitidine results in increased expression of NFATC1 mRNA

NCBI chr18:76,321,386...76,430,997
Ensembl chr18:76,321,386...76,430,990

G

niban apoptosis regulator 1

increases expression
multiple interactions

ISO

Azacitidine results in increased expression of NIBAN1 mRNA
TP73 protein promotes the reaction [Azacitidine results in increased expression of NIBAN1 mRNA]

NCBI chr13:66,224,219...66,377,728
Ensembl chr13:66,224,021...66,377,724

G

NK2 homeobox 5

increases expression

ISO

Azacitidine results in increased expression of NKX2-5 mRNA

NCBI chr10:16,844,888...16,851,458
Ensembl chr10:16,848,582...16,851,452

G

neuroligin 3

increases expression

ISO

Azacitidine results in increased expression of NLGN3 mRNA

NCBI chr X:70,469,251...70,497,380
Ensembl chr X:70,469,457...70,497,379

G

NME/NM23 nucleoside diphosphate kinase 2

increases expression

EXP

Azacitidine results in increased expression of NME2 protein

NCBI chr10:79,394,999...79,400,418
Ensembl chr20:11,179,066...11,179,497
Ensembl chr10:11,179,066...11,179,497

G

N-myc (and STAT) interactor

increases expression

ISO

Azacitidine results in increased expression of NMI mRNA

NCBI chr 3:56,824,778...56,848,891
Ensembl chr 3:56,811,314...56,848,717

G

nicotinamide nucleotide transhydrogenase

increases expression

ISO

Azacitidine results in increased expression of NNT mRNA; Azacitidine results in increased expression of NNT protein

NCBI chr 2:53,144,157...53,237,857
Ensembl chr 2:53,144,160...53,237,310

G

nucleolar protein with MIF4G domain 1

decreases expression

ISO

Azacitidine results in decreased expression of NOM1 mRNA

NCBI chr 4:6,562,931...6,586,093
Ensembl chr 4:6,567,836...6,585,036

G

nephrocystin 1

increases expression

ISO

Azacitidine results in increased expression of NPHP1 mRNA

NCBI chr 3:135,413,927...135,469,505
Ensembl chr 3:135,413,927...135,469,505

G

natriuretic peptide A

increases expression

ISO

Azacitidine results in increased expression of NPPA

NCBI chr 5:163,712,184...163,713,493
Ensembl chr 5:163,712,184...163,713,493

G

natriuretic peptide B

increases expression

ISO

Azacitidine results in increased expression of NPPB

NCBI chr 5:163,699,955...163,701,314
Ensembl chr 5:163,699,839...163,701,310

G

NAD(P)H quinone dehydrogenase 1

multiple interactions

ISO

[Azacitidine co-treated with Butyrates] inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene results in increased expression of NQO1 mRNA]]; Azacitidine inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene results in increased expression of NQO1 mRNA]]

NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260

G

nuclear receptor subfamily 4, group A, member 1

multiple interactions

ISO

[metacept-1 co-treated with Azacitidine] results in increased expression of NR4A1

NCBI chr 7:134,247,153...134,268,044
Ensembl chr 7:134,247,192...134,268,041

G

nuclear receptor interacting protein 1

decreases expression

ISO

Azacitidine results in decreased expression of NRIP1 mRNA

NCBI chr11:28,382,835...28,466,483
Ensembl chr11:28,378,878...28,467,353

G

neuritin 1

decreases expression

ISO

Azacitidine results in decreased expression of NRN1 mRNA

NCBI chr17:28,335,426...28,344,354
Ensembl chr17:28,334,616...28,344,354

G

5' nucleotidase, ecto

increases expression

ISO

Azacitidine results in increased expression of NT5E mRNA

NCBI chr 8:98,150,925...98,195,646
Ensembl chr 8:98,150,900...98,195,645

G

neurotensin

decreases expression

ISO

Azacitidine results in decreased expression of NTS mRNA

NCBI chr 7:39,451,484...39,460,888
Ensembl chr 7:39,451,073...39,460,961

G

nucleolar and spindle associated protein 1

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of NUSAP1 mRNA

NCBI chr 3:127,057,220...127,092,779
Ensembl chr 3:127,057,265...127,087,237

G

nuclear transport factor 2-like export factor 2

increases expression

ISO

Azacitidine results in increased expression of NXT2 mRNA

NCBI chr X:110,652,434...110,659,738
Ensembl chr X:110,652,434...110,659,737

G

occludin

increases expression

ISO

Azacitidine results in increased expression of OCLN mRNA

NCBI chr 2:33,391,303...33,442,207
Ensembl chr 2:33,391,303...33,430,411

G

opioid growth factor receptor-like 1

increases expression

ISO

Azacitidine results in increased expression of OGFRL1 mRNA

NCBI chr 9:33,320,501...33,338,742
Ensembl chr 9:33,324,392...33,339,237

G

8-oxoguanine DNA glycosylase

decreases expression
decreases methylation

ISO

Azacitidine results in decreased expression of OGG1 protein
Azacitidine results in decreased methylation of OGG1 promoter

NCBI chr 4:148,030,237...148,037,599
Ensembl chr 4:148,030,349...148,037,604

G

olfactory receptor family 8 subfamily B member 8

increases expression

ISO

Azacitidine results in increased expression of OR8B8 mRNA

NCBI chr 8:45,882,321...45,883,253
Ensembl chr 8:45,882,321...45,883,253

G

oxidation resistance 1

increases expression

ISO

Azacitidine results in increased expression of OXR1 mRNA

NCBI chr 7:74,413,609...74,850,487
Ensembl chr 7:74,413,590...74,850,487

G

oxytocin receptor

decreases expression

ISO

Azacitidine results in decreased expression of OXTR mRNA

NCBI chr 4:147,154,374...147,171,723
Ensembl chr 4:147,154,374...147,170,750

G

prolyl 4-hydroxylase subunit beta

increases expression

EXP
ISO

Azacitidine results in increased expression of P4HB protein
Azacitidine results in increased expression of P4HB mRNA

PMID:17105402 PMID:20823114

NCBI chr10:106,335,300...106,346,911
Ensembl chr10:106,335,300...106,346,911

G

progestagen associated endometrial protein

decreases expression

ISO

Azacitidine results in decreased expression of PAEP mRNA

NCBI chr 3:28,929,252...28,932,592

G

p21 (RAC1) activated kinase 1

increases expression

ISO

Azacitidine results in increased expression of PAK1 mRNA

NCBI chr 1:161,522,399...161,637,623
Ensembl chr 1:161,491,847...161,637,612

G

pantothenate kinase 3

decreases expression

ISO

Azacitidine results in decreased expression of PANK3 mRNA

NCBI chr10:20,733,191...20,757,017
Ensembl chr10:20,733,127...20,757,015

G

poly (ADP-ribose) polymerase 1

increases cleavage
multiple interactions

ISO

Azacitidine results in increased cleavage of PARP1 protein
Bleomycin inhibits the reaction [Azacitidine results in increased cleavage of PARP1 protein]

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567

G

paired box 4

increases expression

ISO

Azacitidine results in increased expression of PAX4 mRNA

NCBI chr 4:58,023,873...58,032,265
Ensembl chr 4:58,023,914...58,028,858

G

protocadherin 18

decreases expression

ISO

Azacitidine results in decreased expression of PCDH18 mRNA

NCBI chr 2:135,982,929...135,996,917
Ensembl chr 2:135,983,144...135,996,826

G

protocadherin alpha 1

affects methylation

ISO

Azacitidine affects the methylation of PCDHA1 promoter

Ensembl chr18:28,855,256...29,120,227

G

protocadherin alpha 10

affects methylation

ISO

Azacitidine affects the methylation of PCDHA10 promoter

G

protocadherin alpha 11

affects methylation

ISO

Azacitidine affects the methylation of PCDHA11 promoter

G

protocadherin alpha 12

affects methylation

ISO

Azacitidine affects the methylation of PCDHA12 promoter

Ensembl chr18:28,855,256...29,120,227

G

protocadherin alpha 2

affects methylation

ISO

Azacitidine affects the methylation of PCDHA2 promoter

G

protocadherin alpha 3

affects methylation

ISO

Azacitidine affects the methylation of PCDHA3 promoter

G

protocadherin alpha 4

affects methylation

ISO

Azacitidine affects the methylation of PCDHA4 promoter

NCBI chr18:28,688,274...29,120,227
Ensembl chr18:28,855,256...29,120,227

G

protocadherin alpha 5

affects methylation

ISO

Azacitidine affects the methylation of PCDHA5 promoter

G

protocadherin alpha 6

affects methylation

ISO

Azacitidine affects the methylation of PCDHA6 promoter

Ensembl chr18:28,855,256...29,120,227

G

protocadherin alpha 7

affects methylation

ISO

Azacitidine affects the methylation of PCDHA7 promoter

G

protocadherin alpha 9

affects methylation

ISO

Azacitidine affects the methylation of PCDHA8 promoter; Azacitidine affects the methylation of PCDHA9 promoter

G

protocadherin beta 20

decreases expression

ISO

Azacitidine results in decreased expression of PCDHB14 mRNA

NCBI chr18:29,485,888...29,489,282
Ensembl chr18:29,454,999...29,489,427

G

protocadherin beta 5

decreases expression

ISO

Azacitidine results in decreased expression of PCDHB4 mRNA

NCBI chr18:29,302,466...29,305,048

G

proliferating cell nuclear antigen

decreases expression
multiple interactions

EXP

Azacitidine results in decreased expression of PCNA protein
[Cisplatin co-treated with Azacitidine] results in decreased expression of PCNA protein

NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901

G

pyruvate dehydrogenase kinase 1

increases expression

ISO

Azacitidine results in increased expression of PDK1 mRNA

NCBI chr 3:77,113,464...77,144,145
Ensembl chr 3:77,113,473...77,144,145

G

pyruvate dehydrogenase kinase 4

increases expression
decreases methylation

ISO

Azacitidine results in increased expression of PDK4 protein
Azacitidine results in decreased methylation of PDK4 promoter

NCBI chr 4:34,558,327...34,568,329
Ensembl chr 4:34,556,330...34,568,381

G

platelet and endothelial cell adhesion molecule 1

increases expression

EXP

Azacitidine results in increased expression of PECAM1 mRNA

NCBI chr10:92,090,263...92,152,002
Ensembl chr10:92,090,235...92,151,839

G

profilin 1

increases expression

ISO

Azacitidine results in increased expression of PFN1 mRNA

NCBI chr10:55,863,882...55,866,587
Ensembl chr10:55,863,881...55,868,611

G

phosphatase and actin regulator 2

increases expression

ISO

Azacitidine results in increased expression of PHACTR2 mRNA

NCBI chr 1:9,411,412...9,680,648
Ensembl chr 1:9,418,085...9,680,583

G

phosphatidylinositol-4-phosphate 5-kinase, type 1, alpha

decreases expression

ISO

Azacitidine results in decreased expression of PIP5K1A mRNA

NCBI chr 2:185,317,319...185,361,859
Ensembl chr 2:185,317,319...185,360,476

G

phosphatidylinositol transfer protein, cytoplasmic 1

decreases expression

ISO

Azacitidine results in decreased expression of PITPNC1 mRNA

NCBI chr10:92,663,260...92,928,616
Ensembl chr10:92,663,260...92,928,344

G

paired-like homeodomain 3

increases expression

EXP

Azacitidine results in increased expression of PITX3 mRNA

NCBI chr 1:254,942,550...254,955,325
Ensembl chr 1:254,942,608...254,955,336

G

praja ring finger ubiquitin ligase 1

increases expression

ISO

Azacitidine results in increased expression of PJA1 mRNA

NCBI chr X:68,621,101...68,626,001
Ensembl chr X:68,620,084...68,638,407

G

polycystin 2 like 1, transient receptor potential cation channel

increases expression

ISO

Azacitidine results in increased expression of PKD2L1 mRNA

NCBI chr 1:252,982,096...253,019,235
Ensembl chr 1:252,982,096...253,023,359

G

pyruvate kinase M1/2

increases expression

ISO

Azacitidine results in increased expression of PKM mRNA

NCBI chr 8:68,949,731...68,975,394
Ensembl chr 8:68,948,815...68,975,396

G

phospholipase C beta 1

decreases methylation
decreases response to substance
increases response to substance
increases expression

ISO

Azacitidine results in decreased methylation of PLCB1 promoter
PLCB1 promoter modified form results in decreased susceptibility to Azacitidine
PLCB1 mRNA results in increased susceptibility to Azacitidine; PLCB1 protein results in increased susceptibility to Azacitidine
Azacitidine results in increased expression of PLCB1 mRNA; Azacitidine results in increased expression of PLCB1 protein

NCBI chr 3:142,512,765...143,224,042
Ensembl chr 3:142,513,033...143,225,646

G

phospholipid phosphatase 1

increases expression

ISO

Azacitidine results in increased expression of PLPP1 mRNA

NCBI chr 2:46,172,202...46,233,632
Ensembl chr 2:46,172,197...46,234,676

G

plastin 3

decreases expression

ISO

Azacitidine results in decreased expression of PLS3 mRNA

NCBI chr X:116,401,247...116,495,898
Ensembl chr X:116,401,293...116,495,893

G

PML nuclear body scaffold

increases expression

ISO

Azacitidine results in increased expression of PML mRNA

NCBI chr 8:67,523,164...67,557,801
Ensembl chr 8:67,523,164...67,576,083

G

peroxisome proliferator-activated receptor gamma

decreases methylation
increases expression

ISO

Azacitidine results in decreased methylation of PPARG promoter
Azacitidine results in increased expression of PPARG mRNA

NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104

G

protein phosphatase 2 catalytic subunit alpha

multiple interactions
increases expression
decreases methylation

ISO

Azacitidine promotes the reaction [CREB1 protein modified form binds to PPP2CA promoter]
Azacitidine results in increased expression of PPP2CA mRNA
Azacitidine results in decreased methylation of PPP2CA promoter

NCBI chr10:36,856,534...36,878,789

G

peroxiredoxin 4

decreases expression

EXP

Azacitidine results in decreased expression of PRDX4 protein

NCBI chr X:43,876,374...43,893,815
Ensembl chr X:43,876,417...43,893,812

G

perforin 1

multiple interactions

ISO

Azacitidine inhibits the reaction [IL2 protein results in increased secretion of PRF1 protein]

NCBI chr20:29,789,040...29,794,550
Ensembl chr20:29,788,972...29,795,124

G

prolactin

multiple interactions

ISO

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of PRL mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of PRL protein

NCBI chr17:38,287,355...38,298,234
Ensembl chr17:38,288,162...38,298,217

G

prominin 1

increases expression

EXP

Azacitidine results in increased expression of PROM1 mRNA

NCBI chr14:71,202,303...71,307,008
Ensembl chr14:71,202,336...71,307,002

G

serine protease 12

decreases expression

ISO

Azacitidine results in decreased expression of PRSS12 mRNA

NCBI chr 2:214,308,695...214,368,679
Ensembl chr 2:214,308,774...214,369,941

G

presenilin 1

decreases methylation
multiple interactions

ISO

Azacitidine results in decreased methylation of PSEN1 promoter
Betaine inhibits the reaction [Azacitidine results in decreased methylation of PSEN1 promoter]

NCBI chr 6:109,054,160...109,106,191
Ensembl chr 6:109,060,352...109,106,189

G

phosphatase and tensin homolog

multiple interactions

ISO

Azacitidine inhibits the reaction [TGFB1 protein results in decreased expression of PTEN mRNA]; Azacitidine inhibits the reaction [TGFB1 protein results in decreased expression of PTEN protein]; Azacitidine inhibits the reaction [TGFB1 protein results in increased methylation of PTEN promoter]

NCBI chr 1:240,043,707...240,110,330
Ensembl chr 1:240,043,707...240,110,330

G

parathyroid hormone-like hormone

decreases expression

ISO

Azacitidine results in decreased expression of PTHLH mRNA

NCBI chr 4:181,919,400...181,930,454
Ensembl chr 4:181,919,400...181,930,454

G

protein phosphatase 2 phosphatase activator

increases expression

ISO

Azacitidine results in increased expression of PTPA mRNA

NCBI chr 3:34,087,637...34,118,100
Ensembl chr 3:34,087,575...34,162,772

G

protein tyrosine phosphatase, receptor type, C

increases expression

ISO

Azacitidine results in increased expression of PTPRC mRNA

NCBI chr13:52,147,717...52,259,810
Ensembl chr13:52,147,717...52,259,746

G

protein tyrosine phosphatase, receptor type, O

increases expression

EXP

Azacitidine results in increased expression of PTPRO mRNA

NCBI chr 4:171,895,104...172,105,911
Ensembl chr 4:171,895,232...172,105,903

G

RAB13, member RAS oncogene family

decreases methylation

ISO

Azacitidine results in decreased methylation of RAB13 promoter

NCBI chr 2:177,972,535...177,977,679
Ensembl chr 2:177,972,372...177,977,684

G

RAB1B, member RAS oncogene family

increases expression

ISO

Azacitidine results in increased expression of RAB1B mRNA

NCBI chr 1:211,835,133...211,843,408
Ensembl chr 1:211,835,073...211,843,337
Ensembl chr X:211,835,073...211,843,337

G

Rac GTPase-activating protein 1

increases expression

ISO

Azacitidine results in increased expression of RACGAP1 mRNA

NCBI chr 7:132,629,789...132,659,738
Ensembl chr 7:132,620,595...132,659,738

G

RAN binding protein 2

increases expression

ISO

Azacitidine results in increased expression of RANBP2 mRNA

NCBI chr20:26,984,520...27,036,573
Ensembl chr20:26,985,275...27,036,571

G

RAS p21 protein activator 3

increases expression

ISO

Azacitidine results in increased expression of RASA3 mRNA

NCBI chr16:82,557,556...82,671,527
Ensembl chr16:82,557,428...82,672,984

G

reticulocalbin 1

decreases expression

ISO

Azacitidine results in decreased expression of RCN1 mRNA

NCBI chr 3:112,295,838...112,310,082
Ensembl chr 3:112,295,838...112,310,082

G

RELA proto-oncogene, NF-kB subunit

affects localization
decreases expression

ISO

Azacitidine affects the localization of RELA protein
5-azacytidine decreases expression of RELA protein in lung cancer cells

CTD
RGD

PMID:18443271 PMID:24356455

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

ret proto-oncogene

decreases expression

ISO

Azacitidine results in decreased expression of RET mRNA

NCBI chr 4:152,998,344...153,040,556
Ensembl chr 4:152,998,812...153,040,556

G

replication factor C subunit 3

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of RFC3 mRNA

NCBI chr12:5,836,546...5,847,331
Ensembl chr12:5,836,553...5,847,340

G

ras homolog family member B

multiple interactions

ISO

[trichostatin A co-treated with Azacitidine] results in increased expression of RHOB protein; Azacitidine promotes the reaction [trichostatin A results in increased expression of RHOB mRNA]

NCBI chr 6:37,083,030...37,085,204
Ensembl chr 6:37,075,015...37,112,772

G

Ras and Rab interactor 1

increases expression

ISO

Azacitidine results in increased expression of RIN1 mRNA

NCBI chr 1:211,785,107...211,789,755
Ensembl chr 1:211,784,943...211,791,368

G

ribosomal protein L4

increases expression

EXP

Azacitidine results in increased expression of RPL4 mRNA

NCBI chr 8:73,566,477...73,571,600
Ensembl chr 8:73,566,466...73,571,788

G

ribonuclease P/MRP subunit p21

increases expression

ISO

Azacitidine results in increased expression of RPP21 mRNA

NCBI chr20:1,986,225...2,025,308
Ensembl chr20:2,023,186...2,025,308

G

ribosomal protein S6

decreases phosphorylation

ISO

Azacitidine results in decreased phosphorylation of RPS6 protein

NCBI chr 5:106,417,680...106,420,540
Ensembl chr 5:106,417,680...106,420,566

G

ribosomal protein SA

decreases expression

ISO

Azacitidine results in decreased expression of RPSA mRNA

NCBI chr 8:128,728,761...128,732,736
Ensembl chr 8:128,728,862...128,732,737

G

ribonucleotide reductase regulatory subunit M2

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of RRM2 mRNA

NCBI chr 6:47,044,755...47,075,370
Ensembl chr 6:47,067,690...47,075,370

G

ribonucleotide reductase regulatory TP53 inducible subunit M2B

increases expression

ISO

Azacitidine results in increased expression of RRM2B mRNA

NCBI chr 7:70,962,008...70,993,726
Ensembl chr 7:70,965,590...70,993,670

G

RT1 class II, locus Da

multiple interactions

ISO

[Azacitidine promotes the reaction [IFNG protein results in increased expression of CIITA mRNA]] which results in increased expression of HLA-DRA protein

NCBI chr20:4,515,393...4,520,387
Ensembl chr20:4,513,908...4,520,383

G

RUNX family transcription factor 1

multiple interactions

ISO

Azacitidine promotes the reaction [RUNX1 protein binds to KIR2DL2 promoter]; Azacitidine promotes the reaction [RUNX1 protein binds to KIR2DL4 promoter]

NCBI chr11:45,325,778...45,560,300
Ensembl chr11:45,329,044...45,564,925

G

RUNX family transcription factor 2

decreases expression

ISO

Azacitidine results in decreased expression of RUNX2 mRNA

NCBI chr 9:23,661,278...23,990,248
Ensembl chr 9:23,664,952...23,990,027

G

RUNX family transcription factor 3

affects methylation

ISO

Azacitidine affects the methylation of RUNX3 gene

NCBI chr 5:152,644,270...152,702,835
Ensembl chr 5:152,644,270...152,702,835

G

S100 calcium binding protein A14

decreases expression

ISO

Azacitidine results in decreased expression of S100A14 mRNA

NCBI chr 2:178,305,976...178,308,004
Ensembl chr 2:178,306,025...178,307,999

G

S100 calcium binding protein A9

increases expression

ISO

Azacitidine results in increased expression of S100A9 mRNA

NCBI chr 2:178,487,941...178,490,622
Ensembl chr 2:178,487,941...178,490,870

G

spalt-like transcription factor 4

affects methylation

ISO

Azacitidine affects the methylation of SALL4 promoter

NCBI chr 3:177,891,705...177,909,743
Ensembl chr 3:177,891,705...177,909,743

G

secretory carrier membrane protein 4

increases expression

ISO

Azacitidine results in increased expression of SCAMP4 mRNA

NCBI chr 7:9,752,193...9,764,614
Ensembl chr 7:9,752,193...9,778,736

G

syndecan binding protein

decreases expression

ISO

Azacitidine results in decreased expression of SDCBP mRNA

NCBI chr 5:24,245,279...24,314,712
Ensembl chr 5:24,245,033...24,326,197

G

semaphorin 3A

increases expression

ISO

Azacitidine results in increased expression of SEMA3A mRNA

NCBI chr 4:22,239,418...22,709,907
Ensembl chr 4:22,245,322...22,535,774

G

semaphorin 6C

increases expression

ISO

Azacitidine results in increased expression of SEMA6C mRNA

NCBI chr 2:185,422,636...185,436,237
Ensembl chr 2:185,422,639...185,448,689

G

SUMO specific peptidase 3

increases expression

ISO

Azacitidine results in increased expression of SENP3 mRNA

NCBI chr10:54,889,445...54,898,359
Ensembl chr10:54,888,847...54,898,227

G

SIX homeobox 2

decreases expression
multiple interactions

ISO

Azacitidine results in decreased expression of SIX2 mRNA
Cisplatin affects the reaction [Azacitidine results in decreased expression of SIX2 mRNA]

NCBI chr 6:14,727,756...14,734,219
Ensembl chr 6:14,727,859...14,731,941

G

stem-loop histone mRNA binding protein

multiple interactions

ISO

Azacitidine inhibits the reaction [sodium arsenite results in decreased expression of SLBP mRNA]

NCBI chr14:81,295,479...81,306,446
Ensembl chr14:81,296,223...81,306,447

G

solute carrier family 28 member 1

increases response to substance
multiple interactions
increases uptake

ISO

SLC28A1 protein results in increased susceptibility to Azacitidine
[SLC28A1 protein results in increased uptake of Azacitidine] which results in decreased expression of DNMT1 protein; Sodium affects the reaction [SLC28A1 protein results in increased uptake of Azacitidine]

NCBI chr 1:144,490,453...144,532,025
Ensembl chr 1:144,490,623...144,531,544

G

solute carrier family 29 member 2

decreases expression

ISO

Azacitidine results in decreased expression of SLC29A2 mRNA

NCBI chr 1:211,756,588...211,764,561
Ensembl chr 1:211,757,000...211,764,560

G

solute carrier family 5 member 5

multiple interactions
increases expression

ISO

[Azacitidine co-treated with Butyrates] affects the expression of SLC5A5 mRNA
Azacitidine results in increased expression of SLC5A5 mRNA

PMID:16954431 PMID:17164311

NCBI chr16:18,580,705...18,590,692
Ensembl chr16:18,580,705...18,590,691

G

small nuclear ribonucleoprotein 13

increases expression

ISO

Azacitidine results in increased expression of SNU13 mRNA

NCBI chr 7:115,445,415...115,451,008
Ensembl chr 1:269,702,002...269,703,004
Ensembl chr 7:269,702,002...269,703,004

G

suppressor of cytokine signaling 3

affects expression

ISO

Azacitidine affects the expression of SOCS3 protein

NCBI chr10:103,692,579...103,695,975
Ensembl chr10:103,690,976...103,704,825

G

SRY-box transcription factor 13

decreases expression

ISO

Azacitidine results in decreased expression of SOX13 mRNA

NCBI chr13:47,383,145...47,427,572
Ensembl chr13:47,383,145...47,435,663

G

SRY-box transcription factor 2

increases expression

EXP

Azacitidine results in increased expression of SOX2 mRNA

NCBI chr 2:119,465,131...119,467,542
Ensembl chr 2:119,454,541...119,496,350

G

SRY-box transcription factor 8

decreases expression

ISO

Azacitidine results in decreased expression of SOX8 mRNA

NCBI chr10:15,089,357...15,094,345
Ensembl chr10:15,089,357...15,094,345

G

SRY-box transcription factor 9

affects expression
increases expression

ISO

Azacitidine affects the expression of SOX9 mRNA
Azacitidine results in increased expression of SOX9 mRNA

PMID:18033690 PMID:39531065

NCBI chr10:98,305,744...98,311,250
Ensembl chr10:98,305,744...98,311,250

G

Sp1 transcription factor

multiple interactions
decreases expression

ISO

Azacitidine promotes the reaction [SP1 protein binds to KIR2DL2 promoter]; Azacitidine promotes the reaction [SP1 protein binds to KIR2DL4 promoter]
Azacitidine results in decreased expression of SP1 mRNA
Azacitidine promotes the reaction [SP1 protein binds to AQP5 promoter]

PMID:17198683 PMID:18945643 PMID:20823114

NCBI chr 7:135,419,864...135,450,513
Ensembl chr 7:135,420,050...135,450,513

G

Sp7 transcription factor

increases expression

ISO

Azacitidine results in increased expression of SP7 mRNA

NCBI chr 7:135,363,193...135,373,376
Ensembl chr 7:135,363,199...135,373,559

G

sperm associated antigen 5

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of SPAG5 mRNA

NCBI chr10:63,693,300...63,714,813
Ensembl chr10:63,696,466...63,714,811

G

sushi-repeat-containing protein, X-linked

decreases expression

ISO

Azacitidine results in decreased expression of SRPX mRNA

NCBI chr X:15,349,498...15,420,389
Ensembl chr X:15,349,440...15,420,392

G

serine and arginine rich splicing factor 7

decreases expression

ISO

Azacitidine results in decreased expression of SRSF7 mRNA

NCBI chr 6:20,564,035...20,571,205
Ensembl chr 6:20,564,044...20,571,212

G

SSX family member 2 interacting protein

increases expression

ISO

Azacitidine results in increased expression of SSX2IP mRNA

NCBI chr 2:237,958,286...237,991,026
Ensembl chr 2:237,958,465...237,991,017

G

ST3 beta-galactoside alpha-2,3-sialyltransferase 6

increases expression

ISO

Azacitidine results in increased expression of ST3GAL6 mRNA

NCBI chr11:55,530,120...55,590,950
Ensembl chr11:55,530,248...55,598,720

G

ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2

decreases expression

ISO

Azacitidine results in decreased expression of ST8SIA2 mRNA

NCBI chr 1:137,172,354...137,247,796
Ensembl chr 1:137,172,354...137,247,792

G

signal transducer and activator of transcription 3

multiple interactions

ISO

[Azacitidine affects the expression of IL6R protein] which affects the phosphorylation of STAT3 protein

NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359

G

stanniocalcin 2

decreases expression

ISO

Azacitidine results in decreased expression of STC2 mRNA

NCBI chr10:16,755,508...16,765,275
Ensembl chr10:16,755,267...16,767,447

G

serine/threonine kinase 38

decreases expression

ISO

Azacitidine results in decreased expression of STK38 mRNA

NCBI chr20:7,035,923...7,070,657
Ensembl chr20:7,035,933...7,069,711

G

sulfatase 1

decreases expression

ISO

Azacitidine results in decreased expression of SULF1 mRNA

NCBI chr 5:11,145,950...11,308,622
Ensembl chr 5:11,145,950...11,308,643

G

sulfotransferase family 1C member 2A

increases expression

ISO

Azacitidine results in increased expression of SULT1C2 mRNA

NCBI chr 9:7,075,873...7,103,316
Ensembl chr 9:7,066,905...7,244,132

G

tyrosine aminotransferase

increases expression

ISO

Azacitidine results in increased expression of TAT mRNA

NCBI chr19:54,856,604...54,867,168
Ensembl chr19:54,856,563...54,867,482

G

TBC1 domain family, member 4

decreases expression

ISO

Azacitidine results in decreased expression of TBC1D4 mRNA

NCBI chr15:84,670,756...84,848,876
Ensembl chr15:84,670,756...84,848,693

G

transcription elongation factor A1

decreases expression

ISO

Azacitidine results in decreased expression of TCEA1 mRNA

NCBI chr 5:19,414,351...19,466,629
Ensembl chr15:12,831,339...12,834,156
Ensembl chr 5:12,831,339...12,834,156

G

tectonin beta-propeller repeat containing 2

increases expression

ISO

Azacitidine results in increased expression of TECPR2 mRNA

NCBI chr 6:135,720,765...135,823,187
Ensembl chr 6:135,720,656...135,823,187

G

TEK receptor tyrosine kinase

increases expression

EXP

Azacitidine results in increased expression of TEK mRNA

NCBI chr 5:114,722,815...114,849,535
Ensembl chr 5:114,723,006...114,849,991

G

telomerase reverse transcriptase

decreases expression
multiple interactions
decreases methylation
decreases activity

ISO

Azacitidine analog results in decreased expression of TERT mRNA; Azacitidine results in decreased expression of TERT mRNA
E2F1 protein affects the reaction [Azacitidine results in decreased activity of TERT protein]; E2F1 protein affects the reaction [Azacitidine results in decreased expression of TERT mRNA]; MYC protein affects the reaction [Azacitidine results in decreased activity of TERT protein]; MYC protein affects the reaction [Azacitidine results in decreased expression of TERT mRNA]
Azacitidine results in decreased methylation of TERT promoter

PMID:18045574 PMID:19451745

NCBI chr 1:31,465,766...31,488,650
Ensembl chr 1:31,466,056...31,488,111

G

transcription factor binding to IGHM enhancer 3

increases expression

ISO

Azacitidine results in increased expression of TFE3 mRNA

NCBI chr X:17,401,466...17,414,829
Ensembl chr X:17,401,466...17,414,685

G

transforming growth factor, beta 1

multiple interactions

ISO

[Azacitidine co-treated with TGFB1 protein] results in increased expression of FOXP3 protein
Azacitidine inhibits the reaction [TGFB1 protein results in decreased expression of PTEN mRNA]; Azacitidine inhibits the reaction [TGFB1 protein results in decreased expression of PTEN protein]; Azacitidine inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; Azacitidine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]; Azacitidine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein]; Azacitidine inhibits the reaction [TGFB1 protein results in increased methylation of PTEN promoter]; Azacitidine inhibits the reaction [TGFB1 protein results in increased phosphorylation of AKT1 protein]

PMID:18493985 PMID:22841775

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899

G

THUMP domain containing 1

increases expression

ISO

Azacitidine results in increased expression of THUMPD1 mRNA

NCBI chr 1:183,510,242...183,516,282
Ensembl chr 1:183,431,657...183,516,282

G

TIMP metallopeptidase inhibitor 1

increases expression

ISO

Azacitidine results in increased expression of TIMP1 mRNA

NCBI chr X:3,766,509...3,772,578
Ensembl chr X:3,766,510...3,771,135

G

tight junction protein 1

increases expression

ISO

Azacitidine results in increased expression of TJP1 mRNA

NCBI chr 1:128,260,330...128,505,018
Ensembl chr 1:128,260,330...128,505,158

G

transmembrane p24 trafficking protein 3

increases expression

ISO

Azacitidine results in increased expression of TMED3 mRNA

NCBI chr 8:99,121,361...99,129,653
Ensembl chr 8:99,121,361...99,129,215

G

thymopoietin

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of TMPO mRNA

NCBI chr 7:27,529,977...27,554,980
Ensembl chr 7:27,529,978...27,554,937

G

tenascin C

decreases expression

ISO

Azacitidine results in decreased expression of TNC mRNA

NCBI chr 5:82,391,340...82,476,197
Ensembl chr 5:82,391,340...82,476,131

G

tumor necrosis factor

increases expression
increases response to substance

EXP
ISO

Azacitidine results in increased expression of TNF mRNA
Azacitidine results in increased susceptibility to TNF protein

PMID:17156202 PMID:18829727

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

TNF superfamily member 10

increases response to substance

ISO

Azacitidine results in increased susceptibility to TNFSF10 protein

NCBI chr 2:112,136,550...112,155,903

G

troponin I3, cardiac type

increases expression

EXP

Azacitidine results in increased expression of TNNI3 protein

NCBI chr 1:78,342,571...78,346,255
Ensembl chr 1:78,342,592...78,346,253

G

troponin T2, cardiac type

increases expression

EXP

Azacitidine results in increased expression of TNNT2 protein

NCBI chr13:49,819,123...49,837,125
Ensembl chr13:49,822,304...49,837,125

G

DNA topoisomerase II alpha

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of TOP2A mRNA; [Curcumin co-treated with Azacitidine] results in decreased expression of TOP2A mRNA

PMID:18348204 PMID:18720364

NCBI chr10:84,441,954...84,473,093
Ensembl chr10:84,441,954...84,473,366

G

tumor protein p53

affects activity
increases expression

ISO
EXP

Azacitidine affects the activity of TP53 protein
Azacitidine results in increased expression of TP53 mRNA; Azacitidine results in increased expression of TP53 protein

PMID:16427046 PMID:35435491

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299

G

tumor protein p73

multiple interactions

ISO

TP73 protein promotes the reaction [Azacitidine results in increased expression of HMGA2 mRNA]; TP73 protein promotes the reaction [Azacitidine results in increased expression of KLF6 mRNA]; TP73 protein promotes the reaction [Azacitidine results in increased expression of NIBAN1 mRNA]

NCBI chr 5:169,903,801...169,988,075
Ensembl chr 5:169,903,801...169,963,552

G

tumor protein D52

increases expression

EXP

Azacitidine results in increased expression of TPD52 mRNA

NCBI chr 2:94,642,514...94,723,442
Ensembl chr 2:94,642,585...94,724,241

G

tropomyosin 2

increases expression

ISO

Azacitidine results in increased expression of TPM2 mRNA

NCBI chr 5:62,566,712...62,576,066
Ensembl chr 5:62,566,652...62,575,726

G

thyroid peroxidase

increases expression

ISO

Azacitidine results in increased expression of TPO mRNA

NCBI chr 6:52,425,998...52,495,793
Ensembl chr 6:52,426,010...52,495,793

G

tryptase gamma 1

decreases expression

ISO

Azacitidine results in decreased expression of TPSG1 mRNA

NCBI chr10:14,889,838...14,895,605
Ensembl chr10:14,890,734...14,894,786

G

thyrotropin releasing hormone

decreases expression

ISO

Azacitidine results in decreased expression of TRH mRNA

NCBI chr 4:126,299,236...126,301,762
Ensembl chr 4:126,299,236...126,301,762

G

tribbles pseudokinase 1

decreases expression

ISO

Azacitidine results in decreased expression of TRIB1 mRNA

NCBI chr 7:93,096,001...93,102,547
Ensembl chr 7:93,095,973...93,117,480

G

tripartite motif-containing 8

increases expression

ISO

Azacitidine results in increased expression of TRIM8 mRNA

NCBI chr 1:255,311,039...255,325,937
Ensembl chr 1:255,310,457...255,325,937

G

TSC complex subunit 1

multiple interactions

ISO

[Azacitidine affects the methylation of TSC1 promoter] which affects the expression of TSC1 mRNA

NCBI chr 3:32,367,434...32,416,565
Ensembl chr 3:32,367,670...32,416,568

G

TSC complex subunit 2

decreases methylation
multiple interactions
increases expression

ISO

Azacitidine results in decreased methylation of TSC2 promoter
[Azacitidine affects the methylation of TSC2 promoter] which affects the expression of TSC2 mRNA
Azacitidine results in increased expression of TSC2 mRNA

PMID:18538015 PMID:19250671

NCBI chr10:14,125,679...14,160,317
Ensembl chr10:14,125,680...14,160,600

G

thyroid stimulating hormone receptor

increases expression

ISO

Azacitidine results in increased expression of TSHR mRNA

NCBI chr 6:116,072,321...116,206,009
Ensembl chr 6:116,072,281...116,206,010

G

tetraspanin 32

decreases expression

ISO

Azacitidine results in decreased expression of TSPAN32 mRNA

NCBI chr 1:207,619,566...207,633,885
Ensembl chr 1:207,619,567...207,656,946

G

Ttk protein kinase

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of TTK mRNA

NCBI chr 8:93,632,678...93,672,664
Ensembl chr 8:93,634,319...93,672,664

G

ubiquitin-conjugating enzyme E2C

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of UBE2C mRNA

NCBI chr 3:173,925,975...173,928,375
Ensembl chr 3:173,925,934...173,932,678

G

U2AF homology motif kinase 1

increases expression

ISO

Azacitidine results in increased expression of UHMK1 mRNA

NCBI chr13:84,929,418...84,949,194
Ensembl chr13:84,922,829...84,949,061

G

usherin

increases expression

ISO

Azacitidine results in increased expression of USH2A mRNA

NCBI chr13:102,368,783...103,035,230
Ensembl chr13:102,368,783...103,035,217

G

USH1 protein network component harmonin binding protein 1

decreases expression

ISO

Azacitidine results in decreased expression of USHBP1 mRNA

NCBI chr16:18,091,311...18,101,927
Ensembl chr16:18,091,316...18,101,867

G

vimentin

decreases expression
increases expression
multiple interactions

EXP
ISO

Azacitidine results in decreased expression of VIM protein
Azacitidine results in increased expression of VIM mRNA; Azacitidine results in increased expression of VIM protein
[Azacitidine co-treated with Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of VIM protein

PMID:17105402 PMID:20823114

NCBI chr17:81,577,261...81,585,746
Ensembl chr17:81,568,272...81,585,746

G

WD repeat domain 47

decreases expression

ISO

Azacitidine results in decreased expression of WDR47 mRNA

NCBI chr 2:198,914,977...198,975,844
Ensembl chr 2:198,914,940...198,975,841

G

Wnt family member 10B

increases expression

EXP

Azacitidine results in increased expression of WNT10B mRNA

NCBI chr 7:131,801,046...131,806,850
Ensembl chr 7:131,801,046...131,806,850

G

Wnt family member 5A

increases expression

ISO

Azacitidine results in increased expression of WNT5A mRNA

NCBI chr16:3,702,300...3,724,860
Ensembl chr16:3,703,665...3,724,860

G

WW domain containing transcription regulator 1

increases expression

ISO

Azacitidine results in increased expression of WWTR1 mRNA

NCBI chr 2:143,801,181...143,916,941
Ensembl chr 2:143,801,181...143,991,950

G

XIAP associated factor 1

decreases expression
decreases methylation
increases expression

ISO

Azacitidine results in decreased expression of XAF1 mRNA alternative form
Azacitidine results in decreased methylation of XAF1 promoter
Azacitidine results in increased expression of XAF1 mRNA; Azacitidine results in increased expression of XAF1 protein

PMID:19077051 PMID:19549372

NCBI chr10:57,415,935...57,428,348
Ensembl chr10:57,415,658...57,428,349

G

zinc finger protein 189

decreases expression

ISO

Azacitidine results in decreased expression of ZNF189 mRNA

NCBI chr 5:68,668,225...68,679,606
Ensembl chr 5:68,668,244...68,679,812

G

zinc finger protein 64

affects methylation

ISO

Azacitidine affects the methylation of ZFP64 promoter

NCBI chr 3:178,085,604...178,114,557
Ensembl chr 3:178,085,605...178,114,557

G

zona pellucida glycoprotein 3

increases expression

ISO

Azacitidine results in increased expression of ZP3 mRNA

NCBI chr12:26,327,161...26,334,126
Ensembl chr12:26,327,161...26,334,126

acetoacetyl-CoA

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

hydroxysteroid (17-beta) dehydrogenase 2

affects binding

ISO

acetoacetyl CoA binds to HSD17B2 protein

NCBI chr19:62,662,320...62,733,944
Ensembl chr19:62,662,098...62,733,943

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP citrate lyase

increases abundance
affects abundance

ISO

ACLY protein results in increased abundance of Acetyl Coenzyme A
ACLY protein affects the abundance of Acetyl Coenzyme A

PMID:28077572 PMID:36933457

NCBI chr10:85,912,402...85,964,605
Ensembl chr10:85,912,402...85,963,631

G

amyloid beta precursor protein

affects localization
increases secretion
multiple interactions

ISO

APP protein affects the localization of Acetyl Coenzyme A
Acetyl Coenzyme A results in increased secretion of APP protein modified form
Acetyl Coenzyme A inhibits the reaction [Hydrogen Peroxide results in decreased secretion of APP protein modified form]
IL1B protein affects the reaction [APP protein affects the localization of Acetyl Coenzyme A]

PMID:16122837 PMID:22906069

NCBI chr11:37,506,207...37,724,351
Ensembl chr11:37,506,408...37,722,971

G

carnitine O-acetyltransferase

decreases activity

EXP

Acetyl Coenzyme A deficiency results in decreased activity of CRAT protein

NCBI chr 3:34,073,504...34,087,099
Ensembl chr 3:34,073,506...34,087,099

G

ERCC excision repair 6, chromatin remodeling factor

decreases abundance
multiple interactions

ISO

ERCC6 gene mutant form results in decreased abundance of Acetyl Coenzyme A
3-Hydroxybutyric Acid inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Acetyl Coenzyme A]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Acetyl Coenzyme A]

NCBI chr16:7,771,311...7,841,895
Ensembl chr16:7,771,581...7,841,895

G

glucose-6-phosphatase catalytic subunit 1

multiple interactions

ISO

[Fluoxetine results in decreased expression of G6PC1 protein] which results in increased abundance of Acetyl Coenzyme A

NCBI chr10:86,807,659...86,819,023
Ensembl chr10:86,757,899...86,818,033

G

interleukin 1 beta

multiple interactions

ISO

IL1B protein affects the reaction [APP protein affects the localization of Acetyl Coenzyme A]

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

lysine acetyltransferase 2B

affects binding

ISO

Acetyl Coenzyme A binds to KAT2B protein

NCBI chr 9:6,799,101...6,903,616
Ensembl chr 9:6,799,145...6,903,616

G

meteorin-like, glial cell differentiation regulator

multiple interactions

ISO

METRNL protein inhibits the reaction [Dietary Fats results in decreased abundance of Acetyl Coenzyme A]

NCBI chr10:107,462,148...107,476,143
Ensembl chr10:107,462,109...107,476,135

G

N-acetyltransferase 1

multiple interactions
affects binding

ISO

[NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; Acetyl Coenzyme A inhibits the reaction [Cyanamide results in decreased activity of NAT1 protein]; Acetyl Coenzyme A inhibits the reaction [Iodoacetamide results in decreased activity of NAT1 protein]
Acetyl Coenzyme A binds to NAT1 protein

PMID:20545351 PMID:22835378

NCBI chr16:26,984,882...27,005,194
Ensembl chr16:26,982,625...26,986,527

G

N-acetyltransferase 2

multiple interactions

ISO

[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]; [NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[SULT1A2 protein co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]

NCBI chr16:26,974,874...27,005,191
Ensembl chr16:26,974,601...26,976,304

G

NAD(P)H quinone dehydrogenase 1

multiple interactions

ISO

[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]; [NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone

NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

enoyl-CoA hydratase, short chain 1

increases abundance

ISO

ECHS1 gene mutant form results in increased abundance of acryloyl-coenzyme A

NCBI chr 1:204,324,679...204,333,506
Ensembl chr 1:204,324,682...204,333,506

G

3-hydroxyisobutyryl-CoA hydrolase

increases abundance

ISO

HIBCH gene mutant form results in increased abundance of acryloyl-coenzyme A

NCBI chr 9:56,082,082...56,161,796
Ensembl chr 9:56,082,091...56,161,886

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adenosine deaminase

decreases metabolic processing
increases metabolic processing

ISO

ADA alternative form results in decreased metabolism of Adenosine
ADA protein results in increased metabolism of Adenosine

NCBI chr 3:172,818,174...172,842,283
Ensembl chr 3:172,818,176...172,842,293

G

adenosine A1 receptor

multiple interactions
affects binding

ISO
EXP

Adenosine analog binds to and affects the activity of ADORA1 protein; Adenosine analog binds to and results in decreased activity of ADORA1 protein; PD 81723 affects the reaction [Adenosine analog binds to and affects the activity of ADORA1 protein]; VUF 5455 affects the reaction [Adenosine analog binds to and affects the activity of ADORA1 protein]
[lead acetate results in increased expression of ADORA1 protein] which results in increased abundance of Adenosine; Adenosine analog binds to and results in increased activity of ADORA1 protein
Adenosine binds to ADORA1 protein

PMID:10649980 PMID:11520205 PMID:18404447 PMID:20571079 PMID:20932874

NCBI chr13:48,210,922...48,247,826
Ensembl chr13:48,213,273...48,247,190

G

adenosine A2a receptor

multiple interactions
affects binding

ISO

Adenosine analog binds to and results in decreased activity of ADORA2A protein; Adenosine promotes the reaction [Lipopolysaccharides results in increased expression of ADORA2A mRNA]
Adenosine binds to ADORA2A protein

PMID:18404447 PMID:20067761

NCBI chr20:13,315,270...13,332,802
Ensembl chr20:13,315,270...13,332,802

G

adenosine A2B receptor

affects response to substance

ISO

ADORA2B protein affects the susceptibility to Adenosine

NCBI chr10:47,439,712...47,456,092
Ensembl chr10:47,439,701...47,456,091

G

adenosine A3 receptor

multiple interactions
increases expression
affects binding

ISO

Adenosine analog binds to and affects the activity of ADORA3 protein; Adenosine analog binds to and results in decreased activity of ADORA3 protein; Adenosine analog binds to and results in increased activity of ADORA3 protein; PD 81723 affects the reaction [Adenosine analog binds to and affects the activity of ADORA3 protein]; VUF 5455 affects the reaction [Adenosine analog binds to and affects the activity of ADORA3 protein]
Adenosine results in increased expression of ADORA3 mRNA
Adenosine binds to ADORA3 protein

PMID:11520205 PMID:18404447 PMID:20067761 PMID:20571079

NCBI chr 2:196,077,042...196,080,686
Ensembl chr 2:196,077,042...196,080,686

G

alkaline phosphatase, intestinal

multiple interactions

ISO

Adenosine inhibits the reaction [Methotrexate results in increased activity of ALPI protein]

NCBI chr 9:95,221,314...95,224,780
Ensembl chr 9:95,221,314...95,224,780

G

adenosine monophosphate deaminase 2

multiple interactions

ISO

[tofacitinib results in decreased expression of AMPD2 protein] which affects the abundance of Adenosine

NCBI chr 2:198,395,767...198,408,514
Ensembl chr 2:198,395,768...198,408,796

G

BCL2 associated X, apoptosis regulator

increases localization
multiple interactions

ISO

Adenosine results in increased localization of BAX protein
Thymidine inhibits the reaction [Adenosine results in increased localization of BAX protein]

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

Bcl2-like 1

decreases expression
multiple interactions

ISO

Adenosine results in decreased expression of BCL2L1 mRNA; Adenosine results in decreased expression of BCL2L1 protein
Dipyridamole inhibits the reaction [Adenosine results in decreased expression of BCL2L1 mRNA]; Dipyridamole inhibits the reaction [Adenosine results in decreased expression of BCL2L1 protein]

NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907
Ensembl chr 1:161,745,540...161,764,907

G

baculoviral IAP repeat-containing 2

decreases expression

ISO

Adenosine results in decreased expression of BIRC2 mRNA; Adenosine results in decreased expression of BIRC2 protein

NCBI chr 8:13,253,697...13,273,672
Ensembl chr 8:13,253,706...13,271,911

G

baculoviral IAP repeat-containing 3

decreases expression

ISO

Adenosine results in decreased expression of BIRC3 mRNA

NCBI chr 8:13,285,702...13,313,329
Ensembl chr 8:13,285,703...13,298,590

G

bone morphogenetic protein 2

increases expression

ISO

Adenosine results in increased expression of BMP2 mRNA

NCBI chr 3:141,264,648...141,275,416
Ensembl chr 3:141,264,646...141,274,760

G

bone morphogenetic protein 4

increases expression
multiple interactions

ISO

Adenosine results in increased expression of BMP4 mRNA
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Adenosine results in increased expression of BMP4 mRNA]; PSB603 inhibits the reaction [Adenosine results in increased expression of BMP4 mRNA]; ZM 241385 inhibits the reaction [Adenosine results in increased expression of BMP4 mRNA]

NCBI chr15:22,098,191...22,113,145
Ensembl chr15:22,098,470...22,105,172

G

bone morphogenetic protein receptor type 1A

increases expression

ISO

Adenosine results in increased expression of BMPR1A mRNA

NCBI chr16:9,740,751...9,786,861
Ensembl chr16:9,742,875...9,786,861

G

caspase 3

multiple interactions
increases activity

ISO
EXP

Dipyridamole inhibits the reaction [Adenosine results in increased activity of CASP3 protein]; Thymidine inhibits the reaction [Adenosine results in increased activity of CASP3 protein]

PMID:11570579 PMID:16469385 PMID:17303086 PMID:20063052

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caspase 8

increases activity
multiple interactions

ISO
EXP

Adenosine results in increased activity of CASP8 protein
Dipyridamole inhibits the reaction [Adenosine results in increased activity of CASP8 protein]

PMID:16469385 PMID:17303086

NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699

G

caspase 9

increases activity
multiple interactions

ISO
EXP

Adenosine results in increased activity of CASP9 protein
Thymidine inhibits the reaction [Adenosine results in increased activity of CASP9 protein]

PMID:11570579 PMID:16469385

Ensembl chr 5:159,391,188...159,409,648

G

cyclin B1

affects expression

EXP

Adenosine affects the expression of CCNB1 protein

NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:33,646,252...33,655,225

G

cyclin D1

increases expression

ISO
EXP

Adenosine results in increased expression of CCND1 mRNA
Adenosine results in increased expression of CCND1 protein

PMID:19638569 PMID:34070360

NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810

G

cyclin E1

increases expression

EXP

Adenosine results in increased expression of CCNE1 protein

NCBI chr 1:99,918,672...99,927,986
Ensembl chr 1:99,918,674...99,927,822

G

CD14 molecule

increases expression

ISO

Adenosine results in increased expression of CD14 mRNA

NCBI chr18:28,609,558...28,611,409
Ensembl chr18:28,608,883...28,611,292

G

CASP8 and FADD-like apoptosis regulator

decreases expression
multiple interactions

ISO

Adenosine results in decreased expression of CFLAR mRNA; Adenosine results in decreased expression of CFLAR mRNA alternative form; Adenosine results in decreased expression of CFLAR protein
Dipyridamole inhibits the reaction [Adenosine results in decreased expression of CFLAR mRNA alternative form]; Dipyridamole inhibits the reaction [Adenosine results in decreased expression of CFLAR mRNA]; Dipyridamole inhibits the reaction [Adenosine results in decreased expression of CFLAR protein]

NCBI chr 9:67,679,502...67,747,226
Ensembl chr 9:67,679,559...67,726,434

G

CF transmembrane conductance regulator

increases activity
multiple interactions

ISO

Adenosine results in increased activity of CFTR protein
[Isoproterenol co-treated with Adenosine] results in increased activity of CFTR protein

NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:47,526,735...47,694,643

G

cAMP responsive element binding protein 1

increases expression
multiple interactions

ISO

Adenosine results in increased expression of CREB1 mRNA
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Adenosine results in increased expression of CREB1 mRNA]; PSB603 inhibits the reaction [Adenosine results in increased expression of CREB1 mRNA]; ZM 241385 inhibits the reaction [Adenosine results in increased expression of CREB1 mRNA]

NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:73,397,306...73,466,339

G

catenin beta 1

increases expression

ISO

Adenosine results in increased expression of CTNNB1 mRNA

NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:129,517,545...129,544,662

G

diablo, IAP-binding mitochondrial protein

increases expression
multiple interactions

ISO

Adenosine results in increased expression of DIABLO mRNA; Adenosine results in increased expression of DIABLO protein
Dipyridamole inhibits the reaction [Adenosine results in increased expression of DIABLO mRNA]; Dipyridamole inhibits the reaction [Adenosine results in increased expression of DIABLO protein]

NCBI chr12:38,716,668...38,731,285
Ensembl chr12:38,716,668...38,731,265

G

dickkopf WNT signaling pathway inhibitor 1

increases expression

ISO

Adenosine results in increased expression of DKK1 mRNA

NCBI chr 1:237,794,969...237,798,650
Ensembl chr 1:237,794,969...237,798,650

G

dipeptidylpeptidase 4

decreases expression
multiple interactions

ISO

Adenosine results in decreased expression of DPP4 mRNA; Adenosine results in decreased expression of DPP4 protein
[Adenosine results in decreased phosphorylation of MAPK1 protein] which results in decreased expression of DPP4 mRNA; [Adenosine results in decreased phosphorylation of MAPK1 protein] which results in decreased expression of DPP4 protein; [Adenosine results in decreased phosphorylation of MAPK3 protein] which results in decreased expression of DPP4 mRNA; [Adenosine results in decreased phosphorylation of MAPK3 protein] which results in decreased expression of DPP4 protein

NCBI chr 3:67,370,794...67,452,422
Ensembl chr 3:67,370,804...67,452,422

G

E2F transcription factor 1

affects expression

EXP

Adenosine affects the expression of E2F1 protein

NCBI chr 3:163,524,739...163,535,563
Ensembl chr 3:163,524,739...163,535,563

G

E2F transcription factor 3

affects expression

EXP

Adenosine affects the expression of E2F3 protein

NCBI chr17:34,810,355...34,887,725
Ensembl chr17:34,809,998...34,887,725

G

epidermal growth factor

increases expression
multiple interactions

ISO

Adenosine results in increased expression of EGF mRNA
Adenosine results in increased expression of and results in increased secretion of EGF protein

NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:220,893,660...220,976,297

G

estrogen receptor 1

increases expression

ISO

Adenosine results in increased expression of ESR1 protein

NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354

G

estrogen receptor 2

increases expression

ISO

Adenosine results in increased expression of ESR2 protein

NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:100,545,206...100,644,709

G

Fas associated via death domain

decreases expression
multiple interactions

ISO

Adenosine results in decreased expression of FADD mRNA
Dipyridamole inhibits the reaction [Adenosine results in decreased expression of FADD mRNA]

NCBI chr 1:209,169,245...209,175,423
Ensembl chr 1:209,169,318...209,174,976

G

Fas ligand

increases expression
multiple interactions

ISO

Adenosine results in increased expression of FASLG protein
[Adenosine co-treated with Coformycin] results in decreased expression of FASL mRNA

PMID:11992407 PMID:16419169

NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503

G

fibroblast growth factor 6

multiple interactions

ISO

Adenosine results in increased expression of and results in increased secretion of FGF6 protein

NCBI chr 4:161,541,089...161,549,624
Ensembl chr 4:161,541,089...161,553,521

G

follicle stimulating hormone subunit beta

increases expression

ISO

Adenosine results in increased expression of FSHB protein

NCBI chr 3:114,003,262...114,007,072
Ensembl chr 3:114,003,262...114,007,072

G

frizzled class receptor 3

increases expression

ISO

Adenosine results in increased expression of FZD3 mRNA

NCBI chr15:43,596,962...43,664,047
Ensembl chr15:43,596,965...43,663,960

G

frizzled class receptor 5

increases expression

ISO

Adenosine results in increased expression of FZD5 mRNA

NCBI chr 9:73,606,860...73,614,039
Ensembl chr 9:73,606,860...73,618,612

G

glial cell derived neurotrophic factor

increases secretion

ISO

Adenosine results in increased secretion of GDNF protein

NCBI chr 2:58,621,327...58,647,242
Ensembl chr 2:58,621,327...58,647,240

G

glycogen synthase kinase 3 beta

increases phosphorylation
increases expression

ISO

Adenosine results in increased phosphorylation of GSK3B protein
Adenosine results in increased expression of GSK3B mRNA

NCBI chr11:76,004,502...76,154,665
Ensembl chr11:76,009,507...76,153,249

G

granzyme B

multiple interactions

ISO

[Adenosine co-treated with Coformycin] results in decreased expression of GZMB mRNA

NCBI chr15:34,459,007...34,462,469
Ensembl chr15:34,459,007...34,462,469

G

H2A.X variant histone

multiple interactions

ISO

Adenosine promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]

NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079

G

hepatocyte growth factor

affects expression

EXP

Adenosine affects the expression of HGF protein

NCBI chr 4:19,628,902...19,700,467
Ensembl chr 4:19,632,267...19,700,851

G

hypoxia inducible factor 1 subunit alpha

increases expression

ISO

Adenosine results in increased expression of HIF1A mRNA

NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323

G

isocitrate dehydrogenase (NADP(+)) 2

increases abundance
multiple interactions

ISO

IDH2 protein mutant form results in increased abundance of Adenosine
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Adenosine]

NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:143,439,323...143,467,248

G

interferon gamma

multiple interactions

ISO

[Adenosine co-treated with Coformycin] results in decreased expression of IFNG protein

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216

G

insulin-like growth factor 1

affects expression
multiple interactions

ISO

Adenosine affects the expression of IGF1 mRNA
Adenosine results in increased expression of and results in increased secretion of IGF1 protein

NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:24,130,137...24,246,764

G

insulin-like growth factor 2

multiple interactions

ISO

Adenosine results in increased expression of and results in increased secretion of IGF2 protein

NCBI chr 1:207,243,873...207,261,263
Ensembl chr 1:207,243,873...207,260,667

G

interleukin 10

multiple interactions
increases expression

ISO

Adenosine promotes the reaction [Lipopolysaccharides results in increased secretion of IL10 protein]
Adenosine results in increased expression of IL10 mRNA; Adenosine results in increased expression of IL10 protein

NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580

G

interleukin 12B

decreases expression
multiple interactions

ISO

Adenosine results in decreased expression of IL12B protein
Adenosine inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein]

NCBI chr10:29,390,300...29,405,194
Ensembl chr10:29,389,905...29,405,194

G

interleukin 1 beta

multiple interactions

EXP

Adenosine inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide]; Adenosine inhibits the reaction [IL1B protein results in increased expression of IL1R1]; Adenosine inhibits the reaction [IL1B protein results in increased expression of NOS2 mRNA]; Adenosine inhibits the reaction [IL1B protein results in increased expression of NOS2 protein]

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 1 receptor type 1

multiple interactions

EXP

Adenosine inhibits the reaction [IL1B protein results in increased expression of IL1R1]

NCBI chr 9:50,000,558...50,076,579
Ensembl chr 9:50,000,566...50,076,579

G

interleukin 2

multiple interactions

ISO

[Adenosine co-treated with Coformycin] results in decreased expression of IL2 protein

NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:121,932,968...121,937,672

G

lymphoid enhancer binding factor 1

increases expression

ISO

Adenosine results in increased expression of LEF1 mRNA

NCBI chr 2:222,340,541...222,453,931
Ensembl chr 2:222,340,704...222,453,929

G

lymphocyte antigen 96

increases expression

ISO

Adenosine results in increased expression of LY96 mRNA

NCBI chr 5:7,365,536...7,397,864
Ensembl chr 5:7,365,557...7,395,816

G

mitogen activated protein kinase kinase 1

increases phosphorylation

ISO

Adenosine results in increased phosphorylation of MAP2K1 protein

NCBI chr 8:73,578,747...73,650,184
Ensembl chr 8:73,578,752...73,650,184

G

mitogen activated protein kinase kinase 2

increases phosphorylation

ISO

Adenosine results in increased phosphorylation of MAP2K2 protein

NCBI chr 7:9,241,449...9,264,216
Ensembl chr 7:9,241,310...9,260,940

G

mitogen activated protein kinase 1

multiple interactions
decreases phosphorylation

ISO

[Adenosine results in decreased phosphorylation of MAPK1 protein] which results in decreased expression of DPP4 mRNA; [Adenosine results in decreased phosphorylation of MAPK1 protein] which results in decreased expression of DPP4 protein

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 3

decreases phosphorylation
multiple interactions

ISO

Adenosine results in decreased phosphorylation of MAPK3 protein
[Adenosine results in decreased phosphorylation of MAPK3 protein] which results in decreased expression of DPP4 mRNA; [Adenosine results in decreased phosphorylation of MAPK3 protein] which results in decreased expression of DPP4 protein

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

MET proto-oncogene, receptor tyrosine kinase

increases expression

EXP

Adenosine results in increased expression of MET protein

NCBI chr 4:46,756,823...46,864,041
Ensembl chr 4:46,756,506...46,870,821

G

marker of proliferation Ki-67

affects expression
increases expression

ISO
EXP

Adenosine affects the expression of MKI67 mRNA
Adenosine results in increased expression of MKI67 protein

PMID:19638569 PMID:34070360

NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:199,926,150...199,952,593

G

mechanistic target of rapamycin kinase

increases phosphorylation

ISO

Adenosine results in increased phosphorylation of MTOR protein

NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435

G

MYC proto-oncogene, bHLH transcription factor

decreases expression
increases expression
multiple interactions

ISO
EXP

Adenosine results in decreased expression of MYC protein
Adenosine results in increased expression of MYC protein
Adenosine results in increased expression of MYC mRNA
Thymidine inhibits the reaction [Adenosine results in decreased expression of MYC protein]; Uridine inhibits the reaction [Adenosine results in decreased expression of MYC protein]

PMID:9808420 PMID:19638569 PMID:34070360

NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028

G

NFKB inhibitor alpha

multiple interactions

ISO

[Adenosine co-treated with Homocysteine] affects the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]; [Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of NFKBIA mRNA]; [Adenosine co-treated with Homocysteine] results in decreased expression of NFKBIA mRNA

NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072

G

nitric oxide synthase 2

decreases stability
multiple interactions

EXP

Adenosine results in decreased stability of NOS2 mRNA
Adenosine inhibits the reaction [IL1B protein results in increased expression of NOS2 mRNA]; Adenosine inhibits the reaction [IL1B protein results in increased expression of NOS2 protein]

NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880

G

5' nucleotidase, ecto

multiple interactions

ISO

[alpha,beta-methyleneadenosine 5'-diphosphate results in decreased activity of NT5E protein] inhibits the reaction [Oxygen deficiency results in increased abundance of Adenosine]

NCBI chr 8:98,150,925...98,195,646
Ensembl chr 8:98,150,900...98,195,645

G

proliferating cell nuclear antigen

increases expression

EXP

Adenosine results in increased expression of PCNA protein

NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901

G

placental growth factor

increases secretion

ISO

Adenosine results in increased secretion of PGF protein

NCBI chr 6:110,547,165...110,557,747
Ensembl chr 6:110,547,153...110,557,747

G

PPARG coactivator 1 alpha

increases expression

ISO

Adenosine results in increased expression of PPARGC1A mRNA

NCBI chr14:63,073,505...63,729,215
Ensembl chr14:63,273,189...63,729,213

G

perforin 1

multiple interactions

ISO

[Adenosine co-treated with Coformycin] results in decreased expression of PRF1 mRNA

NCBI chr20:29,789,040...29,794,550
Ensembl chr20:29,788,972...29,795,124

G

prostaglandin D2 receptor

multiple interactions

ISO

[Prostaglandin D2 results in increased activity of PTGDR protein] which results in increased metabolism of Adenosine; [Prostaglandin D2 results in increased activity of PTGDR protein] which results in increased secretion of Adenosine

NCBI chr15:19,790,499...19,797,873
Ensembl chr15:19,790,499...19,797,873

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

ISO

[Adenosine co-treated with Homocysteine] affects the reaction [TNF protein affects the localization of RELA protein modified form]; [Adenosine co-treated with Homocysteine] affects the reaction [TNF protein results in increased phosphorylation of RELA protein]

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

renin

decreases secretion

EXP

Adenosine results in decreased secretion of REN protein

NCBI chr13:47,348,312...47,359,539
Ensembl chr13:47,348,143...47,359,543

G

receptor interacting serine/threonine kinase 1

multiple interactions

ISO

[Adenosine co-treated with Homocysteine co-treated with TNF protein] results in increased cleavage of RIPK1 protein

NCBI chr17:31,044,983...31,077,167
Ensembl chr17:31,044,994...31,077,167

G

ribosomal protein S6 kinase B1

increases phosphorylation

ISO

Adenosine results in increased phosphorylation of RPS6KB1 protein

NCBI chr10:71,817,794...71,865,211
Ensembl chr10:71,815,614...71,865,238

G

solute carrier family 28 member 1

affects transport
multiple interactions

ISO

SLC28A1 protein affects the transport of Adenosine
Adenosine inhibits the reaction [SLC28A1 protein results in increased uptake of Uridine]

NCBI chr 1:144,490,453...144,532,025
Ensembl chr 1:144,490,623...144,531,544

G

solute carrier family 28 member 2

increases transport

ISO

SLC28A2 protein results in increased transport of Adenosine

NCBI chr 3:129,778,425...129,841,292
Ensembl chr 3:129,807,537...129,841,291

G

solute carrier family 29 member 1

multiple interactions
increases uptake
affects abundance

ISO
EXP

4-nitrobenzylthioinosine inhibits the reaction [SLC29A1 protein alternative form results in increased uptake of Adenosine]; 4-nitrobenzylthioinosine inhibits the reaction [SLC29A1 protein results in increased uptake of Adenosine]; [4-nitrobenzylthioinosine results in decreased activity of SLC29A1 protein] inhibits the reaction [Oxygen deficiency results in increased abundance of Adenosine]; [SLC29A1 co-treated with Oxygen deficiency] affects the abundance of Adenosine; Dipyridamole inhibits the reaction [SLC29A1 protein alternative form results in increased uptake of Adenosine]; Dipyridamole inhibits the reaction [SLC29A1 protein results in increased uptake of Adenosine]; Dipyridamole promotes the reaction [[SLC29A1 co-treated with Oxygen deficiency] affects the abundance of Adenosine]
SLC29A1 protein alternative form results in increased uptake of Adenosine; SLC29A1 protein results in increased uptake of Adenosine
cilostazol inhibits the reaction [SLC29A1 protein results in increased uptake of Adenosine]; Dipyridamole inhibits the reaction [SLC29A1 protein results in increased uptake of Adenosine]; draflazine inhibits the reaction [SLC29A1 protein results in increased uptake of Adenosine]; Ethanol promotes the reaction [SLC29A1 protein alternative form results in increased uptake of Adenosine]; Ethanol promotes the reaction [SLC29A1 protein results in increased uptake of Adenosine]; Ticagrelor inhibits the reaction [SLC29A1 protein results in increased uptake of Adenosine]
Adenosine inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine]
SLC29A1 affects the abundance of Adenosine

PMID:9353301 PMID:9396714 PMID:11179696 PMID:21283641 PMID:21872611 More...

NCBI chr 9:22,897,099...22,911,640
Ensembl chr 9:22,902,471...22,914,620

G

solute carrier family 29 member 2

increases uptake

ISO

SLC29A2 protein results in increased uptake of Adenosine

NCBI chr 1:211,756,588...211,764,561
Ensembl chr 1:211,757,000...211,764,560

G

solute carrier family 29 member 3

affects transport

ISO

SLC29A3 protein affects the transport of Adenosine

NCBI chr20:29,191,086...29,228,299
Ensembl chr20:29,191,127...29,228,299

G

solute carrier family 5 member 5

increases expression

EXP

Adenosine results in increased expression of SLC5A5 mRNA; Adenosine results in increased expression of SLC5A5 protein

NCBI chr16:18,580,705...18,590,692
Ensembl chr16:18,580,705...18,590,691

G

transforming growth factor alpha

increases secretion

ISO

Adenosine results in increased secretion of TGFA protein

NCBI chr 4:120,175,549...120,258,342
Ensembl chr 4:120,175,593...120,258,339

G

transforming growth factor, beta 1

increases expression

ISO

Adenosine results in increased expression of TGFB1 mRNA; Adenosine results in increased expression of TGFB1 protein

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899

G

transforming growth factor, beta 2

increases expression
multiple interactions

ISO

Adenosine results in increased expression of TGFB2 mRNA
Adenosine results in increased expression of and results in increased secretion of TGFB2 protein

NCBI chr13:100,691,540...100,793,227
Ensembl chr13:100,692,953...100,792,856

G

toll-like receptor 4

increases expression
affects localization
multiple interactions

ISO

Adenosine results in increased expression of TLR4 mRNA
Adenosine affects the localization of TLR4 protein
Adenosine promotes the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of TLR4 protein]

NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:85,161,192...85,175,007

G

tumor necrosis factor

multiple interactions
decreases expression

ISO

5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine inhibits the reaction [Adenosine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]]; [Adenosine co-treated with Homocysteine co-treated with TNF protein] results in increased cleavage of RIPK1 protein; [Adenosine co-treated with Homocysteine] affects the reaction [TNF protein affects the localization of RELA protein modified form]; [Adenosine co-treated with Homocysteine] affects the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]; [Adenosine co-treated with Homocysteine] affects the reaction [TNF protein results in increased phosphorylation of RELA protein]; [Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of CXCL8 mRNA]; [Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of NFKBIA mRNA]; [Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of TNFAIP3 mRNA]; [Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of TNFAIP3 protein]; [Adenosine co-treated with Homocysteine] results in increased susceptibility to TNF protein; Adenosine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF mRNA]; Adenosine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]; ZM 241385 inhibits the reaction [Adenosine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]]
Adenosine results in decreased expression of TNF protein

PMID:11023991 PMID:21538184 PMID:24224954

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

TNF alpha induced protein 3

multiple interactions

ISO

[Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of TNFAIP3 mRNA]; [Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of TNFAIP3 protein]; [Adenosine co-treated with Homocysteine] results in decreased expression of TNFAIP3 mRNA; [Adenosine co-treated with Homocysteine] results in decreased expression of TNFAIP3 protein

NCBI chr 1:15,528,921...15,543,993
Ensembl chr 1:15,528,921...15,543,979

G

TNF superfamily member 10

multiple interactions

ISO

[Adenosine co-treated with Coformycin] results in decreased expression of TNFSF10 mRNA

NCBI chr 2:112,136,550...112,155,903

G

tumor protein p53 binding protein 1

multiple interactions

ISO

Adenosine promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]

NCBI chr 3:128,620,320...128,724,716
Ensembl chr 3:128,620,322...128,696,747

G

uridine phosphorylase 1

increases metabolic processing

ISO

UPP1 protein results in increased metabolism of Adenosine

NCBI chr14:88,023,155...88,043,036
Ensembl chr14:88,023,351...88,043,034

G

vascular endothelial growth factor A

multiple interactions
increases expression
increases secretion

ISO

Adenosine promotes the reaction [Dipyridamole results in increased secretion of VEGFA protein]; Adenosine results in increased expression of and results in increased secretion of VEGFA protein
Adenosine results in increased expression of VEGFA mRNA
Adenosine results in increased secretion of VEGFA protein

PMID:20067761 PMID:34070360

NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194

adenosine 3',5'-bismonophosphate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

sulfotransferase family 1A member 1

multiple interactions

EXP

Glutathione Disulfide affects the reaction [adenosine 3'-phosphate-5'-phosphate binds to SULT1A1 protein]; Glutathione Disulfide affects the reaction [Polychlorinated Biphenyls analog affects the reaction [adenosine 3'-phosphate-5'-phosphate binds to SULT1A1 protein]]; Polychlorinated Biphenyls analog affects the reaction [adenosine 3'-phosphate-5'-phosphate binds to SULT1A1 protein]

NCBI chr 1:190,702,592...190,706,112
Ensembl chr 1:190,702,592...190,706,131

G

sulfotransferase family 1E member 1

multiple interactions

ISO

[2,2',4,4'-tetrabromodiphenyl ether metabolite co-treated with adenosine 3'-phosphate-5'-phosphate] binds to SULT1E1 protein; [Estradiol co-treated with adenosine 3'-phosphate-5'-phosphate] binds to SULT1E1 protein; [tetrabromobisphenol A co-treated with adenosine 3'-phosphate-5'-phosphate] binds to SULT1E1 protein; Estradiol inhibits the reaction [[tetrabromobisphenol A co-treated with adenosine 3'-phosphate-5'-phosphate] binds to SULT1E1 protein]; tetrabromobisphenol A inhibits the reaction [[Estradiol co-treated with adenosine 3'-phosphate-5'-phosphate] binds to SULT1E1 protein]

NCBI chr14:20,700,444...20,718,719
Ensembl chr14:20,700,292...20,718,716

G

sulfotransferase family 2A member 1

affects binding
multiple interactions

ISO

adenosine 3'-phosphate-5'-phosphate binds to SULT2A1 protein
Benzoquinones analog inhibits the reaction [adenosine 3'-phosphate-5'-phosphate binds to SULT2A1 protein]; Dehydroepiandrosterone inhibits the reaction [Benzoquinones analog inhibits the reaction [adenosine 3'-phosphate-5'-phosphate binds to SULT2A1 protein]]

NCBI chr 1:84,582,011...84,639,001

adenosine 5'-(hexahydrogen pentaphosphate)

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

nudix hydrolase 11

multiple interactions

ISO

[NUDT11 protein results in increased metabolism of diadenosine 5',5''''-P1,P6-hexaphosphate] which results in increased chemical synthesis of adenosine 5'-pentaphosphate

NCBI chr X:18,998,587...19,005,208
Ensembl chr X:18,998,461...19,005,208

adenosine 5'-[gamma-thio]triphosphate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

Cd80 molecule

increases expression

ISO

adenosine 5'-O-(3-thiotriphosphate) results in increased expression of CD80 protein

NCBI chr11:75,760,073...75,798,978
Ensembl chr11:75,760,147...75,797,540

G

CD86 molecule

increases expression

ISO

adenosine 5'-O-(3-thiotriphosphate) results in increased expression of CD86 protein

NCBI chr11:77,647,565...77,706,178
Ensembl chr11:77,647,600...77,725,361

G

interleukin 10

decreases expression

ISO

adenosine 5'-O-(3-thiotriphosphate) results in decreased expression of IL10 protein

NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580

G

interleukin 12B

increases expression

ISO

adenosine 5'-O-(3-thiotriphosphate) results in increased expression of IL12B protein

NCBI chr10:29,390,300...29,405,194
Ensembl chr10:29,389,905...29,405,194

G

interleukin 1 beta

increases expression

ISO

adenosine 5'-O-(3-thiotriphosphate) results in increased expression of IL1B protein

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

purinergic receptor P2X 7

affects response to substance

ISO

P2RX7 protein affects the susceptibility to adenosine 5'-O-(3-thiotriphosphate)

NCBI chr12:39,550,531...39,594,984
Ensembl chr12:39,540,567...39,595,193

G

prostaglandin D2 receptor

multiple interactions

ISO

adenosine 5'-O-(3-thiotriphosphate) inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]

NCBI chr15:19,790,499...19,797,873
Ensembl chr15:19,790,499...19,797,873

G

transient receptor potential cation channel, subfamily V, member 1

increases activity
multiple interactions

EXP

adenosine 5'-O-(3-thiotriphosphate) results in increased activity of TRPV1 protein
Capsaicin promotes the reaction [adenosine 5'-O-(3-thiotriphosphate) results in increased activity of TRPV1 protein]; capsazepine inhibits the reaction [adenosine 5'-O-(3-thiotriphosphate) results in increased activity of TRPV1 protein]

NCBI chr10:58,349,936...58,375,021
Ensembl chr10:58,340,223...58,375,021

adenosine 5'-monophosphate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 9

multiple interactions

ISO

Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]; Creatine metabolite inhibits the reaction [Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]]

NCBI chr 4:177,262,848...177,386,837
Ensembl chr 4:177,262,848...177,386,348

G

aldehyde dehydrogenase 1 family, member A1

multiple interactions

ISO

[4-dimethylaminocinnamaldehyde co-treated with Adenosine Monophosphate] binds to ALDH1A1 protein

NCBI chr 1:227,426,939...227,579,497
Ensembl chr 1:227,427,070...227,579,500

G

ERCC excision repair 6, chromatin remodeling factor

increases abundance

ISO

ERCC6 gene mutant form results in increased abundance of Adenosine Monophosphate

NCBI chr16:7,771,311...7,841,895
Ensembl chr16:7,771,581...7,841,895

G

H2A.X variant histone

multiple interactions

ISO

Adenosine Monophosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]

NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079

G

potassium inwardly-rectifying channel, subfamily J, member 11

multiple interactions

ISO

Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]; Creatine metabolite inhibits the reaction [Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]]

NCBI chr 1:105,727,473...105,731,167
Ensembl chr 1:105,727,570...105,731,169

G

nudix hydrolase 11

multiple interactions

ISO

[NUDT11 protein results in increased metabolism of diadenosine 5',5''''-P1,P6-hexaphosphate] which results in increased chemical synthesis of Adenosine Monophosphate; [NUDT11 protein results in increased metabolism of P(1),P(5)-di(adenosine-5'-)pentaphosphate] which results in increased chemical synthesis of Adenosine Monophosphate

NCBI chr X:18,998,587...19,005,208
Ensembl chr X:18,998,461...19,005,208

G

PPARG coactivator 1 alpha

increases expression

ISO

Adenosine Monophosphate results in increased expression of PPARGC1A mRNA

NCBI chr14:63,073,505...63,729,215
Ensembl chr14:63,273,189...63,729,213

G

tumor protein p53 binding protein 1

multiple interactions

ISO

Adenosine Monophosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]

NCBI chr 3:128,620,320...128,724,716
Ensembl chr 3:128,620,322...128,696,747

G

tumor protein p73

affects abundance

ISO

TP73 protein affects the abundance of Adenosine Monophosphate

NCBI chr 5:169,903,801...169,988,075
Ensembl chr 5:169,903,801...169,963,552

ADP

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 1

multiple interactions
affects binding

ISO

estradiol-17 beta-glucuronide inhibits the reaction [Adenosine Diphosphate binds to ABCC1 protein mutant form]; estradiol-17 beta-glucuronide inhibits the reaction [Adenosine Diphosphate binds to ABCC1 protein]; Vanadates promotes the reaction [Adenosine Diphosphate binds to ABCC1 protein]
Adenosine Diphosphate binds to ABCC1 protein; Adenosine Diphosphate binds to ABCC1 protein mutant form

NCBI chr10:1,022,041...1,162,431
Ensembl chr10:1,038,947...1,162,404

G

aryl hydrocarbon receptor

multiple interactions

EXP

Adenosine Diphosphate affects the folding of [Tetrachlorodibenzodioxin binds to AHR protein]

NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901

G

adenylate kinase 1

increases abundance

ISO

AK1 protein results in increased abundance of Adenosine Diphosphate

NCBI chr 3:36,310,113...36,320,760
Ensembl chr 3:36,310,197...36,320,757

G

albumin

decreases secretion
multiple interactions

ISO

Adenosine Diphosphate results in decreased secretion of ALB protein
Aspirin inhibits the reaction [Adenosine Diphosphate results in decreased secretion of ALB protein]

NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,891,582...17,911,865

G

amyloid beta precursor protein

multiple interactions
increases abundance

ISO

PF-06840003 inhibits the reaction [APP protein mutant form results in increased abundance of Adenosine Diphosphate]
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in increased abundance of Adenosine Diphosphate; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in increased abundance of Adenosine Diphosphate]

NCBI chr11:37,506,207...37,724,351
Ensembl chr11:37,506,408...37,722,971

G

Axl receptor tyrosine kinase

decreases response to substance

ISO

AXL protein results in decreased susceptibility to Adenosine Diphosphate

NCBI chr 1:90,392,864...90,424,123
Ensembl chr 1:90,392,864...90,424,009

G

catalase

multiple interactions

EXP

CAT protein inhibits the reaction [Adenosine Diphosphate results in increased glutathionylation of PTPN1 protein]

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

CD40 ligand

increases expression
multiple interactions

ISO

Adenosine Diphosphate results in increased expression of CD40LG protein
clopidogrel inhibits the reaction [Adenosine Diphosphate results in increased expression of CD40LG protein]

PMID:11297035 PMID:17043144

NCBI chr X:140,164,341...140,176,057
Ensembl chr X:140,164,302...140,176,475

G

CF transmembrane conductance regulator

multiple interactions

ISO

Adenosine Diphosphate binds to and results in decreased activity of CFTR protein; P(1),P(5)-di(adenosine-5'-)pentaphosphate inhibits the reaction [Adenosine Diphosphate binds to and results in decreased activity of CFTR protein]

NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:47,526,735...47,694,643

G

cysteine and histidine rich domain containing 1

multiple interactions

ISO

Adenosine Diphosphate binds to and affects the folding of CHORDC1 protein; Adenosine Diphosphate promotes the reaction [CHORDC1 protein binds to CHORDC1 protein]; Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to CHORDC1 protein]

NCBI chr 8:23,650,721...23,674,786
Ensembl chr 8:23,650,865...23,677,696

G

cytochrome P450, family 2, subfamily C, polypeptide 6

multiple interactions

ISO

CYP2C19 gene affects the susceptibility to [Adenosine Diphosphate co-treated with clopidogrel]; CYP2C19 gene SNP affects the reaction [Adenosine Diphosphate results in increased expression of SELP protein]; CYP2C19 gene SNP affects the susceptibility to [Adenosine Diphosphate co-treated with Arachidonic Acid]

PMID:16772608 PMID:18004210 PMID:18394438

NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:247,879,078...247,916,798

G

deoxythymidylate kinase

multiple interactions

ISO

DTYMK protein binds to [N1-(4-bis(pivaloyloxymethyl)phosphinylbuten-2-yl)thymine co-treated with Adenosine Diphosphate]

NCBI chr 9:101,762,899...101,771,733
Ensembl chr 9:101,762,899...101,774,504

G

dual specificity phosphatase 1

multiple interactions

ISO

Adenosine Diphosphate inhibits the reaction [Cesium-137 results in increased expression of DUSP1 protein]; Anthraquinones analog inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in decreased expression of DUSP1 protein]]

NCBI chr10:17,184,853...17,187,646
Ensembl chr10:17,184,823...17,187,644

G

dual specificity phosphatase 6

multiple interactions

ISO

Adenosine Diphosphate inhibits the reaction [Cesium-137 results in increased expression of DUSP6 protein]; Anthraquinones analog inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in decreased expression of DUSP6 protein]]

NCBI chr 7:35,979,502...35,983,834
Ensembl chr 7:35,977,921...35,983,833

G

Eph receptor A4

increases phosphorylation
multiple interactions

ISO

Adenosine Diphosphate results in increased phosphorylation of EPHA4 protein
Benzoic Acid analog inhibits the reaction [Adenosine Diphosphate results in increased phosphorylation of EPHA4 protein]

NCBI chr 9:86,263,982...86,406,744
Ensembl chr 9:86,263,982...86,406,755

G

endoplasmic reticulum to nucleus signaling 1

multiple interactions
decreases activity

ISO

Adenosine Diphosphate inhibits the reaction [ERN1 protein binds to ERN1 protein]
Adenosine Diphosphate results in decreased activity of ERN1 protein

NCBI chr10:91,826,663...91,920,976
Ensembl chr10:91,830,428...91,920,791

G

coagulation factor II, thrombin

increases abundance
multiple interactions

ISO

F2 protein results in increased abundance of Adenosine Diphosphate
Quercetin inhibits the reaction [F2 protein results in increased abundance of Adenosine Diphosphate]; resveratrol inhibits the reaction [F2 protein results in increased abundance of Adenosine Diphosphate]

NCBI chr 3:98,051,958...98,065,246
Ensembl chr 3:98,051,960...98,065,246

G

fibrinogen alpha chain

multiple interactions
increases secretion

ISO

Aspirin promotes the reaction [Adenosine Diphosphate results in increased secretion of FGA protein]

NCBI chr 2:170,672,169...170,679,572
Ensembl chr 2:170,672,012...170,679,577

G

fibrinogen beta chain

decreases secretion
multiple interactions

ISO

Adenosine Diphosphate results in decreased secretion of FGB protein
Aspirin inhibits the reaction [Adenosine Diphosphate results in decreased secretion of FGB protein]

NCBI chr 2:170,693,966...170,700,875
Ensembl chr 2:170,692,965...170,705,434

G

fibrinogen gamma chain

increases secretion
multiple interactions

ISO

Adenosine Diphosphate results in increased secretion of FGG protein
Aspirin promotes the reaction [Adenosine Diphosphate results in increased secretion of FGG protein]

NCBI chr 2:170,652,929...170,660,372
Ensembl chr 2:170,652,234...170,661,170

G

glyceraldehyde-3-phosphate dehydrogenase

multiple interactions

ISO

Adenosine Diphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]

NCBI chr 4:159,648,592...159,653,436
Ensembl chr 4:159,648,592...159,653,377

G

growth arrest specific 6

increases response to substance

ISO

GAS6 protein results in increased susceptibility to Adenosine Diphosphate

NCBI chr16:82,747,676...82,778,090
Ensembl chr16:82,747,345...82,778,088

G

H2A.X variant histone

multiple interactions

ISO

Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]; Anthraquinones analog inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]]; U 0126 inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]]

NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079

G

HRas proto-oncogene, GTPase

multiple interactions

ISO

Adenosine Diphosphate binds to and affects the folding of HRAS protein

NCBI chr 1:205,712,625...205,729,406
Ensembl chr 1:205,725,975...205,729,590

G

heat shock protein 90 alpha family class A member 1

multiple interactions

ISO

Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]; Calcium promotes the reaction [Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]]

NCBI chr 6:135,523,604...135,529,687
Ensembl chr 6:135,523,616...135,528,499

G

isocitrate dehydrogenase (NADP(+)) 2

multiple interactions
increases abundance

ISO

Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Adenosine Diphosphate]

NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:143,439,323...143,467,248

G

interleukin 6

increases expression
multiple interactions

ISO

Adenosine Diphosphate results in increased expression of IL6 protein
MRS 2211 inhibits the reaction [Adenosine Diphosphate results in increased expression of IL6 protein]

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

integrin subunit alpha 2

multiple interactions

ISO

ITGA2 gene SNP affects the susceptibility to [Aspirin co-treated with clopidogrel co-treated with Adenosine Diphosphate]

NCBI chr 2:48,253,412...48,354,509
Ensembl chr 2:48,253,412...48,354,509

G

integrin subunit alpha 2b

multiple interactions

ISO

cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]]

NCBI chr10:87,908,697...87,926,225
Ensembl chr10:87,908,697...87,925,833

G

integrin subunit beta 1 binding protein 2

multiple interactions

ISO

Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to CHORDC1 protein]; Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]; Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to ITGB1BP2 protein]; Calcium promotes the reaction [Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]]

NCBI chr X:70,612,118...70,617,158
Ensembl chr X:70,612,521...70,617,158

G

integrin subunit beta 3

multiple interactions

ISO

cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]]

NCBI chr10:90,009,927...90,067,787
Ensembl chr10:90,009,900...90,067,800

G

mitogen activated protein kinase 1

increases phosphorylation
multiple interactions

ISO

Adenosine Diphosphate results in increased phosphorylation of MAPK1 protein
Anthraquinones analog inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased phosphorylation of MAPK1 protein]]

PMID:15034929 PMID:32941855

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 3

increases phosphorylation
multiple interactions

ISO

Adenosine Diphosphate results in increased phosphorylation of MAPK3 protein
Anthraquinones analog inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased phosphorylation of MAPK3 protein]]

PMID:15034929 PMID:32941855

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

mitogen-activated protein kinase 8

multiple interactions

ISO

Dicumarol inhibits the reaction [Adenosine Diphosphate results in increased phosphorylation of MAPK8 protein]

NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427

G

mitogen-activated protein kinase 9

multiple interactions

ISO

Dicumarol inhibits the reaction [Adenosine Diphosphate results in increased phosphorylation of MAPK9 protein]

NCBI chr10:34,670,750...34,711,972
Ensembl chr10:34,670,756...34,712,228

G

microtubule-associated protein tau

multiple interactions
increases abundance

ISO

PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased abundance of Adenosine Diphosphate]

NCBI chr10:89,638,618...89,736,108
Ensembl chr10:89,638,599...89,736,108

G

MER proto-oncogene, tyrosine kinase

increases response to substance

ISO

MERTK protein results in increased susceptibility to Adenosine Diphosphate

NCBI chr 3:136,391,936...136,498,366
Ensembl chr 3:136,383,560...136,500,192

G

nitric oxide synthase 2

multiple interactions

ISO

NOS2 protein affects the susceptibility to [Phenylephrine co-treated with Adenosine Diphosphate]

NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880

G

5' nucleotidase, ecto

decreases activity

ISO

Adenosine Diphosphate analog results in decreased activity of NT5E protein

NCBI chr 8:98,150,925...98,195,646
Ensembl chr 8:98,150,900...98,195,645

G

purinergic receptor P2Y12

affects response to substance
increases response to substance
multiple interactions

ISO
EXP

P2RY12 gene polymorphism affects the susceptibility to Adenosine Diphosphate; P2RY12 protein affects the susceptibility to Adenosine Diphosphate
P2RY12 protein results in increased susceptibility to Adenosine Diphosphate
Epinephrine inhibits the reaction [P2RY12 gene mutant form results in decreased susceptibility to Adenosine Diphosphate]
P2RY12 protein affects the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]

PMID:11196645 PMID:11413167 PMID:18404433 PMID:23849096

NCBI chr 2:145,631,487...145,673,194
Ensembl chr 2:145,629,967...145,633,410

G

platelet derived growth factor subunit B

increases secretion
multiple interactions

ISO

Adenosine Diphosphate results in increased secretion of PDGFB protein
Aspirin promotes the reaction [Adenosine Diphosphate results in increased secretion of PDGFB protein]

NCBI chr 7:113,419,882...113,438,343
Ensembl chr 7:113,420,710...113,438,343

G

platelet factor 4

increases secretion
multiple interactions

ISO

Adenosine Diphosphate results in increased secretion of PF4 protein
silidianin inhibits the reaction [Adenosine Diphosphate results in increased secretion of PF4 protein]; Silybin inhibits the reaction [Adenosine Diphosphate results in increased secretion of PF4 protein]; silychristin inhibits the reaction [Adenosine Diphosphate results in increased secretion of PF4 protein]

PMID:19428933 PMID:29439388

NCBI chr14:17,582,477...17,583,392
Ensembl chr14:17,582,477...17,583,392

G

phosphofructokinase, muscle

multiple interactions

ISO

Adenosine Diphosphate inhibits the reaction [resveratrol results in decreased activity of PFKM protein]

NCBI chr 7:131,100,684...131,138,250
Ensembl chr 7:131,100,753...131,138,248

G

phosphoglycolate phosphatase

decreases phosphorylation

ISO

PGP protein results in decreased phosphorylation of Adenosine Diphosphate

NCBI chr10:13,999,782...14,002,408
Ensembl chr10:13,999,331...14,002,408

G

pro-platelet basic protein

increases secretion

ISO

Adenosine Diphosphate results in increased secretion of PPBP protein

NCBI chr14:17,586,495...17,587,299
Ensembl chr14:17,586,495...17,587,299

G

protein phosphatase 5, catalytic subunit

multiple interactions

ISO

Adenosine Diphosphate binds to and affects the folding of PPP5C protein

NCBI chr 1:86,818,297...86,842,505
Ensembl chr 1:86,818,297...86,842,950

G

presenilin 1

multiple interactions

ISO

[APP protein mutant form co-treated with PSEN1 protein mutant form] results in increased abundance of Adenosine Diphosphate; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in increased abundance of Adenosine Diphosphate]

NCBI chr 6:109,054,160...109,106,191
Ensembl chr 6:109,060,352...109,106,189

G

protein tyrosine phosphatase, non-receptor type 1

increases glutathionylation
multiple interactions

EXP

Adenosine Diphosphate results in increased glutathionylation of PTPN1 protein
CAT protein inhibits the reaction [Adenosine Diphosphate results in increased glutathionylation of PTPN1 protein]

NCBI chr 3:177,056,588...177,106,424
Ensembl chr 3:177,057,659...177,106,416

G

selectin P

multiple interactions
increases expression

ISO

cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]; CYP2C19 gene SNP affects the reaction [Adenosine Diphosphate results in increased expression of SELP protein]; Heparin promotes the reaction [Adenosine Diphosphate affects the localization of SELP protein]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate inhibits the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]]; P2RY12 protein affects the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]; Quercetin inhibits the reaction [Adenosine Diphosphate results in increased expression of SELP protein]

PMID:9740346 PMID:18394438 PMID:18404433 PMID:23249183

NCBI chr13:79,009,379...79,044,994
Ensembl chr13:79,009,475...79,044,987

G

sirtuin 3

decreases abundance

ISO

SIRT3 protein results in decreased abundance of Adenosine Diphosphate

NCBI chr 1:205,371,703...205,394,145
Ensembl chr 1:205,371,710...205,394,076

G

transaldolase 1

increases abundance

ISO

TALDO1 gene mutant form results in increased abundance of Adenosine Diphosphate

NCBI chr 1:205,923,196...205,933,526
Ensembl chr 1:205,923,165...205,933,535

G

thrombospondin 1

increases secretion

ISO

Adenosine Diphosphate results in increased secretion of THBS1 protein

NCBI chr 3:125,510,250...125,525,402
Ensembl chr 3:125,510,250...125,525,402

G

tumor protein p53 binding protein 1

multiple interactions

ISO

Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]; Anthraquinones analog inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]]; U 0126 inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]]

NCBI chr 3:128,620,320...128,724,716
Ensembl chr 3:128,620,322...128,696,747

G

TYRO3 protein tyrosine kinase

increases response to substance

ISO

TYRO3 protein results in increased susceptibility to Adenosine Diphosphate

NCBI chr 3:127,231,468...127,254,806
Ensembl chr 3:127,231,903...127,250,943

G

vasodilator-stimulated phosphoprotein

increases phosphorylation
multiple interactions

ISO

Adenosine Diphosphate results in increased phosphorylation of VASP protein
N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Adenosine Diphosphate results in increased phosphorylation of VASP protein]

NCBI chr 1:88,038,026...88,053,783
Ensembl chr 1:88,038,037...88,058,650

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ADP-ribosylarginine hydrolase

increases hydrolysis

ISO

ADPRH protein results in increased hydrolysis of Adenosine Diphosphate Ribose metabolite

NCBI chr11:75,805,347...75,811,686
Ensembl chr11:75,805,310...75,812,452

G

ADP-ribosylserine hydrolase

increases hydrolysis
multiple interactions

ISO

ADPRS protein results in increased hydrolysis of Adenosine Diphosphate Ribose metabolite
Adenosine Diphosphate Ribose inhibits the reaction [ADPRS protein results in increased hydrolysis of O-Acetyl-ADP-Ribose]

NCBI chr 5:143,898,542...143,903,816
Ensembl chr 5:143,898,542...143,903,816

G

nitric oxide synthase 1

multiple interactions

ISO

NOS1 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased ribosylation of Adenosine Diphosphate Ribose]

NCBI chr12:44,276,011...44,456,371
Ensembl chr12:44,287,614...44,371,837

G

transient receptor potential cation channel, subfamily M, member 2

multiple interactions
increases activity

EXP
ISO

Adenosine Diphosphate Ribose promotes the reaction [TRPM2 protein results in increased transport of Calcium]; Clotrimazole inhibits the reaction [Adenosine Diphosphate Ribose promotes the reaction [TRPM2 protein results in increased transport of Calcium]]; Flufenamic Acid inhibits the reaction [Adenosine Diphosphate Ribose promotes the reaction [TRPM2 protein results in increased transport of Calcium]]
Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein
2-aminoethoxydiphenyl borate inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Cisplatin promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Eicosapentaenoic Acid promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Eicosapentaenoic Acid promotes the reaction [Cisplatin promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]]]; Cisplatin promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Copper Sulfate inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Eicosapentaenoic Acid promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Eicosapentaenoic Acid promotes the reaction [Cisplatin promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]]; ferrous chloride inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; lead nitrate inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Mercuric Chloride inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Miconazole inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Selenium Oxides inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]
4-amylcinnamoylanthranilic acid inhibits the reaction [[Buthionine Sulfoximine co-treated with Adenosine Diphosphate Ribose] results in increased activity of TRPM2 protein]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; [Buthionine Sulfoximine co-treated with Adenosine Diphosphate Ribose] results in increased activity of TRPM2 protein; Glutathione inhibits the reaction [[Buthionine Sulfoximine co-treated with Adenosine Diphosphate Ribose] results in increased activity of TRPM2 protein]; Glutathione inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; TRPM2 protein promotes the reaction [Adenosine Diphosphate Ribose results in increased uptake of Calcium]

PMID:18204483 PMID:20878536 PMID:21900507 PMID:22750002 PMID:33309544 More...

NCBI chr20:10,703,190...10,752,795
Ensembl chr20:10,704,482...10,752,802

aldehydo-D-ribose

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

advanced glycosylation end product-specific receptor

multiple interactions
increases expression

ISO

[Ribose co-treated with Glucose] results in increased expression of AGER protein; AGER protein affects the reaction [Ribose promotes the reaction [Glucose results in increased phosphorylation of RELA protein]]
Ribose results in increased expression of AGER protein

NCBI chr20:4,152,758...4,155,956
Ensembl chr20:4,151,965...4,155,685

G

beta-2 microglobulin

increases glycation

ISO

Ribose results in increased glycation of B2M protein

NCBI chr 3:129,549,236...129,555,354
Ensembl chr 3:129,549,318...129,555,356

G

caspase 3

multiple interactions

EXP

[Creatine co-treated with Ribose] results in decreased activity of CASP3 protein

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

component of inhibitor of nuclear factor kappa B kinase complex

increases phosphorylation

ISO

Ribose results in increased phosphorylation of CHUK protein

NCBI chr 1:252,908,748...252,944,273
Ensembl chr 1:252,908,749...252,944,273

G

inhibitor of nuclear factor kappa B kinase subunit beta

increases phosphorylation

ISO

Ribose results in increased phosphorylation of IKBKB protein

NCBI chr16:76,021,968...76,075,717
Ensembl chr16:76,022,008...76,081,911

G

insulin 1

increases secretion

ISO

Ribose results in increased secretion of INS1 protein

NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:261,186,119...261,186,682

G

NFKB inhibitor alpha

multiple interactions
increases phosphorylation

ISO

[Ribose co-treated with Glucose] results in increased phosphorylation of NFKBIA protein
Ribose results in increased phosphorylation of NFKBIA protein

NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072

G

ornithine aminotransferase

multiple interactions

EXP

Ribose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]

NCBI chr 1:196,777,973...196,797,754
Ensembl chr 1:196,777,975...196,797,754

G

RELA proto-oncogene, NF-kB subunit

increases phosphorylation
multiple interactions

ISO

Ribose results in increased phosphorylation of RELA protein
[Ribose co-treated with Glucose] affects the localization of RELA protein; AGER protein affects the reaction [Ribose promotes the reaction [Glucose results in increased phosphorylation of RELA protein]]; Ribose promotes the reaction [Glucose results in increased phosphorylation of RELA protein]

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aryl hydrocarbon receptor

multiple interactions

EXP

Adenylyl Imidodiphosphate affects the folding of [Tetrachlorodibenzodioxin binds to AHR protein]

NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901

G

CF transmembrane conductance regulator

affects activity

ISO

Adenylyl Imidodiphosphate affects the activity of CFTR protein

NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:47,526,735...47,694,643

G

casein kinase 2 alpha 1

affects binding

ISO

Adenylyl Imidodiphosphate binds to CSNK2A1 protein

NCBI chr 3:161,170,295...161,217,073
Ensembl chr 3:161,170,405...161,215,698

G

prostaglandin D2 receptor

multiple interactions

ISO

Adenylyl Imidodiphosphate inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]

NCBI chr15:19,790,499...19,797,873
Ensembl chr15:19,790,499...19,797,873

arachidonoyl-CoA

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

peroxisome proliferator activated receptor alpha

multiple interactions

ISO

arachidonyl-coenzyme A binds to and results in increased activity of PPARA protein

NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714

ATP

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 8

multiple interactions

ISO

Adenosine Triphosphate affects the reaction [ABCA8 protein results in increased uptake of estradiol-17 beta-glucuronide]

NCBI chr10:95,416,984...95,490,647
Ensembl chr10:95,416,205...95,490,452

G

ATP binding cassette subfamily B member 11

multiple interactions

ISO
EXP

Adenosine Triphosphate promotes the reaction [ABCB11 protein results in increased uptake of fexofenadine]

NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581

G

ATP binding cassette subfamily B member 1A

multiple interactions
affects binding
increases hydrolysis

ISO
EXP

[Cobalt results in increased activity of ABCB1 protein] which results in increased hydrolysis of Adenosine Triphosphate; [Magnesium results in increased activity of ABCB1 protein] which results in increased hydrolysis of Adenosine Triphosphate; [Manganese results in increased activity of ABCB1 protein] which results in increased hydrolysis of Adenosine Triphosphate; ABCB1 protein binds to and results in increased hydrolysis of Adenosine Triphosphate; aurapten promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]; crizotinib promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]; Disulfiram affects the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]; lapatinib promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]; nobiletin promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]
Adenosine Triphosphate binds to ABCB1 protein
[Rifampin metabolite results in decreased activity of ABCB1A protein] which results in decreased abundance of Adenosine Triphosphate

PMID:2900677 PMID:14978246 PMID:18829547 PMID:18955043 PMID:22233293 More...

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135

G

ATP binding cassette subfamily C member 1

multiple interactions
affects activity
increases hydrolysis
affects binding

ISO

[Adenosine Triphosphate affects the activity of ABCC1 protein] which results in increased transport of Acetaminophen metabolite; ABCC1 protein binds to and results in increased degradation of Adenosine Triphosphate; ABCC1 protein binds to and results in increased hydrolysis of Adenosine Triphosphate; ABCC1 protein mutant form binds to and results in increased hydrolysis of Adenosine Triphosphate; Adenosine Triphosphate binds to and affects the folding of ABCC1 protein; Adenosine Triphosphate promotes the reaction [ABCC1 protein affects the transport of Bilirubin]; Adenosine Triphosphate promotes the reaction [ABCC1 protein affects the transport of estradiol-17 beta-glucuronide]; Adenosine Triphosphate promotes the reaction [ABCC1 protein affects the transport of Leukotriene C4]; daidzein promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Disulfiram affects the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; hesperetin promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; naringenin promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; nobiletin promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Quercetin affects the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Resveratrol promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Silymarin inhibits the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]
Daunorubicin promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Vanadates inhibits the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]
Adenosine Triphosphate binds to ABCC1 protein

PMID:10856430 PMID:11278000 PMID:14978246 PMID:15245331 PMID:15355964 More...

NCBI chr10:1,022,041...1,162,431
Ensembl chr10:1,038,947...1,162,404

G

ATP binding cassette subfamily C member 2

multiple interactions
affects activity
affects metabolic processing

EXP
ISO

Adenosine Triphosphate promotes the reaction [ABCC2 protein results in increased secretion of Fluo-3]; Adenosine Triphosphate promotes the reaction [ABCC2 protein results in increased transport of temocaprilat]
Adenosine Triphosphate affects the activity of ABCC2 protein
[Adenosine Triphosphate affects the activity of ABCC2 protein] which results in increased transport of Acetaminophen metabolite; [Adenosine Triphosphate co-treated with ABCC2 protein] results in increased uptake of estradiol-17 beta-glucuronide; Adenosine Triphosphate affects the reaction [ABCC2 protein results in increased transport of Mercury]; verlukast inhibits the reaction [[Adenosine Triphosphate co-treated with ABCC2 protein] results in increased uptake of estradiol-17 beta-glucuronide]
ABCC2 protein affects the metabolism of Adenosine Triphosphate
Adenosine Triphosphate promotes the reaction [ABCC2 protein results in increased transport of S-1,2-dichlorovinyl-N-acetylcysteine]

PMID:9067317 PMID:9794919 PMID:20060011 PMID:22027652 PMID:24039982 More...

NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471

G

ATP binding cassette subfamily C member 3

multiple interactions

ISO

Adenosine Triphosphate promotes the reaction [ABCC3 protein affects the transport of fexofenadine]

NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,793,583...79,839,494

G

ATP binding cassette subfamily C member 4

multiple interactions
affects activity
increases hydrolysis

ISO

[Adenosine Triphosphate affects the activity of ABCC4 protein] which results in increased transport of Acetaminophen metabolite; ABCC4 protein binds to and results in increased hydrolysis of Adenosine Triphosphate; daidzein promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; Disulfiram inhibits the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; hesperetin promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; naringenin promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; Quercetin affects the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; Quercetin inhibits the reaction [Alprostadil promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]]; Resveratrol promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; Silymarin inhibits the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; Silymarin inhibits the reaction [Alprostadil promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]]

PMID:14978246 PMID:16156793 PMID:32472168

NCBI chr15:101,948,387...102,182,912
Ensembl chr15:101,949,433...102,181,375

G

ATP binding cassette subfamily C member 6

affects binding

ISO

Adenosine Triphosphate binds to ABCC6 protein

NCBI chr 1:105,583,681...105,637,895
Ensembl chr 1:105,583,682...105,637,895

G

ATP binding cassette subfamily C member 8

multiple interactions

EXP

Adenosine Triphosphate deficiency inhibits the reaction [Estradiol inhibits the reaction [Glyburide binds to ABCC8 protein]]

NCBI chr 1:105,734,992...105,816,272
Ensembl chr 1:105,734,992...105,815,982

G

ATP binding cassette subfamily C member 9

multiple interactions

EXP
ISO

Adenosine Triphosphate results in decreased activity of [KCNJ8 protein binds to ABCC9 protein]
Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]; Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]; Creatine metabolite inhibits the reaction [Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]]

PMID:11390963 PMID:28842488

NCBI chr 4:177,262,848...177,386,837
Ensembl chr 4:177,262,848...177,386,348

G

ATP binding cassette subfamily G member 2

increases hydrolysis
multiple interactions

ISO

ABCG2 protein results in increased hydrolysis of Adenosine Triphosphate
[Adenosine Triphosphate co-treated with ABCG2 protein] results in increased uptake of estrone sulfate; Lapatinib promotes the reaction [ABCG2 protein results in increased hydrolysis of Adenosine Triphosphate]; Sulfasalazine inhibits the reaction [[Adenosine Triphosphate co-treated with ABCG2 protein] results in increased uptake of estrone sulfate]

PMID:18829547 PMID:32003934

NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493

G

ABL proto-oncogene 1, non-receptor tyrosine kinase

multiple interactions
increases chemical synthesis

ISO

[ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein; sorafenib inhibits the reaction [[ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein]
ABL1 protein mutant form results in increased chemical synthesis of Adenosine Triphosphate

PMID:19366808 PMID:33070465

NCBI chr 3:35,377,587...35,480,843
Ensembl chr 3:35,377,391...35,480,846

G

acyl-CoA synthetase long-chain family member 5

multiple interactions

ISO

[ACSL5 protein affects the susceptibility to Palmitic Acid] which affects the abundance of Adenosine Triphosphate

NCBI chr 1:264,294,851...264,341,943
Ensembl chr 1:264,294,864...264,341,943

G

actin alpha 2, smooth muscle

multiple interactions

ISO

3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 mRNA]; 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 protein]; [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 mRNA; [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 protein; Adenosine Triphosphate promotes the reaction [[lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of Biological Factors] which results in increased expression of ACTA2 mRNA]; Adenosine Triphosphate promotes the reaction [[lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of Biological Factors] which results in increased expression of ACTA2 protein]; Adenosine Triphosphate promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of ACTA2 mRNA]; Adenosine Triphosphate promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of ACTA2 protein]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 mRNA]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 protein]; L 709049 inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 mRNA]; L 709049 inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 protein]

NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503

G

adenylate cyclase activating polypeptide 1

increases secretion

EXP

ADCYAP1 protein results in increased secretion of Adenosine Triphosphate

NCBI chr 9:120,550,236...120,569,096
Ensembl chr 9:120,550,328...120,556,383

G

angiotensin II receptor, type 1a

multiple interactions
decreases expression

EXP

Adenosine Triphosphate results in decreased expression of and results in decreased activity of AGTR1A protein; ARRB2 protein affects the reaction [Adenosine Triphosphate results in decreased activity of AGTR1A protein]; CABIN1 protein inhibits the reaction [Adenosine Triphosphate results in decreased expression of and results in decreased activity of AGTR1A protein]; Cyclosporine inhibits the reaction [Adenosine Triphosphate results in decreased expression of AGTR1A mRNA]; N-((3-(aminomethyl)phenyl)methyl)ethanimidamide inhibits the reaction [Adenosine Triphosphate results in decreased expression of AGTR1A mRNA]; N-((3-(aminomethyl)phenyl)methyl)ethanimidamide inhibits the reaction [Adenosine Triphosphate results in decreased expression of AGTR1A protein]

NCBI chr17:34,383,397...34,435,523
Ensembl chr17:34,381,467...34,435,660

G

aryl hydrocarbon receptor

multiple interactions

EXP

Adenosine Triphosphate affects the folding of [Tetrachlorodibenzodioxin binds to AHR protein]

NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901

G

AKT serine/threonine kinase 1

decreases activity
multiple interactions

ISO

Adenosine Triphosphate results in decreased activity of AKT1 protein
Alcohols inhibits the reaction [Adenosine Triphosphate results in decreased activity of AKT1 protein]

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

aldehyde dehydrogenase 5 family, member A1

increases abundance

ISO

ALDH5A1 gene mutant form results in increased abundance of Adenosine Triphosphate

NCBI chr17:40,560,373...40,586,711
Ensembl chr17:40,558,347...40,586,714

G

ALK receptor tyrosine kinase

affects binding
multiple interactions

ISO

ALK protein binds to Adenosine Triphosphate
[ALK protein mutant form promotes the reaction [ALK protein binds to Adenosine Triphosphate]] which results in decreased susceptibility to crizotinib; ALK protein mutant form promotes the reaction [ALK protein binds to Adenosine Triphosphate]

NCBI chr 6:28,631,431...29,351,321
Ensembl chr 6:28,632,197...29,349,721

G

alkaline phosphatase, biomineralization associated

increases response to substance
multiple interactions

ISO

ALPL gene mutant form results in increased susceptibility to Adenosine Triphosphate
ALPL gene mutant form promotes the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA]

NCBI chr 5:155,234,770...155,289,785
Ensembl chr 5:155,234,775...155,254,167

G

annexin A1

multiple interactions

EXP

[Magnesium co-treated with Adenosine Triphosphate] affects the activity of ANXA1 protein; arsenite affects the reaction [[Magnesium co-treated with Adenosine Triphosphate] affects the activity of ANXA1 protein]; Cadmium affects the reaction [[Magnesium co-treated with Adenosine Triphosphate] affects the activity of ANXA1 protein]; chromium hexavalent ion affects the reaction [[Magnesium co-treated with Adenosine Triphosphate] affects the activity of ANXA1 protein]; Lead affects the reaction [[Magnesium co-treated with Adenosine Triphosphate] affects the activity of ANXA1 protein]

NCBI chr 1:227,287,713...227,306,739
Ensembl chr 1:227,287,717...227,306,831

G

amyloid beta precursor protein

multiple interactions
increases secretion

ISO

Adenosine Triphosphate inhibits the reaction [Hydrogen Peroxide results in decreased secretion of APP protein modified form]; Adenosine Triphosphate inhibits the reaction [Rotenone results in decreased secretion of APP protein modified form]; Rotenone inhibits the reaction [Adenosine Triphosphate results in increased secretion of APP protein modified form]; Sodium Azide inhibits the reaction [Adenosine Triphosphate results in increased secretion of APP protein modified form]
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Adenosine Triphosphate; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Adenosine Triphosphate]

PMID:22906069 PMID:39172838

NCBI chr11:37,506,207...37,724,351
Ensembl chr11:37,506,408...37,722,971

G

arrestin, beta 2

multiple interactions

EXP

Adenosine Triphosphate promotes the reaction [RELA protein binds to ARRB2 protein]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to ARRB2 protein]]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NFKBIA protein]]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NOS2 protein]]; ARRB2 protein affects the reaction [Adenosine Triphosphate results in decreased activity of AGTR1A protein]

NCBI chr10:55,645,539...55,653,485
Ensembl chr10:55,645,357...55,653,487

G

acid sensing ion channel subunit 1

multiple interactions

EXP

[Acids binds to and affects the activity of ASIC1 protein] which results in increased secretion of Adenosine Triphosphate

NCBI chr 7:132,677,158...132,707,379
Ensembl chr 7:132,698,723...132,707,832

G

acid sensing ion channel subunit 2

multiple interactions

EXP

[Acids binds to and affects the activity of ASIC2 protein] which results in increased secretion of Adenosine Triphosphate

NCBI chr10:66,368,308...67,438,237
Ensembl chr10:66,368,310...66,636,245

G

acid sensing ion channel subunit 3

multiple interactions

EXP

[Acids binds to and affects the activity of ASIC3 protein] which results in increased secretion of Adenosine Triphosphate

NCBI chr 4:11,652,946...11,657,415
Ensembl chr 4:11,652,946...11,657,367

G

ATPase copper transporting alpha

multiple interactions

ISO

[Copper co-treated with Adenosine Triphosphate] results in increased phosphorylation of ATP7A protein

NCBI chr X:75,159,635...75,267,094
Ensembl chr X:75,159,782...75,267,093

G

ATPase copper transporting beta

multiple interactions
increases phosphorylation

ISO

[Copper co-treated with Adenosine Triphosphate] results in increased phosphorylation of ATP7B protein
Adenosine Triphosphate results in increased phosphorylation of ATP7B protein

PMID:19405516 PMID:20964302

NCBI chr16:76,654,725...76,726,092
Ensembl chr16:76,653,660...76,728,801

G

ATPase phospholipid transporting 8B1

increases hydrolysis

EXP

ATP8B1 protein results in increased hydrolysis of Adenosine Triphosphate

NCBI chr18:60,286,605...60,427,862
Ensembl chr18:60,288,464...60,427,027

G

arginine vasopressin

multiple interactions
increases secretion

EXP

Adenosine Triphosphate promotes the reaction [Phenylephrine results in increased secretion of AVP protein]; bisindolylmaleimide I inhibits the reaction [[Phenylephrine co-treated with Adenosine Triphosphate] results in increased secretion of AVP protein]; Dactinomycin inhibits the reaction [[Phenylephrine co-treated with Adenosine Triphosphate] results in increased secretion of AVP protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Phenylephrine co-treated with Adenosine Triphosphate] results in increased secretion of AVP protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate results in increased secretion of AVP protein]

NCBI chr 3:138,246,544...138,248,522
Ensembl chr 3:138,246,554...138,248,522

G

BCL2, apoptosis regulator

multiple interactions

ISO

[Adenosine Triphosphate binds to P2RY11 protein] which results in decreased expression of BCL2 protein

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

BCR activator of RhoGEF and GTPase

multiple interactions

ISO

[BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein; sorafenib inhibits the reaction [[BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein]

NCBI chr20:13,468,732...13,596,333
Ensembl chr20:13,468,732...13,596,333

G

baculoviral IAP repeat-containing 5

increases abundance

ISO

BIRC5 protein results in increased abundance of Adenosine Triphosphate

NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,572,080...103,582,155

G

calcineurin binding protein 1

multiple interactions

EXP

CABIN1 protein inhibits the reaction [Adenosine Triphosphate results in decreased expression of and results in decreased activity of AGTR1A protein]

NCBI chr20:12,892,750...13,014,801
Ensembl chr20:12,892,771...13,014,800

G

calcitonin-related polypeptide alpha

increases secretion
multiple interactions

EXP

Adenosine Triphosphate results in increased secretion of CALCA protein
Adenosine Triphosphate promotes the reaction [Protons results in increased secretion of CALCA protein]; Flurbiprofen inhibits the reaction [Adenosine Triphosphate promotes the reaction [Protons results in increased secretion of CALCA protein]]; Suramin inhibits the reaction [Adenosine Triphosphate promotes the reaction [Protons results in increased secretion of CALCA protein]]

NCBI chr 1:178,312,636...178,317,588
Ensembl chr 1:178,312,638...178,317,529

G

caspase 1

increases activity
multiple interactions

EXP
ISO

Adenosine Triphosphate results in increased activity of CASP1 mRNA; Adenosine Triphosphate results in increased activity of CASP1 protein
[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]
[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP1 protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of and results in increased cleavage of CASP1 protein; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of CASP1 mRNA; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased secretion of and results in increased activity of CASP1 protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of CASP1 mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein modified form; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased cleavage of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein; Acetylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP1 protein]; dapansutrile inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein]; fraxinellone inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein]; HK1 protein affects the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of CASP1 protein]; HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of CASP1 protein]]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of and results in increased cleavage of CASP1 protein]; KN 62 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of CASP1 protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein modified form]; neoisoliquiritin affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP1 protein]; Resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of CASP1 mRNA]; Resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased secretion of and results in increased activity of CASP1 protein]; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]
[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased cleavage of CASP1 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of CASP1 mRNA; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP1 protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of CASP1 protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of CASP1 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of CASP1 protein modified form; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] promotes the reaction [PYCARD protein binds to CASP1 protein]; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein modified form; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to CASP1 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [PML protein binds to CASP1 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased activity of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein; [Niclosamide co-treated with Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of CASP1 protein; Adenosine Triphosphate promotes the reaction [[CSTB gene mutant form results in increased susceptibility to lipopolysaccharide, E coli O55-B5] which results in increased cleavage of CASP1 protein]; Arsenic Trioxide inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein]; Chlorquinaldol inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of CASP1 protein]; dapansutrile inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of CASP1 protein modified form]; Ibuprofen inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; leojaponin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased activity of CASP1 protein]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] promotes the reaction [PYCARD protein binds to CASP1 protein]]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein modified form]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to CASP1 protein]]; prim-O-glucosylcimifugin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased cleavage of CASP1 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of CASP1 mRNA]; tabersonine inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP1 protein]

PMID:18604214 PMID:19130485 PMID:21832250 PMID:23430110 PMID:24149798 More...

NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:10,746,333...10,882,275

G

caspase 3

increases expression
multiple interactions

ISO

Adenosine Triphosphate results in increased expression of CASP3
Adenosine Triphosphate inhibits the reaction [chromium hexavalent ion results in increased activity of CASP3 protein]; Suramin inhibits the reaction [Adenosine Triphosphate results in increased expression of CASP3]

PMID:19448140 PMID:24732427

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caspase 4

multiple interactions

ISO

[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of CASP4 mRNA; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased secretion of and results in increased activity of CASP4 protein; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of CASP4 mRNA]; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased secretion of and results in increased activity of CASP4 protein]
Adenosine Triphosphate promotes the reaction [[CSTB gene mutant form results in increased susceptibility to lipopolysaccharide, E coli O55-B5] which results in increased cleavage of CASP4 protein]

PMID:24149798 PMID:25288807

NCBI chr 8:10,883,817...10,919,978
Ensembl chr 8:10,883,769...10,920,727

G

catalase

increases expression

ISO

Adenosine Triphosphate results in increased expression of CAT mRNA

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

C-C motif chemokine ligand 3

increases secretion
multiple interactions

ISO

Adenosine Triphosphate results in increased secretion of CCL3 protein
azetidine inhibits the reaction [Adenosine Triphosphate results in increased secretion of CCL3 protein]

NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,948,889...68,950,439

G

CF transmembrane conductance regulator

multiple interactions

ISO

3-((3-trifluoromethyl)phenyl)-5-((3-carboxyphenyl)methylene)-2-thioxo-4-thiazolidinone inhibits the reaction [Adenosine Triphosphate promotes the reaction [CFTR protein results in increased export of Chlorides]]; [Phosphatidylinositol 4,5-Diphosphate co-treated with Adenosine Triphosphate] results in increased activity of CFTR protein; Adenosine Triphosphate affects the reaction [Curcumin results in increased activity of CFTR protein mutant form]; Adenosine Triphosphate binds to and results in increased activity of CFTR protein; Adenosine Triphosphate promotes the reaction [CFTR protein results in increased export of Chlorides]

PMID:14710196 PMID:15623556 PMID:17178710 PMID:20675434

NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:47,526,735...47,694,643

G

cysteine and histidine rich domain containing 1

multiple interactions

ISO

Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to PPP5C protein]; Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to SUGT1 protein]
Adenosine Triphosphate binds to and affects the folding of CHORDC1 protein; Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to CHORDC1 protein]; Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to HSP90AA1 protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to CHORDC1 protein]

NCBI chr 8:23,650,721...23,674,786
Ensembl chr 8:23,650,865...23,677,696

G

collagen type I alpha 1 chain

multiple interactions

ISO

3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 mRNA]; 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 protein]; [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 mRNA; [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 protein; Adenosine Triphosphate promotes the reaction [[lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of Biological Factors] which results in increased expression of COL1A1 mRNA]; Adenosine Triphosphate promotes the reaction [[lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of Biological Factors] which results in increased expression of COL1A1 protein]; Adenosine Triphosphate promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of COL1A1 mRNA]; Adenosine Triphosphate promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of COL1A1 protein]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 mRNA]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 protein]; L 709049 inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 mRNA]; L 709049 inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 protein]

NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460

G

catechol-O-methyltransferase

multiple interactions

ISO

[Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased activity of COMT protein] which results in decreased abundance of Adenosine Triphosphate; [tolcapone results in decreased activity of COMT protein] which results in decreased abundance of Adenosine Triphosphate

NCBI chr11:96,072,371...96,091,956
Ensembl chr11:96,072,489...96,092,533

G

carnitine palmitoyltransferase 2

multiple interactions

ISO

[Bezafibrate results in increased activity of CPT2 protein] which results in increased abundance of Adenosine Triphosphate; Carnitine promotes the reaction [[Bezafibrate results in increased activity of CPT2 protein] which results in increased abundance of Adenosine Triphosphate]

NCBI chr 5:127,893,450...127,911,347
Ensembl chr 5:127,893,207...127,910,818

G

CRK like proto-oncogene, adaptor protein

multiple interactions

ISO

[ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein; [BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein; sorafenib inhibits the reaction [[ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein]; sorafenib inhibits the reaction [[BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein]

NCBI chr11:97,033,033...97,067,457
Ensembl chr11:97,024,782...97,067,457

G

colony stimulating factor 2

multiple interactions

ISO

[CSF2 protein affects the susceptibility to stearic acid] which affects the abundance of Adenosine Triphosphate

NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,887,692...38,890,031

G

casein kinase 2 alpha 1

multiple interactions
affects binding

ISO

silmitasertib inhibits the reaction [Adenosine Triphosphate binds to [CSNK2A1 protein binds to CSNK2A1 protein binds to CSNK2B protein binds to CSNK2B protein]]

NCBI chr 3:161,170,295...161,217,073
Ensembl chr 3:161,170,405...161,215,698

G

casein kinase 2 beta

multiple interactions
affects binding

ISO

silmitasertib inhibits the reaction [Adenosine Triphosphate binds to [CSNK2A1 protein binds to CSNK2A1 protein binds to CSNK2B protein binds to CSNK2B protein]]

NCBI chr20:3,704,833...3,709,999
Ensembl chr20:3,704,904...3,710,525

G

cystatin B

multiple interactions

ISO

Adenosine Triphosphate promotes the reaction [[CSTB gene mutant form results in increased susceptibility to lipopolysaccharide, E coli O55-B5] which results in increased cleavage of CASP1 protein]; Adenosine Triphosphate promotes the reaction [[CSTB gene mutant form results in increased susceptibility to lipopolysaccharide, E coli O55-B5] which results in increased cleavage of CASP4 protein]

NCBI chr20:10,245,157...10,247,199
Ensembl chr20:10,245,158...10,247,199

G

cathepsin B

increases activity
multiple interactions

ISO

Adenosine Triphosphate results in increased activity of CTSB protein
azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased expression of CTSB protein]

NCBI chr15:41,565,607...41,586,479
Ensembl chr15:41,565,611...41,586,478

G

C-X-C motif chemokine ligand 2

increases secretion
multiple interactions

ISO

Adenosine Triphosphate results in increased secretion of CXCL2 protein
azetidine inhibits the reaction [Adenosine Triphosphate results in increased secretion of CXCL2 protein]

NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,465,242...17,467,255

G

dystrophin

increases secretion
multiple interactions

ISO

DMD gene mutant form results in increased secretion of Adenosine Triphosphate
Nifedipine inhibits the reaction [DMD gene mutant form results in increased secretion of Adenosine Triphosphate]

NCBI chr X:51,070,098...53,437,845
Ensembl chr X:51,070,273...53,437,835

G

dual specificity phosphatase 1

multiple interactions

ISO

Adenosine Triphosphate inhibits the reaction [Cesium-137 results in increased expression of DUSP1 protein]; AZ10606120 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in decreased expression of DUSP1 protein]]

NCBI chr10:17,184,853...17,187,646
Ensembl chr10:17,184,823...17,187,644

G

dual specificity phosphatase 6

multiple interactions

ISO

Adenosine Triphosphate inhibits the reaction [Cesium-137 results in increased expression of DUSP6 protein]; AZ10606120 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in decreased expression of DUSP6 protein]]

NCBI chr 7:35,979,502...35,983,834
Ensembl chr 7:35,977,921...35,983,833

G

epidermal growth factor receptor

multiple interactions
increases phosphorylation

ISO

sodium arsenite promotes the reaction [Adenosine Triphosphate results in increased phosphorylation of EGFR protein]

NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358

G

early growth response 1

multiple interactions
increases expression

EXP

Iodoacetates inhibits the reaction [Adenosine Triphosphate results in increased expression of EGR1 mRNA]; Potassium Cyanide inhibits the reaction [Adenosine Triphosphate results in increased expression of EGR1 mRNA]; Sodium Azide inhibits the reaction [Adenosine Triphosphate results in increased expression of EGR1 mRNA]

NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,736,838...26,740,843

G

ectonucleotide pyrophosphatase/phosphodiesterase 2

multiple interactions

ISO

Adenosine Triphosphate promotes the reaction [Toluene 2,4-Diisocyanate results in increased expression of ENPP2 protein]

NCBI chr 7:88,092,140...88,214,758
Ensembl chr 7:88,092,140...88,214,957

G

ectonucleotide pyrophosphatase/phosphodiesterase 7

decreases activity

ISO

Adenosine Triphosphate results in decreased activity of ENPP7 protein

NCBI chr10:104,740,763...104,745,760
Ensembl chr10:104,740,763...104,745,760

G

ERCC excision repair 6, chromatin remodeling factor

decreases abundance
multiple interactions

ISO

ERCC6 gene mutant form results in decreased abundance of Adenosine Triphosphate
nicotinamide-beta-riboside inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Adenosine Triphosphate]

NCBI chr16:7,771,311...7,841,895
Ensembl chr16:7,771,581...7,841,895

G

coagulation factor II, thrombin

multiple interactions
increases transport
increases abundance
increases secretion

ISO

2,4,3',5'-tetramethoxystilbene inhibits the reaction [F2 protein results in increased secretion of Adenosine Triphosphate]; [RWJ-56110 co-treated with 2,4,3',5'-tetramethoxystilbene] inhibits the reaction [F2 protein results in increased secretion of Adenosine Triphosphate]; calmidazolium affects the reaction [F2 protein results in increased secretion of Adenosine Triphosphate]; Fendiline affects the reaction [F2 protein results in increased secretion of Adenosine Triphosphate]; Quercetin inhibits the reaction [F2 protein results in increased abundance of Adenosine Triphosphate]; Resveratrol inhibits the reaction [F2 protein results in increased abundance of Adenosine Triphosphate]
F2 protein results in increased transport of Adenosine Triphosphate
STXBP2 protein affects the reaction [F2 protein results in increased transport of Adenosine Triphosphate]

PMID:2030746 PMID:15342215 PMID:30696774 PMID:35288162

NCBI chr 3:98,051,958...98,065,246
Ensembl chr 3:98,051,960...98,065,246

G

fatty acid synthase

multiple interactions
decreases abundance

ISO

FASN protein promotes the reaction [rosiglitazone promotes the reaction [PPARG protein results in decreased abundance of Adenosine Triphosphate]]; Protein Kinase Inhibitors inhibits the reaction [FASN protein results in decreased abundance of Adenosine Triphosphate]

NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,570,413...106,588,583

G

fructose-bisphosphatase 1

multiple interactions

ISO

[Enzyme Inhibitors results in decreased activity of FBP1 protein] which results in decreased abundance of Adenosine Triphosphate

NCBI chr17:2,212,941...2,235,749
Ensembl chr17:2,213,492...2,235,746

G

F-box protein 3

multiple interactions

EXP

FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]

NCBI chr 3:110,872,185...110,904,479
Ensembl chr 3:110,872,220...110,904,479

G

Fos proto-oncogene, AP-1 transcription factor subunit

increases expression
multiple interactions

EXP
ISO

Adenosine Triphosphate results in increased expression of FOS mRNA
ALPL gene mutant form promotes the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA]
[Phenylephrine co-treated with Adenosine Triphosphate] results in increased expression of FOS mRNA; Glucose affects the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA]; Iodoacetates inhibits the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA]; Potassium Cyanide inhibits the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA]; Sodium Azide inhibits the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA]

PMID:10723097 PMID:19463813 PMID:27466191

NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598

G

fascin actin-bundling protein 1

increases expression
multiple interactions

ISO

Adenosine Triphosphate results in increased expression of FSCN1 mRNA
Niclosamide inhibits the reaction [Adenosine Triphosphate results in increased expression of FSCN1 mRNA]

NCBI chr12:16,710,601...16,723,734
Ensembl chr12:16,710,601...16,723,734

G

glyceraldehyde-3-phosphate dehydrogenase

multiple interactions

ISO

Adenosine Triphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]

NCBI chr 4:159,648,592...159,653,436
Ensembl chr 4:159,648,592...159,653,377

G

growth hormone 1

multiple interactions
increases secretion

ISO
EXP

oxophenylarsine inhibits the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein]; Phosphatidylinositol 4,5-Diphosphate affects the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein]
NCS1 protein promotes the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein]; oxophenylarsine inhibits the reaction [NCS1 protein promotes the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein]]

NCBI chr10:91,727,883...91,729,860
Ensembl chr10:91,727,884...91,729,859

G

gap junction protein, alpha 1

increases export

ISO

GJA1 protein mutant form results in increased export of Adenosine Triphosphate; GJA1 protein results in increased export of Adenosine Triphosphate

NCBI chr20:36,302,490...36,315,010
Ensembl chr20:36,302,352...36,319,689

G

gasdermin D

multiple interactions

ISO
EXP

[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of GSDMD protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of GSDMD protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein; Disulfiram inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]; HK1 protein affects the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of GSDMD protein]; HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of GSDMD protein]]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of GSDMD protein]; Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of GSDMD protein]
[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of GSDMD protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased cleavage of GSDMD protein; Hirudins inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased cleavage of GSDMD protein]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of GSDMD protein]

PMID:33851234 PMID:34212273 PMID:34217685 PMID:35962723 PMID:36577999 More...

NCBI chr 7:109,423,209...109,427,771
Ensembl chr 7:109,422,910...109,430,722

G

glutathione S-transferase pi 1

multiple interactions

ISO

[GSTP1 protein co-treated with Glutathione] inhibits the reaction [[Adenosine Triphosphate results in increased metabolism of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased abundance of 2-amino-1-methyl-6-phenolimidazo(4,5-b)pyridine-DNA adduct]; [GSTP1 protein co-treated with Glutathione] inhibits the reaction [Adenosine Triphosphate results in increased activity of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine]

NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:210,767,237...210,769,705

G

H2A.X variant histone

multiple interactions

ISO

Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]; AZ10606120 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]]; U 0126 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]]

NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079

G

HCK proto-oncogene, Src family tyrosine kinase

multiple interactions
affects binding

ISO

[Curcumin binds to 4-bis(2-chloroethyl)aminobenzaldehyde] inhibits the reaction [HCK protein binds to Adenosine Triphosphate]

NCBI chr 3:162,031,833...162,074,933
Ensembl chr 3:162,031,817...162,074,935

G

hypoxia inducible factor 1 subunit alpha

multiple interactions

ISO

Adenosine Triphosphate inhibits the reaction [protoporphyrin IX results in decreased activity of HIF1A protein]

NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323

G

hexokinase 1

multiple interactions

ISO

[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of HK1 protein; HK1 protein affects the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of CASP1 protein]; HK1 protein affects the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of GSDMD protein]; HK1 protein affects the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL1B protein]; HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of CASP1 protein]]; HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of GSDMD protein]]; HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL1B protein]]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of HK1 protein]

NCBI chr20:30,773,222...30,874,814
Ensembl chr20:30,773,220...30,874,814

G

hexokinase 2

multiple interactions

ISO

[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of HK2 mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of HK2 protein

NCBI chr 4:116,792,258...116,841,275
Ensembl chr 4:116,792,258...116,841,275

G

high mobility group box 1

affects chemical synthesis
multiple interactions

ISO

HMGB1 protein affects the chemical synthesis of Adenosine Triphosphate
[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased cleavage of CASP1 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of CASP1 mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL18 mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL1B mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of MYD88 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK1 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK3 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of RELA protein; Adenosine Triphosphate promotes the reaction [fullerene C60 results in increased secretion of HMGB1 protein]; Adenosine Triphosphate promotes the reaction [graphene oxide results in increased secretion of HMGB1 protein]; Adenosine Triphosphate promotes the reaction [Nanotubes, Carbon results in increased secretion of HMGB1 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased cleavage of CASP1 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of CASP1 mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL18 mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL1B mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of MYD88 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK1 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK3 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of RELA protein]

PMID:21641551 PMID:31504961 PMID:34405489

NCBI chr12:11,009,236...11,015,941
Ensembl chr16:39,039,050...39,041,327
Ensembl chr12:39,039,050...39,041,327

G

heme oxygenase 1

multiple interactions

ISO

[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of HMOX1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of HMOX1 protein; Luteolin promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of HMOX1 protein]; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of HMOX1 protein]; SR18292 inhibits the reaction [malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of HMOX1 protein]]

PMID:34217685 PMID:38135199

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818

G

heat shock protein 90 alpha family class A member 1

multiple interactions

ISO

Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to HSP90AA1 protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]; Calcium promotes the reaction [Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]]

NCBI chr 6:135,523,604...135,529,687
Ensembl chr 6:135,523,616...135,528,499

G

heat shock protein family A (Hsp70) member 5

multiple interactions

ISO

[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of HSPA5 mRNA; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of HSPA5 protein; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of HSPA5 mRNA]; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of HSPA5 protein]

NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:38,453,041...38,458,790

G

heat shock protein family B (small) member 1

affects chemical synthesis

ISO

HSPB1 protein affects the chemical synthesis of Adenosine Triphosphate

NCBI chr12:26,430,640...26,432,301
Ensembl chr12:26,430,640...26,432,301

G

heat shock protein family D (Hsp60) member 1

multiple interactions
increases expression

EXP

bisindolylmaleimide I inhibits the reaction [Adenosine Triphosphate results in increased expression of HSPD1 protein]; chelerythrine inhibits the reaction [Adenosine Triphosphate results in increased expression of HSPD1 protein]; Neomycin inhibits the reaction [Adenosine Triphosphate results in increased expression of HSPD1 protein]; resveratrol inhibits the reaction [Adenosine Triphosphate results in increased expression of HSPD1 protein]; tricyclodecane-9-yl-xanthogenate inhibits the reaction [Adenosine Triphosphate results in increased expression of HSPD1 protein]

NCBI chr 9:64,073,610...64,084,332
Ensembl chr 9:64,073,611...64,084,037

G

intercellular adhesion molecule 1

multiple interactions

ISO

Adenosine Triphosphate inhibits the reaction [Fructose results in increased expression of ICAM1 protein]

NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617

G

interferon gamma

multiple interactions

ISO

Adenosine Triphosphate promotes the reaction [[TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Dinoprostone]

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216

G

interleukin 12B

multiple interactions

ISO

Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of IL12B protein]

NCBI chr10:29,390,300...29,405,194
Ensembl chr10:29,389,905...29,405,194

G

interleukin 18

multiple interactions
increases secretion

ISO
EXP

[Adenosine Triphosphate co-treated with K-12 lipopolysaccharide] results in increased secretion of IL18 protein; [Disulfiram co-treated with Adenosine Triphosphate] inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL18 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein; Disulfiram inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein]; Resveratrol promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 mRNA]; Resveratrol promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein]; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein]
[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein]
Adenosine Triphosphate results in increased secretion of IL18 protein
3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL18 protein]; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL18 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of IL18 mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL18 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein; Acetylcysteine inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL18 protein]; diphenyleneiodonium inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL18 protein]; Hirudins inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein]; Ibuprofen inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL18 protein]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL18 protein]; prim-O-glucosylcimifugin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL18 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL18 mRNA]

PMID:17404311 PMID:24149798 PMID:26431797 PMID:27311643 PMID:29378952 More...

NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:59,809,592...59,831,286

G

interleukin 1 alpha

multiple interactions

ISO

(N-(1-(((cyanoimino)(5-quinolinylamino) methyl) amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide) inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1A protein]; (N-(1-(((cyanoimino)(5-quinolinylamino) methyl) amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide) inhibits the reaction [Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of IL1A protein]]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1A protein; Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of IL1A protein]

NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013

G

interleukin 1 beta

multiple interactions
increases expression
increases secretion
decreases abundance

EXP
ISO

[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein; Enzyme Inhibitors inhibits the reaction [IL1B protein results in decreased abundance of Adenosine Triphosphate]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; IL1B protein inhibits the reaction [Adenosine Triphosphate results in increased secretion of INS1 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; Quercetin inhibits the reaction [IL1B protein inhibits the reaction [Adenosine Triphosphate results in increased secretion of INS1 protein]]
Adenosine Triphosphate results in increased expression of IL1B protein
Adenosine Triphosphate results in increased secretion of IL1B protein
(N-(1-(((cyanoimino)(5-quinolinylamino) methyl) amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide) inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; (N-(1-(((cyanoimino)(5-quinolinylamino) methyl) amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide) inhibits the reaction [Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]; 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL1B protein]; [[Air Pollutants results in increased abundance of Particulate Matter] results in increased susceptibility to [Dietary Fats co-treated with Lipopolysaccharides co-treated with Adenosine Triphosphate]] which results in increased secretion of IL1B protein; [[Air Pollutants results in increased abundance of Particulate Matter] results in increased susceptibility to [Lipopolysaccharides co-treated with Adenosine Triphosphate]] which results in increased secretion of IL1B protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL1B mRNA; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of and results in increased secretion of IL1B protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased activity of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein; Acetylcysteine inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL1B protein]; Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; Adenosine Triphosphate promotes the reaction [[TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Dinoprostone]; Adenosine Triphosphate promotes the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; Adenosine Triphosphate promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; Arsenic Trioxide inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; Chlorquinaldol inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; dapansutrile inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein]; diphenyleneiodonium inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL1B protein]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; ginsenoside Rg3 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; gypenoside LXXV inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; Hirudins inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; Ibuprofen inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein]; leojaponin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of and affects the cleavage of IL1B protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein]; N-acetyl-tyrosyl-valyl-alanyl-aspartyl chloromethyl ketone inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of IL1B protein]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein]; Okadaic Acid inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; PML protein promotes the reaction [[resiquimod co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; prim-O-glucosylcimifugin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL1B mRNA]; tabersonine inhibits the reaction [Adenosine Triphosphate results in increased expression of IL1B protein]; zinc chloride inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]]
2-(1,3-benzodioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl)-1,3-thiazol-2-yl)acetamide inhibits the reaction [malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of IL1B protein]]; 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; [Adenosine Triphosphate co-treated with K-12 lipopolysaccharide] results in increased secretion of IL1B protein modified form; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA; [Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of IL1B protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL1B protein; [Disulfiram co-treated with Adenosine Triphosphate] inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased cleavage of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein; [Tetradecanoylphorbol Acetate co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein; Adenosine Triphosphate promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL1B protein]; Adenosine Triphosphate promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; Adenosine Triphosphate results in increased cleavage of and results in increased secretion of IL1B protein; Apigenin inhibits the reaction [Adenosine Triphosphate results in increased cleavage of and results in increased secretion of IL1B protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; dapansutrile inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; Disulfiram inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; flavone analog inhibits the reaction [Adenosine Triphosphate results in increased cleavage of and results in increased secretion of IL1B protein]; HK1 protein affects the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL1B protein]; HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL1B protein]]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of IL1B protein]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL1B protein]; KN 62 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein]; L 709049 inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of IL1B protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; MitoTEMPO inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; neoisoliquiritin affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; Resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein]; Resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA]; Resveratrol promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; SR18292 inhibits the reaction [malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of IL1B protein]]; tyrosyl-valyl-alanyl-aspartic acid fluoromethyl ketone analog inhibits the reaction [Adenosine Triphosphate results in increased cleavage of and results in increased secretion of IL1B protein]; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA]

PMID:10365824 PMID:14623498 PMID:17404311 PMID:18604214 PMID:19130485 More...

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 6

multiple interactions
increases expression

ISO
EXP

[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL6 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL6 protein; Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; Disulfiram inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL6 protein]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL6 protein]; NF157 compound inhibits the reaction [Adenosine Triphosphate results in increased expression of IL6 protein]; sodium arsenite promotes the reaction [Adenosine Triphosphate results in increased expression of IL6 protein]; Suramin inhibits the reaction [Adenosine Triphosphate results in increased expression of IL6 protein]
Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]; coomassie Brilliant Blue inhibits the reaction [Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]]; resveratrol inhibits the reaction [Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]]; SB 203580 inhibits the reaction [Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]]
[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of IL6 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of IL6 protein; azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased expression of IL6 protein]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of IL6 mRNA]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of IL6 protein]; MRS 2211 inhibits the reaction [Adenosine Triphosphate results in increased expression of IL6 protein]

PMID:17707769 PMID:24793913 PMID:24849676 PMID:25348860 PMID:26104857 More...

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

insulin 1

multiple interactions
increases secretion

ISO
EXP

Adenosine Triphosphate inhibits the reaction [Glucose results in increased secretion of INS1 protein]
Adenosine Triphosphate results in increased secretion of INS1 protein
[[Glucose co-treated with INS1 protein] results in increased abundance of Adenosine Triphosphate] which results in increased secretion of LEP protein; [Glucose co-treated with INS1 protein] results in increased abundance of Adenosine Triphosphate; IL1B protein inhibits the reaction [Adenosine Triphosphate results in increased secretion of INS1 protein]; Quercetin inhibits the reaction [IL1B protein inhibits the reaction [Adenosine Triphosphate results in increased secretion of INS1 protein]]; SIRT1 protein promotes the reaction [[Glucose results in increased abundance of Adenosine Triphosphate] which results in increased expression of INS1 protein]

PMID:10535451 PMID:10780946 PMID:16366736 PMID:22221676

NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:261,186,119...261,186,682

G

insulin 2

multiple interactions

ISO

[ammonium ferrous sulfate results in increased activity of INS protein modified form] which results in increased secretion of Adenosine Triphosphate; [chromic chloride results in increased activity of INS protein modified form] which results in increased secretion of Adenosine Triphosphate; INS protein inhibits the reaction [Acetaminophen results in decreased abundance of Adenosine Triphosphate]; Mannose inhibits the reaction [[chromic chloride results in increased activity of INS protein modified form] which results in increased secretion of Adenosine Triphosphate]; Phloretin inhibits the reaction [[chromic chloride results in increased activity of INS protein modified form] which results in increased secretion of Adenosine Triphosphate]

PMID:17965850 PMID:26739624

NCBI chr 1:207,272,738...207,421,998
Ensembl chr 1:207,272,742...207,273,805

G

interferon regulatory factor 2

multiple interactions

ISO

[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IRF2 mRNA; Hirudins inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IRF2 mRNA]

NCBI chr16:52,171,855...52,283,620
Ensembl chr16:52,164,442...52,282,627

G

integrin subunit beta 1 binding protein 2

multiple interactions

ISO

Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to PPP5C protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to SUGT1 protein]; Calcium promotes the reaction [Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to SUGT1 protein]]
Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to CHORDC1 protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to ITGB1BP2 protein]; Calcium promotes the reaction [Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]]

NCBI chr X:70,612,118...70,617,158
Ensembl chr X:70,612,521...70,617,158

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

ISO

[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of JUN protein; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of JUN protein]

NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285

G

potassium voltage-gated channel subfamily D member 2

multiple interactions
increases abundance

ISO

[[FAM66C mRNA binds to and results in decreased expression of MIR23 mRNA] which results in increased expression of KCND2 protein] which results in increased abundance of Adenosine Triphosphate; [[MIR23B mRNA binds to KCND2 3' UTR] which results in decreased expression of KCND2 protein] which results in decreased abundance of Adenosine Triphosphate
KCND2 protein results in increased abundance of Adenosine Triphosphate

NCBI chr 4:50,741,595...51,243,540
Ensembl chr 4:50,742,839...51,243,522

G

potassium voltage-gated channel subfamily H member 2

decreases activity

ISO

Adenosine Triphosphate deficiency results in decreased activity of KCNH2 protein

NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421

G

potassium inwardly-rectifying channel, subfamily J, member 11

multiple interactions
decreases response to substance

ISO

Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]; Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]; Creatine metabolite inhibits the reaction [Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]]
KCNJ11 protein mutant form results in decreased susceptibility to Adenosine Triphosphate

PMID:11390963 PMID:28842488

NCBI chr 1:105,727,473...105,731,167
Ensembl chr 1:105,727,570...105,731,169

G

potassium inwardly-rectifying channel, subfamily J, member 15

increases activity

ISO

Adenosine Triphosphate results in increased activity of KCNJ15 protein

NCBI chr11:48,046,953...48,091,285
Ensembl chr11:48,035,655...48,092,457

G

potassium inwardly-rectifying channel, subfamily J, member 8

multiple interactions
decreases response to substance

EXP

Adenosine Triphosphate results in decreased activity of [KCNJ8 protein binds to ABCC9 protein]
KCNJ8 protein mutant form results in decreased susceptibility to Adenosine Triphosphate

NCBI chr 4:177,240,692...177,246,548
Ensembl chr 4:177,239,908...177,246,531

G

ketohexokinase

multiple interactions

ISO

KHK protein promotes the reaction [Fructose results in decreased abundance of Adenosine Triphosphate]

NCBI chr 6:31,165,246...31,175,779
Ensembl chr 6:31,165,248...31,175,481

G

kinesin family member 5A

multiple interactions
increases hydrolysis

ISO

Adenosine Triphosphate inhibits the reaction [zinc chloride results in decreased activity of KIF5A protein]; Cadmium Chloride inhibits the reaction [KIF5A protein results in increased hydrolysis of Adenosine Triphosphate]; Egtazic Acid inhibits the reaction [Cadmium Chloride inhibits the reaction [KIF5A protein results in increased hydrolysis of Adenosine Triphosphate]]

PMID:24239783 PMID:28122263

NCBI chr 7:64,937,210...64,974,339
Ensembl chr 7:64,934,740...64,978,272

G

leptin

multiple interactions

EXP

[[Glucose co-treated with INS1 protein] results in increased abundance of Adenosine Triphosphate] which results in increased secretion of LEP protein; [Deoxyglucose results in decreased abundance of Adenosine Triphosphate] which results in decreased secretion of LEP protein

NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:58,626,523...58,640,661

G

lipase E, hormone sensitive type

increases activity

ISO

Adenosine Triphosphate results in increased activity of LIPE protein

NCBI chr 1:90,093,433...90,112,117
Ensembl chr 1:90,093,433...90,112,117

G

lipoprotein lipase

affects response to substance

ISO

LPL protein affects the susceptibility to Adenosine Triphosphate

NCBI chr16:25,596,205...25,621,928
Ensembl chr16:25,596,211...25,622,107

G

mitogen activated protein kinase kinase 1

affects binding

ISO

Adenosine Triphosphate binds to MAP2K1 protein

NCBI chr 8:73,578,747...73,650,184
Ensembl chr 8:73,578,752...73,650,184

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation
increases activity

ISO
EXP

1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK1 protein]; [Alcohols co-treated with Adenosine Triphosphate] results in increased activity of MAPK1 protein; Alcohols inhibits the reaction [Adenosine Triphosphate results in increased activity of MAPK1 protein]; AZ10606120 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased phosphorylation of MAPK1 protein]]; sodium arsenite promotes the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK1 protein]
[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK1 protein; azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK1 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK1 protein]

PMID:12513686 PMID:15034929 PMID:21503959 PMID:24300283 PMID:26104857 More...

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation
increases activity

ISO
EXP

1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK3 protein]; [Alcohols co-treated with Adenosine Triphosphate] results in increased activity of MAPK3 protein; Alcohols inhibits the reaction [Adenosine Triphosphate results in increased activity of MAPK3 protein]; AZ10606120 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased phosphorylation of MAPK3 protein]]; sodium arsenite promotes the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK3 protein]
[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK3 protein; azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK3 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK3 protein]

PMID:12513686 PMID:15034929 PMID:21503959 PMID:24300283 PMID:26104857 More...

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

microtubule-associated protein tau

multiple interactions
decreases abundance

EXP
ISO

[annonacin results in decreased abundance of Adenosine Triphosphate] which affects the localization of MAPT protein
MAPT protein mutant form results in decreased abundance of Adenosine Triphosphate
PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of Adenosine Triphosphate]

PMID:17634376 PMID:39172838

NCBI chr10:89,638,618...89,736,108
Ensembl chr10:89,638,599...89,736,108

G

meteorin-like, glial cell differentiation regulator

multiple interactions

ISO

METRNL protein inhibits the reaction [Dietary Fats results in decreased abundance of Adenosine Triphosphate]

NCBI chr10:107,462,148...107,476,143
Ensembl chr10:107,462,109...107,476,135

G

mitofusin 2

decreases response to substance
multiple interactions
increases chemical synthesis

ISO
EXP

MFN2 results in decreased susceptibility to Adenosine Triphosphate deficiency
MFN2 protein inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased chemical synthesis of Adenosine Triphosphate]
MFN2 protein inhibits the reaction [TNF protein results in decreased chemical synthesis of Adenosine Triphosphate]
MFN2 protein results in increased chemical synthesis of Adenosine Triphosphate

PMID:22292091 PMID:24898700 PMID:25416777

NCBI chr 5:163,587,463...163,617,363
Ensembl chr 5:163,587,463...163,618,495

G

microRNA 219a-1

multiple interactions

EXP

[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of MIR219A1 mRNA; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]

NCBI chr20:4,831,580...4,831,689
Ensembl chr20:4,831,580...4,831,689

G

microRNA 23b

multiple interactions
decreases abundance

ISO

[[MIR23B mRNA binds to KCND2 3' UTR] which results in decreased expression of KCND2 protein] which results in decreased abundance of Adenosine Triphosphate
MIR23B mRNA results in decreased abundance of Adenosine Triphosphate

NCBI chr17:1,819,386...1,819,482

G

matrix metallopeptidase 2

multiple interactions

ISO

[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of MMP2 mRNA; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of MMP2 mRNA]

NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856

G

matrix metallopeptidase 9

multiple interactions
increases activity
increases secretion

EXP
ISO

1,10-phenanthroline inhibits the reaction [Adenosine Triphosphate results in increased activity of MMP9 protein]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Adenosine Triphosphate results in increased activity of MMP9 protein]; SB 3CT compound inhibits the reaction [Adenosine Triphosphate results in increased activity of MMP9 protein]; wortmannin inhibits the reaction [Adenosine Triphosphate results in increased activity of MMP9 protein]
[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of MMP9 mRNA; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of MMP9 mRNA]
azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased expression of MMP9 protein]
Adenosine Triphosphate results in increased secretion of MMP9 protein

PMID:20195827 PMID:26522449 PMID:36847822

NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442

G

mitochondrially encoded ATP synthase membrane subunit 6

affects abundance

EXP

ATP6 protein affects the abundance of Adenosine Triphosphate

NCBI chr MT:7,919...8,599
Ensembl chr MT:7,904...8,584

G

mitochondrially encoded cytochrome c oxidase III

increases abundance

ISO

COX3 protein results in increased abundance of Adenosine Triphosphate

NCBI chr MT:8,599...9,382
Ensembl chr MT:8,584...9,367

G

mevalonate diphosphate decarboxylase

increases hydrolysis

ISO

MVD protein results in increased hydrolysis of Adenosine Triphosphate

NCBI chr19:67,404,911...67,414,974
Ensembl chr19:67,404,911...67,422,366

G

mevalonate kinase

increases hydrolysis
multiple interactions

ISO

MVK protein results in increased hydrolysis of Adenosine Triphosphate
3,3-dimethylallyl pyrophosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; dolichol monophosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; Farnesol inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; farnesyl pyrophosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; geranyl diphosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; geranylgeranyl pyrophosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; isopentenyl pyrophosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]

NCBI chr12:47,802,002...47,819,503
Ensembl chr12:47,802,002...47,819,503

G

MYD88, innate immune signal transduction adaptor

multiple interactions

ISO

[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of MYD88 protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of MYD88 protein; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of MYD88 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of MYD88 protein]

PMID:34405489 PMID:37544346

NCBI chr 8:127,952,161...127,956,230
Ensembl chr 8:127,952,161...127,956,230

G

myosin heavy chain 7

increases abundance

ISO

MYH7 gene mutant form results in increased abundance of Adenosine Triphosphate

NCBI chr15:32,416,525...32,439,851
Ensembl chr15:32,416,527...32,438,194

G

NAD synthetase 1

multiple interactions

ISO

[Ammonium Chloride co-treated with nicotinic acid adenine dinucleotide co-treated with Adenosine Triphosphate] results in increased activity of NADSYN1 protein; [NADSYN1 protein co-treated with Ammonium Chloride co-treated with nicotinic acid adenine dinucleotide co-treated with Adenosine Triphosphate] results in increased chemical synthesis of NAD

NCBI chr 1:208,410,914...208,439,242
Ensembl chr 1:208,410,914...208,439,207

G

neuronal calcium sensor 1

multiple interactions
increases response to substance

EXP

NCS1 protein promotes the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein]; oxophenylarsine inhibits the reaction [NCS1 protein promotes the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein]]
NCS1 protein results in increased susceptibility to Adenosine Triphosphate

NCBI chr 3:34,920,949...34,966,554
Ensembl chr 3:34,920,971...34,968,711

G

NIMA-related kinase 7

multiple interactions

ISO

[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] promotes the reaction [NLRP3 protein binds to NEK7 protein]

NCBI chr13:52,573,730...52,700,869
Ensembl chr13:52,573,730...52,700,823

G

nuclear factor of activated T-cells 1

affects localization
multiple interactions

EXP
ISO

Adenosine Triphosphate affects the localization of NFATC1 protein
azetidine analog inhibits the reaction [Adenosine Triphosphate affects the localization of NFATC1 protein]

PMID:21464294 PMID:26522449

NCBI chr18:76,321,386...76,430,997
Ensembl chr18:76,321,386...76,430,990

G

nuclear factor of activated T-cells 3

affects localization

EXP

Adenosine Triphosphate affects the localization of NFATC3 protein

NCBI chr19:50,870,464...50,944,992
Ensembl chr19:50,870,489...50,944,992

G

NFE2 like bZIP transcription factor 2

multiple interactions

ISO

[Lipopolysaccharides co-treated with Adenosine Triphosphate] affects the localization of NFE2L2 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] inhibits the reaction [PPARGC1A protein binds to NFE2L2 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of NFE2L2 protein; Luteolin promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] affects the localization of NFE2L2 protein]; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] inhibits the reaction [PPARGC1A protein binds to NFE2L2 protein]]; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of NFE2L2 protein]; SR18292 inhibits the reaction [malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of NFE2L2 protein]]

PMID:34217685 PMID:38135199

NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090

G

NFKB inhibitor alpha

multiple interactions

EXP
ISO

Adenosine Triphosphate promotes the reaction [RELA protein binds to NFKBIA protein]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NFKBIA protein]]
[Adenosine Triphosphate co-treated with Lipopolysaccharides] affects the localization of NFKBIA protein; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] affects the localization of NFKBIA protein]

PMID:21464294 PMID:24149798

NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072

G

nerve growth factor

multiple interactions

EXP

[NGF protein co-treated with Adenosine Triphosphate] results in increased uptake of Calcium

NCBI chr 2:192,589,580...192,642,971
Ensembl chr 2:192,589,582...192,643,834

G

NLR family, pyrin domain containing 1A

multiple interactions

ISO

[Lipopolysaccharides co-treated with Adenosine Triphosphate co-treated with resveratrol] results in increased expression of NLRP1 mRNA

NCBI chr10:56,277,134...56,332,229
Ensembl chr10:56,277,134...56,323,880

G

NLR family, pyrin domain containing 3

multiple interactions

ISO
EXP

[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] promotes the reaction [NLRP3 protein binds to NEK7 protein]; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] promotes the reaction [NLRP3 protein binds to PYCARD protein]; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased activity of NLRP3 protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of NLRP3 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to CASP1 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PML protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PYCARD protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 mRNA]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of NLRP3 protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to CASP1 protein]]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PYCARD protein]]; prim-O-glucosylcimifugin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 protein]; tabersonine inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] promotes the reaction [NLRP3 protein binds to PYCARD protein]]; tabersonine inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased activity of NLRP3 protein]
[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]
2-(1,3-benzodioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl)-1,3-thiazol-2-yl)acetamide inhibits the reaction [malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]]; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of NLRP3 protein; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased activity of NLRP3 protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate co-treated with Resveratrol] results in increased expression of NLRP3 mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein; Acetylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein]; KN 62 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; neoisoliquiritin affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein]; SR18292 inhibits the reaction [malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]]; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]

PMID:18604214 PMID:23430110 PMID:24149798 PMID:26086368 PMID:26586371 More...

NCBI chr10:44,826,299...44,853,373
Ensembl chr10:44,828,014...44,853,394

G

nucleolar and coiled-body phosphoprotein 1

multiple interactions

ISO

Adenosine Triphosphate affects the reaction [Doxorubicin binds to NOLC1 protein]

NCBI chr 1:254,870,195...254,881,070
Ensembl chr 1:254,870,319...254,881,069

G

nitric oxide synthase 2

multiple interactions
increases expression

ISO
EXP

[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NOS2 protein; NOS2 protein affects the reaction [Adenosine Triphosphate results in increased metabolism of RELA protein]; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NOS2 protein]
azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased expression of NOS2 protein]
[Adenosine Triphosphate results in increased expression of NOS2 protein] promotes the reaction [NOS2 protein binds to RELA protein]; Adenosine Triphosphate promotes the reaction [RELA protein binds to NOS2 protein]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NOS2 protein]]; Cyclosporine inhibits the reaction [[Adenosine Triphosphate results in increased expression of NOS2 protein] promotes the reaction [NOS2 protein binds to RELA protein]]; N-((3-(aminomethyl)phenyl)methyl)ethanimidamide inhibits the reaction [Adenosine Triphosphate results in increased expression of NOS2 protein]; NOS2 protein affects the reaction [Adenosine Triphosphate results in increased abundance of Nitric Oxide]

PMID:21464294 PMID:26522449 PMID:36847822

NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880

G

nitric oxide synthase 3

multiple interactions

ISO

Adenosine Triphosphate affects the reaction [Alcohols affects the phosphorylation of NOS3 protein]; Adenosine Triphosphate inhibits the reaction [Alcohols results in decreased expression of NOS3 protein]

NCBI chr 4:11,686,088...11,706,604
Ensembl chr 4:11,686,268...11,706,664

G

neuropeptide Y

affects response to substance

ISO

NPY protein affects the susceptibility to Adenosine Triphosphate

NCBI chr 4:80,212,111...80,219,310
Ensembl chr 4:80,212,111...80,219,310

G

nuclear receptor subfamily 4, group A, member 1

increases expression

EXP

Adenosine Triphosphate results in increased expression of NR4A1 mRNA

NCBI chr 7:134,247,153...134,268,044
Ensembl chr 7:134,247,192...134,268,041

G

2'-5' oligoadenylate synthetase 1A

multiple interactions

ISO

[OAS1 protein results in increased metabolism of Adenosine Triphosphate] which results in increased chemical synthesis of 2',5'-oligoadenylate

NCBI chr12:41,330,423...41,341,130
Ensembl chr12:41,285,211...41,341,128

G

oxytocin/neurophysin I prepropeptide

multiple interactions
increases secretion

EXP

Adenosine Triphosphate promotes the reaction [Phenylephrine results in increased secretion of OXT protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Phenylephrine co-treated with Adenosine Triphosphate] results in increased secretion of OXT protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate results in increased secretion of OXT protein]

NCBI chr 3:138,235,754...138,236,594
Ensembl chr 3:138,235,754...138,236,594

G

purinergic receptor P2X 1

multiple interactions
affects binding

EXP

geldanamycin promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX1]; herbimycin promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX1]; monorden promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX1]
ATP binds to P2rx1 protein

CTD
RGD

PMID:11930156 PMID:12237343

NCBI chr10:58,117,107...58,132,167
Ensembl chr10:58,117,088...58,132,164

G

purinergic receptor P2X 2

multiple interactions
affects activity
increases activity
affects response to substance

EXP
ISO

1-amino-4-(3-(4,6-dichloro(1,3,5)triazine-2-ylamino)phenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Acetylcysteine inhibits the reaction [Hydrogen Peroxide promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]]; Acetylcysteine inhibits the reaction [Rotenone promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]]; Cadmium Chloride affects the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; cobaltous chloride affects the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Copper promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; cupric chloride promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Dithiothreitol inhibits the reaction [Hydrogen Peroxide promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]]; Hydrogen Peroxide promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Mercuric Chloride promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Mercury promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; methyl methanethiosulfonate inhibits the reaction [Hydrogen Peroxide promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]]; methyl methanethiosulfonate inhibits the reaction [Mercury promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]]; myxothiazol promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; nickel chloride promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; palladium chloride promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Rotenone promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; zinc chloride promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Zinc promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]
ATP affects activity of rat P2x2 receptor in transfected glial cells
P2RX2 protein affects the susceptibility to Adenosine Triphosphate

CTD
RGD

PMID:15081800 PMID:16190872 PMID:19793987 PMID:21207957 PMID:16388598

NCBI chr12:51,999,107...52,002,627
Ensembl chr12:51,999,372...52,002,627

G

purinergic receptor P2X 3

multiple interactions
increases activity
affects activity

EXP

Eugenol inhibits the reaction [P2RX3 protein affects the activity of Adenosine Triphosphate]
Adenosine Triphosphate results in increased activity of P2RX3 protein

PMID:19967073 PMID:27481062

NCBI chr 3:90,487,506...90,531,315
Ensembl chr 3:90,487,506...90,531,794

G

purinergic receptor P2X 4

multiple interactions
increases activity

EXP
ISO

[Cadmium co-treated with Zinc] promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; [Mercury co-treated with Copper] inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Cadmium promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Cobalt promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Copper inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Copper inhibits the reaction [Zinc promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]]; Mercury inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Zinc promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]
5-(3-bromophenyl)-1,3-dihydro-2H-benzofuro(3,2-e)-1,4-diazepin-2-one inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; [ginsenoside compound K co-treated with Adenosine Triphosphate] results in increased activity of P2RX4 protein; [Resveratrol co-treated with Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX4 mRNA; [Resveratrol co-treated with Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX4 protein; ginsenoside compound K promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; ginsenoside Rb1 promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; ginsenoside Rd promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Ivermectin promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]

PMID:10737610 PMID:15629187 PMID:19793987 PMID:21638035 PMID:24149798 More...

NCBI chr12:39,505,438...39,523,349
Ensembl chr12:39,505,438...39,523,094

G

purinergic receptor P2X 5

affects transport

EXP

ATP affects transport ion flux of P2rx5 receptor

RGD

NCBI chr10:58,276,329...58,291,108
Ensembl chr10:58,276,257...58,287,935

G

purinergic receptor P2X 7

multiple interactions
increases response to substance
increases expression
decreases response to substance
increases activity

ISO
EXP

[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX7 mRNA; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX7 protein; Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein; AZ 11645373 inhibits the reaction [Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein]; AZ10606120 inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX7 protein]; calmidazolium inhibits the reaction [Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein]; coomassie Brilliant Blue inhibits the reaction [Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein]; KN 62 inhibits the reaction [Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein]; P2RX7 protein affects the reaction [Adenosine Triphosphate results in increased secretion of SELL protein]; P2RX7 protein affects the reaction [Adenosine Triphosphate results in increased transport of Barium]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein]; Resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX7 mRNA]; Resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX7 protein]; ZINC58368839 inhibits the reaction [Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein]
P2RX7 protein results in increased susceptibility to Adenosine Triphosphate
Adenosine Triphosphate results in increased expression of P2RX7 protein
P2RX7 gene mutant form results in decreased susceptibility to Adenosine Triphosphate
3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX7 protein]; azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased expression of P2RX7 protein]; coomassie Brilliant Blue inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX7 protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX7 protein]

PMID:11003599 PMID:17728465 PMID:19023039 PMID:21638035 PMID:23565201 More...

NCBI chr12:39,550,531...39,594,984
Ensembl chr12:39,540,567...39,595,193

G

purinergic receptor P2Y1

multiple interactions
affects activity

ISO
EXP

[Adenosine Triphosphate binds to and results in increased activity of P2RY1 protein] which results in increased abundance of Calcium; Adenosine Triphosphate binds to and results in increased activity of P2RY1 protein; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate inhibits the reaction [P2RY1 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide]]; P2RY1 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide]; Trichloroethylene inhibits the reaction [[Adenosine Triphosphate binds to and results in increased activity of P2RY1 protein] which results in increased abundance of Calcium]
[N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate binds to and results in decreased activity of P2RY1 protein] inhibits the reaction [Adenosine Triphosphate results in increased uptake of Calcium]
Adenosine Triphosphate affects the activity of P2RY1 protein

PMID:12694404 PMID:15243297 PMID:16973929 PMID:22129738

NCBI chr 2:147,391,661...147,397,870
Ensembl chr 2:147,390,681...147,398,027

G

purinergic receptor P2Y13

multiple interactions

ISO

MRS 2211 inhibits the reaction [P2RY13 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide]]; P2RY13 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide]

NCBI chr 2:145,620,321...145,624,730
Ensembl chr 2:145,619,655...145,622,787

G

purinergic receptor P2Y2

multiple interactions
affects activity
increases activity

ISO
EXP

[Adenosine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Calcium
[Adenosine Triphosphate results in increased activity of P2RY2 protein] which results in increased uptake of Calcium
Adenosine Triphosphate affects the activity of P2RY2 protein

PMID:11527950 PMID:15243297 PMID:17003265

NCBI chr 1:164,764,119...164,779,578
Ensembl chr 1:164,759,213...164,781,852

G

pyrimidinergic receptor P2Y4

multiple interactions

ISO

[Adenosine Triphosphate binds to and results in increased activity of P2RY4 protein] which results in increased abundance of Calcium; Adenosine Triphosphate binds to and results in increased activity of P2RY4 protein; Trichloroethylene inhibits the reaction [[Adenosine Triphosphate binds to and results in increased activity of P2RY4 protein] which results in increased abundance of Calcium]

NCBI chr X:69,722,604...69,757,726
Ensembl chr X:69,721,753...69,753,510

G

pyrimidinergic receptor P2Y6

multiple interactions

ISO

N,N''-1,4-butanediylbis(N'-(3-isothiocyanatophenyl))thiourea inhibits the reaction [P2RY6 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide]]; P2RY6 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide]

NCBI chr 1:164,707,188...164,742,689
Ensembl chr 1:164,706,116...164,743,588

G

Pannexin 1

decreases activity
multiple interactions
increases export

ISO

Adenosine Triphosphate results in decreased activity of PANX1 protein
Carbenoxolone inhibits the reaction [PANX1 protein results in increased export of Adenosine Triphosphate]; Probenecid inhibits the reaction [PANX1 protein results in increased export of Adenosine Triphosphate]

PMID:19023039 PMID:19213873

NCBI chr 8:20,128,783...20,171,200
Ensembl chr 8:20,132,165...20,171,200

G

poly (ADP-ribose) polymerase 1

multiple interactions
increases expression

ISO

PARP1 mutant form inhibits the reaction [Cadmium results in decreased abundance of Adenosine Triphosphate]
PARP1 protein affects the reaction [pyrithione zinc results in decreased abundance of Adenosine Triphosphate]; PARP1 protein affects the reaction [Zinc results in decreased abundance of Adenosine Triphosphate]
Adenosine Triphosphate results in increased expression of PARP1 protein

PMID:17728843 PMID:19809895 PMID:21767558 PMID:22253048

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567

G

pyruvate dehydrogenase kinase 1

multiple interactions
affects response to substance

ISO

[PDK1 protein affects the susceptibility to Adenosine Triphosphate] which affects the abundance of Calcium; Adenosine Triphosphate promotes the reaction [PDK1 protein affects the abundance of Calcium]; tubacin affects the reaction [[PDK1 protein affects the susceptibility to Adenosine Triphosphate] which affects the abundance of Calcium]

NCBI chr 3:77,113,464...77,144,145
Ensembl chr 3:77,113,473...77,144,145

G

phosphofructokinase, muscle

multiple interactions

ISO

Adenosine Triphosphate promotes the reaction [resveratrol results in decreased activity of PFKM protein]

NCBI chr 7:131,100,684...131,138,250
Ensembl chr 7:131,100,753...131,138,248

G

phosphoglycolate phosphatase

decreases phosphorylation

ISO

PGP protein results in decreased phosphorylation of Adenosine Triphosphate

NCBI chr10:13,999,782...14,002,408
Ensembl chr10:13,999,331...14,002,408

G

phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha

multiple interactions
affects binding

ISO

2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine inhibits the reaction [Adenosine Triphosphate binds to PIK3CA protein]; Adenosine Triphosphate inhibits the reaction [resveratrol results in decreased activity of [PIK3R1 protein binds to PIK3CA protein]]

PMID:17550345 PMID:18754654

NCBI chr 2:117,103,643...117,177,411
Ensembl chr 2:117,143,468...117,177,411

G

phosphoinositide-3-kinase regulatory subunit 1

multiple interactions

ISO

Adenosine Triphosphate inhibits the reaction [resveratrol results in decreased activity of [PIK3R1 protein binds to PIK3CA protein]]

NCBI chr 2:34,612,946...34,697,660
Ensembl chr 2:34,612,946...34,626,347

G

phospholipase A2 group 4A

increases activity

ISO

Adenosine Triphosphate results in increased activity of PLA2G4A protein

NCBI chr13:64,427,921...64,572,352
Ensembl chr13:64,427,916...64,589,641

G

plasminogen activator, urokinase

increases secretion

ISO

Adenosine Triphosphate results in increased secretion of PLAU protein

NCBI chr15:3,505,485...3,511,987
Ensembl chr15:3,505,487...3,512,030

G

phospholipid phosphatase 3

decreases chemical synthesis

ISO

PLPP3 gene mutant form results in decreased chemical synthesis of Adenosine Triphosphate

NCBI chr 5:125,156,000...125,231,119
Ensembl chr 5:125,155,945...125,235,667

G

PML nuclear body scaffold

multiple interactions

ISO

[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PML protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [PML protein binds to CASP1 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PML protein; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to CASP1 protein]]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PYCARD protein]]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased abundance of Reactive Oxygen Species]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; PML protein promotes the reaction [[resiquimod co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]

NCBI chr 8:67,523,164...67,557,801
Ensembl chr 8:67,523,164...67,576,083

G

phosphomevalonate kinase

increases hydrolysis

ISO

PMVK protein results in increased hydrolysis of Adenosine Triphosphate

NCBI chr 2:177,174,344...177,184,076
Ensembl chr 2:177,174,335...177,184,080

G

peroxisome proliferator activated receptor alpha

multiple interactions

ISO

[Fenofibrate results in increased activity of PPARA protein] which results in decreased abundance of Adenosine Triphosphate

NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714

G

peroxisome proliferator-activated receptor gamma

multiple interactions
decreases abundance

ISO

FASN protein promotes the reaction [rosiglitazone promotes the reaction [PPARG protein results in decreased abundance of Adenosine Triphosphate]]; rosiglitazone promotes the reaction [PPARG protein results in decreased abundance of Adenosine Triphosphate]; UCP1 protein promotes the reaction [PPARG protein mutant form results in decreased abundance of Adenosine Triphosphate]; UCP1 protein promotes the reaction [rosiglitazone promotes the reaction [PPARG protein results in decreased abundance of Adenosine Triphosphate]]
PPARG protein mutant form results in decreased abundance of Adenosine Triphosphate; PPARG protein results in decreased abundance of Adenosine Triphosphate

NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104

G

PPARG coactivator 1 alpha

multiple interactions

ISO

[Lipopolysaccharides co-treated with Adenosine Triphosphate] inhibits the reaction [PPARGC1A protein binds to NFE2L2 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of PPARGC1A protein; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] inhibits the reaction [PPARGC1A protein binds to NFE2L2 protein]]; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of PPARGC1A protein]

NCBI chr14:63,073,505...63,729,215
Ensembl chr14:63,273,189...63,729,213

G

protein phosphatase 5, catalytic subunit

multiple interactions

ISO

Adenosine Triphosphate binds to and affects the folding of PPP5C protein; Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to PPP5C protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to PPP5C protein]

NCBI chr 1:86,818,297...86,842,505
Ensembl chr 1:86,818,297...86,842,950

G

peroxiredoxin 2

increases expression

EXP

Adenosine Triphosphate results in increased expression of PRDX2 protein modified form

NCBI chr19:40,085,788...40,091,083
Ensembl chr19:40,084,430...40,091,006

G

protein kinase AMP-activated catalytic subunit alpha 1

multiple interactions

ISO

[[PRKAA1 gene co-treated with PRKAA2 gene] affects the susceptibility to Metformin] which results in decreased abundance of Adenosine Triphosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to [Dihydroxyacetone co-treated with S 4048]] which results in decreased abundance of Adenosine Triphosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to [Glucose co-treated with S 4048]] which results in decreased abundance of Adenosine Triphosphate

NCBI chr 2:55,967,766...56,003,450
Ensembl chr 2:55,967,351...56,003,450

G

protein kinase AMP-activated catalytic subunit alpha 2

multiple interactions

ISO

[[PRKAA1 gene co-treated with PRKAA2 gene] affects the susceptibility to Metformin] which results in decreased abundance of Adenosine Triphosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to [Dihydroxyacetone co-treated with S 4048]] which results in decreased abundance of Adenosine Triphosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to [Glucose co-treated with S 4048]] which results in decreased abundance of Adenosine Triphosphate

NCBI chr 5:125,036,945...125,109,010
Ensembl chr 5:125,042,179...125,108,324

G

protein kinase C, alpha

multiple interactions

ISO

[[Adenosine Triphosphate co-treated with PRKCA protein] results in increased phosphorylation of RALBP1 protein] which results in increased transport of Doxorubicin

NCBI chr10:93,388,991...93,787,617
Ensembl chr10:93,388,991...93,787,572

G

presenilin 1

multiple interactions

ISO

[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Adenosine Triphosphate; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Adenosine Triphosphate]

NCBI chr 6:109,054,160...109,106,191
Ensembl chr 6:109,060,352...109,106,189

G

prostaglandin-endoperoxide synthase 2

multiple interactions

ISO

[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein]

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320

G

PYD and CARD domain containing

multiple interactions

ISO
EXP

[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of PYCARD mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]; neoisoliquiritin affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]; Resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of PYCARD mRNA]
[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]
[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] promotes the reaction [NLRP3 protein binds to PYCARD protein]; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased polymerization of PYCARD protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in decreased expression of PYCARD mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] promotes the reaction [PYCARD protein binds to CASP1 protein]; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] promotes the reaction [PYCARD protein binds to PYCARD protein]; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PYCARD protein]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] promotes the reaction [PYCARD protein binds to CASP1 protein]]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] promotes the reaction [PYCARD protein binds to PYCARD protein]]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PYCARD protein]]; PYCARD gene mutant form inhibits the reaction [Adenosine Triphosphate results in increased abundance of G(M3) Ganglioside]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD protein]; tabersonine inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] promotes the reaction [NLRP3 protein binds to PYCARD protein]]; tabersonine inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased polymerization of PYCARD protein]

PMID:18604214 PMID:23430110 PMID:24149798 PMID:24475307 PMID:29378952 More...

NCBI chr 1:192,032,124...192,033,419
Ensembl chr 1:192,032,124...192,033,419

G

ralA binding protein 1

multiple interactions

ISO

[[Adenosine Triphosphate co-treated with PRKCA protein] results in increased phosphorylation of RALBP1 protein] which results in increased transport of Doxorubicin; Adenosine Triphosphate promotes the reaction [RALBP1 protein affects the transport of Leukotriene C4]

PMID:15386349 PMID:16087181

NCBI chr 9:112,903,289...112,940,093
Ensembl chr 9:112,903,302...112,939,659

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

EXP
ISO

[Adenosine Triphosphate results in increased expression of NOS2 protein] promotes the reaction [NOS2 protein binds to RELA protein]; Adenosine Triphosphate promotes the reaction [RELA protein binds to ARRB2 protein]; Adenosine Triphosphate promotes the reaction [RELA protein binds to NFKBIA protein]; Adenosine Triphosphate promotes the reaction [RELA protein binds to NOS2 protein]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to ARRB2 protein]]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NFKBIA protein]]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NOS2 protein]]; Cyclosporine inhibits the reaction [[Adenosine Triphosphate results in increased expression of NOS2 protein] promotes the reaction [NOS2 protein binds to RELA protein]]
[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of RELA protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of and results in increased phosphorylation of RELA protein; [Carbonyl Cyanide m-Chlorophenyl Hydrazone co-treated with Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of RELA protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased phosphorylation of RELA protein; [mitochondrial uncoupler BAM15 co-treated with Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of RELA protein; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased phosphorylation of RELA protein]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased phosphorylation of RELA protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased phosphorylation of RELA protein]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of and results in increased phosphorylation of RELA protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of RELA protein]
[Adenosine Triphosphate co-treated with Lipopolysaccharides] affects the localization of RELA protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased phosphorylation of and affects the localization of RELA protein; Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased phosphorylation of and affects the localization of RELA protein]; NOS2 protein affects the reaction [Adenosine Triphosphate results in increased metabolism of RELA protein]; Resveratrol promotes the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] affects the localization of RELA protein]; S-Nitrosoglutathione promotes the reaction [Adenosine Triphosphate results in increased metabolism of RELA protein]

PMID:21464294 PMID:24149798 PMID:33524445 PMID:34217685 PMID:34405489 More...

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

ras homolog family member F, filopodia associated

multiple interactions
increases expression

ISO

Niclosamide inhibits the reaction [Adenosine Triphosphate results in increased expression of RHOF mRNA]

NCBI chr12:39,082,413...39,107,528
Ensembl chr12:39,091,979...39,107,528

G

S100 calcium binding protein A10

increases expression

ISO

Adenosine Triphosphate results in increased expression of S100A10 mRNA

NCBI chr 2:181,904,454...181,913,101
Ensembl chr 2:181,904,261...181,913,103

G

S100 calcium binding protein A11

increases expression

ISO

Adenosine Triphosphate results in increased expression of S100A11 mRNA

NCBI chr 2:181,875,132...181,880,542
Ensembl chr 2:181,875,130...181,880,541

G

S100 calcium-binding protein A4

multiple interactions
increases expression

ISO

Adenosine Triphosphate results in increased expression of and results in increased secretion of S100A4 protein; Niclosamide inhibits the reaction [Adenosine Triphosphate results in increased expression of S100A4 protein]
Adenosine Triphosphate results in increased expression of S100A4 mRNA

NCBI chr 2:178,388,529...178,390,838
Ensembl chr 2:178,388,526...178,390,837

G

S100 calcium binding protein A6

increases expression

ISO

Adenosine Triphosphate results in increased expression of S100A6 mRNA

NCBI chr 2:178,398,189...178,399,763
Ensembl chr 2:178,398,481...178,399,762

G

selectin L

multiple interactions

ISO

P2RX7 protein affects the reaction [Adenosine Triphosphate results in increased secretion of SELL protein]

NCBI chr13:78,950,100...78,969,604
Ensembl chr13:78,950,015...78,969,600

G

surfactant protein A1

multiple interactions

ISO

[SFTPA1 protein polymorphism binds to SFTPA2 protein polymorphism] inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]; Ozone inhibits the reaction [[SFTPA1 protein polymorphism binds to SFTPA2 protein polymorphism] inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]]; Ozone inhibits the reaction [SFTPA1 protein polymorphism inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]]

NCBI chr16:17,042,264...17,045,770
Ensembl chr16:17,042,255...17,045,769

G

surfactant protein B

increases secretion
multiple interactions

ISO
EXP

Adenosine Triphosphate results in increased secretion of SFTPB protein
Ro 31-8220 inhibits the reaction [Adenosine Triphosphate results in increased secretion of SFTPB protein]

PMID:11704537 PMID:14565945

NCBI chr 4:105,917,495...105,926,631
Ensembl chr 4:105,917,578...105,927,646

G

surfactant protein C

increases secretion
multiple interactions

EXP
ISO

Adenosine Triphosphate results in increased secretion of SFTPC protein
Ro 31-8220 inhibits the reaction [Adenosine Triphosphate results in increased secretion of SFTPC protein]

PMID:11704537 PMID:14565945

NCBI chr15:52,006,274...52,009,324
Ensembl chr15:52,006,283...52,009,475

G

sirtuin 1

multiple interactions

EXP
ISO

[SIRT1 protein results in decreased expression of UCP2 mRNA] promotes the reaction [Glucose results in increased abundance of Adenosine Triphosphate]; SIRT1 protein promotes the reaction [[Glucose results in increased abundance of Adenosine Triphosphate] which results in increased expression of INS1 protein]; SIRT1 protein promotes the reaction [Glucose results in increased abundance of Adenosine Triphosphate]
[STK11 protein co-treated with Adenosine Triphosphate] results in increased activity of and results in increased phosphorylation of SIRT1 protein

PMID:16366736 PMID:34216621

NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,305,476...25,328,000

G

sirtuin 3

multiple interactions

ISO

SIRT3 protein inhibits the reaction [Metformin results in decreased abundance of Adenosine Triphosphate]

NCBI chr 1:205,371,703...205,394,145
Ensembl chr 1:205,371,710...205,394,076

G

solute carrier family 25 member 14

decreases chemical synthesis

ISO

SLC25A14 protein results in decreased chemical synthesis of Adenosine Triphosphate

NCBI chr X:132,685,518...132,723,705
Ensembl chr X:132,676,818...132,723,703

G

solute carrier family 2 member 1

decreases stability

ISO

Adenosine Triphosphate results in decreased stability of SLC2A1 protein

NCBI chr 5:138,002,522...138,030,742
Ensembl chr 5:138,002,522...138,030,742

G

solute carrier family 2 member 4

increases abundance

ISO

SLC2A4 protein results in increased abundance of Adenosine Triphosphate

NCBI chr10:55,164,721...55,170,289
Ensembl chr10:55,164,721...55,170,270

G

solute carrier family 46 member 1

multiple interactions

ISO

[SLC46A1 protein results in increased susceptibility to N-((5-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo(2,3-d)pyrimidin-6-yl)propyl)thiophen-2-yl)carbonyl)glutamic acid] which results in decreased chemical synthesis of Adenosine Triphosphate

NCBI chr10:63,859,551...63,865,987
Ensembl chr10:63,859,504...63,866,869

G

solute carrier family 5 member 5

multiple interactions

ISO

Adenosine Triphosphate inhibits the reaction [TSHB protein results in increased expression of SLC5A5 protein]

NCBI chr16:18,580,705...18,590,692
Ensembl chr16:18,580,705...18,590,691

G

synuclein alpha

multiple interactions
decreases abundance

ISO

GW8510 inhibits the reaction [SNCA protein results in decreased abundance of Adenosine Triphosphate]; SB 216763 inhibits the reaction [SNCA protein results in decreased abundance of Adenosine Triphosphate]

NCBI chr 4:91,026,474...91,127,444
Ensembl chr 4:91,026,474...91,126,315

G

superoxide dismutase 1

increases expression

EXP
ISO

Adenosine Triphosphate results in increased expression of SOD1 protein

PMID:16178011 PMID:22129738

NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399

G

superoxide dismutase 2

affects chemical synthesis
decreases abundance
multiple interactions

ISO

SOD2 protein affects the chemical synthesis of Adenosine Triphosphate
SOD2 gene mutant form results in decreased abundance of Adenosine Triphosphate
MK-886 promotes the reaction [SOD2 gene mutant form results in decreased abundance of Adenosine Triphosphate]

PMID:20638473 PMID:25362851

NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168

G

serine racemase

multiple interactions

ISO

Adenosine Triphosphate inhibits the reaction [Edetic Acid inhibits the reaction [SRR protein results in increased abundance of D-Aspartic Acid]]; Adenosine Triphosphate promotes the reaction [SRR protein results in increased abundance of D-Aspartic Acid]

NCBI chr10:60,267,936...60,285,094
Ensembl chr10:60,268,859...60,285,100

G

serine/threonine kinase 11

multiple interactions

ISO

[STK11 protein co-treated with Adenosine Triphosphate] results in increased activity of and results in increased phosphorylation of SIRT1 protein

NCBI chr 7:10,225,204...10,241,965
Ensembl chr 7:10,225,204...10,241,965

G

syntaxin binding protein 2

multiple interactions

ISO

STXBP2 protein affects the reaction [F2 protein results in increased transport of Adenosine Triphosphate]

NCBI chr12:6,487,265...6,498,351
Ensembl chr12:6,487,297...6,504,212

G

SGT1 homolog, MIS12 kinetochore complex assembly cochaperone

multiple interactions

ISO

Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to SUGT1 protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to SUGT1 protein]; Calcium promotes the reaction [Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to SUGT1 protein]]

NCBI chr15:61,400,478...61,441,303
Ensembl chr15:61,400,004...61,468,852

G

synapsin II

multiple interactions

ISO

SYN2 mutant form inhibits the reaction [Adenosine Triphosphate results in increased abundance of Calcium]

NCBI chr 4:149,858,919...150,016,845
Ensembl chr 4:149,851,520...150,019,650

G

tachykinin, precursor 1

increases secretion
multiple interactions

EXP

Adenosine Triphosphate results in increased secretion of TAC1 protein
Iloprost promotes the reaction [Adenosine Triphosphate results in increased secretion of TAC1 protein]

NCBI chr 4:36,645,344...36,653,548
Ensembl chr 4:36,645,571...36,653,546

G

transaldolase 1

increases abundance

ISO

TALDO1 gene mutant form results in increased abundance of Adenosine Triphosphate

NCBI chr 1:205,923,196...205,933,526
Ensembl chr 1:205,923,165...205,933,535

G

taste receptor, type 2, member 145

increases activity

ISO

Adenosine Triphosphate results in increased activity of TAS2R131 protein

NCBI chr 4:167,869,406...167,870,356
Ensembl chr 4:167,869,358...167,870,544

G

transforming growth factor, beta 1

multiple interactions

ISO

[Dimethyl Sulfoxide co-treated with TGFB1 protein] results in decreased abundance of Adenosine Triphosphate

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899

G

translocase of inner mitochondrial membrane 17A

multiple interactions
decreases expression

ISO

1,10-phenanthroline inhibits the reaction [Adenosine Triphosphate results in decreased expression of TIMM17A protein]

NCBI chr13:49,282,918...49,296,363
Ensembl chr13:49,282,918...49,307,904

G

TIMP metallopeptidase inhibitor 1

decreases secretion
multiple interactions

ISO

Adenosine Triphosphate results in decreased secretion of TIMP1 protein
azetidine analog inhibits the reaction [Adenosine Triphosphate results in decreased secretion of TIMP1 protein]

NCBI chr X:3,766,509...3,772,578
Ensembl chr X:3,766,510...3,771,135

G

toll-like receptor 4

multiple interactions

ISO

[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of TLR4 protein; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of TLR4 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 protein]

PMID:34405489 PMID:37544346

NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:85,161,192...85,175,007

G

tumor necrosis factor

multiple interactions
decreases chemical synthesis

ISO
EXP

[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of TNF mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of TNF protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein; Adenosine Triphosphate deficiency inhibits the reaction [TNF protein results in increased transport of Chlorides]; Adenosine Triphosphate deficiency inhibits the reaction [TNF protein results in increased transport of Potassium]; Adenosine Triphosphate promotes the reaction [[TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Dinoprostone]; azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased secretion of TNF protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of TNF mRNA]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein]; ginsenoside Rg3 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein]; gypenoside LXXV inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA]
Adenosine Triphosphate inhibits the reaction [Sunitinib results in increased expression of TNF protein]; TNF protein promotes the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased chemical synthesis of Adenosine Triphosphate]
TNF protein results in decreased chemical synthesis of Adenosine Triphosphate
[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of TNF protein; [Asbestos, Amosite co-treated with TNF protein] results in increased metabolism of Adenosine Triphosphate; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein; Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Disulfiram inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of TNF protein]; MFN2 protein inhibits the reaction [TNF protein results in decreased chemical synthesis of Adenosine Triphosphate]; Rosiglitazone inhibits the reaction [TNF protein results in decreased chemical synthesis of Adenosine Triphosphate]; Vitamin K 3 promotes the reaction [[Asbestos, Amosite co-treated with TNF protein] results in increased metabolism of Adenosine Triphosphate]

PMID:8817062 PMID:10783394 PMID:14623498 PMID:17707769 PMID:23430110 More...

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

TNF superfamily member 11

increases abundance

ISO

TNFSF11 protein results in increased abundance of Adenosine Triphosphate

NCBI chr15:60,083,008...60,114,479
Ensembl chr15:60,083,008...60,114,479

G

DNA topoisomerase II alpha

multiple interactions
increases hydrolysis

ISO

Cannabidiol metabolite inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate]; copper-thiosemicarbazone complex analog inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate]; Dithiothreitol inhibits the reaction [Cannabidiol metabolite inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate]]; Emodin inhibits the reaction [TOP2A results in increased hydrolysis of Adenosine Triphosphate]; Etoposide metabolite inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate]; Thiosemicarbazones analog inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate]
TOP2A protein results in increased hydrolysis of Adenosine Triphosphate; TOP2A results in increased hydrolysis of Adenosine Triphosphate

PMID:20855424 PMID:26982206 PMID:27533850 PMID:29272108

NCBI chr10:84,441,954...84,473,093
Ensembl chr10:84,441,954...84,473,366

G

DNA topoisomerase II beta

increases hydrolysis
multiple interactions

ISO

TOP2B protein results in increased hydrolysis of Adenosine Triphosphate
cannabidiol hydroxyquinone inhibits the reaction [TOP2B protein results in increased hydrolysis of Adenosine Triphosphate]; Cannabidiol metabolite inhibits the reaction [TOP2B protein results in increased hydrolysis of Adenosine Triphosphate]

NCBI chr15:11,482,089...11,542,464
Ensembl chr15:11,482,089...11,542,464

G

tumor protein p53

multiple interactions
increases abundance

ISO

TP53 protein inhibits the reaction [Deoxyglucose results in decreased abundance of Adenosine Triphosphate]
TP53 gene mutant form results in increased abundance of Adenosine Triphosphate

PMID:21042727 PMID:33070465

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299

G

tumor protein p53 binding protein 1

multiple interactions

ISO

Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]; AZ10606120 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]]; U 0126 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]]

NCBI chr 3:128,620,320...128,724,716
Ensembl chr 3:128,620,322...128,696,747

G

transient receptor potential cation channel, subfamily C, member 3

multiple interactions
increases activity

ISO

ethyl-1-(4-(2*3*3-trichloroacrylamide)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate inhibits the reaction [Adenosine Triphosphate results in increased activity of TRPC3 protein]

NCBI chr 2:121,409,436...121,487,095
Ensembl chr 2:121,409,436...121,475,823

G

transient receptor potential cation channel, subfamily C, member 5

increases activity

ISO

Adenosine Triphosphate results in increased activity of TRPC5 protein

NCBI chr X:112,742,828...113,027,638
Ensembl chr X:112,742,828...113,027,638

G

transient receptor potential cation channel, subfamily C, member 6

increases activity

ISO

Adenosine Triphosphate results in increased activity of TRPC6 protein

NCBI chr 8:14,044,216...14,148,808
Ensembl chr 8:14,043,877...14,149,304

G

transient receptor potential cation channel, subfamily C, member 7

increases activity

ISO

Adenosine Triphosphate results in increased activity of TRPC7 protein

NCBI chr17:7,707,954...7,839,064
Ensembl chr17:7,714,505...7,838,745

G

transient receptor potential cation channel, subfamily M, member 4

decreases activity

ISO
EXP

Adenosine Triphosphate results in decreased activity of TRPM4 protein

PMID:16966582 PMID:17188667

NCBI chr 1:104,918,462...104,949,453
Ensembl chr 1:104,918,462...104,948,653

G

transient receptor potential cation channel, subfamily V, member 1

multiple interactions

EXP

[Capsaicin binds to and affects the activity of TRPV1 protein] which results in increased secretion of Adenosine Triphosphate

NCBI chr10:58,349,936...58,375,021
Ensembl chr10:58,340,223...58,375,021

G

thyroid stimulating hormone subunit beta

multiple interactions

ISO

Adenosine Triphosphate inhibits the reaction [TSHB protein results in increased expression of SLC5A5 protein]

NCBI chr 2:192,913,171...192,918,054
Ensembl chr 2:192,913,171...192,942,984

G

thioredoxin 1

increases expression

ISO

Adenosine Triphosphate results in increased expression of TXN protein

NCBI chr 5:77,507,455...77,519,685
Ensembl chr 5:77,507,321...77,520,307

G

thioredoxin interacting protein

increases activity

EXP

Adenosine Triphosphate results in increased activity of TXNIP mRNA

NCBI chr 2:186,781,933...186,785,736
Ensembl chr 2:186,781,163...186,785,731

G

uncoupling protein 1

multiple interactions
decreases abundance

EXP
ISO

Adenosine Triphosphate inhibits the reaction [UCP1 protein results in increased transport of Protons]
UCP1 results in decreased abundance of Adenosine Triphosphate
UCP1 protein promotes the reaction [PPARG protein mutant form results in decreased abundance of Adenosine Triphosphate]; UCP1 protein promotes the reaction [rosiglitazone promotes the reaction [PPARG protein results in decreased abundance of Adenosine Triphosphate]]

PMID:12734183 PMID:26670611

NCBI chr19:41,713,350...41,721,421
Ensembl chr19:41,713,351...41,721,420

G

uncoupling protein 2

multiple interactions

ISO
EXP

Adenosine Triphosphate inhibits the reaction [UCP2 protein results in increased transport of Protons]
[SIRT1 protein results in decreased expression of UCP2 mRNA] promotes the reaction [Glucose results in increased abundance of Adenosine Triphosphate]

PMID:12734183 PMID:16366736

NCBI chr 1:164,251,373...164,257,742
Ensembl chr 1:164,251,373...164,257,743

G

uncoupling protein 3

multiple interactions

ISO

Adenosine Triphosphate inhibits the reaction [UCP3 protein results in increased transport of Protons]

NCBI chr 1:164,227,910...164,240,893
Ensembl chr 1:164,227,882...164,241,210

G

voltage-dependent anion channel 1

multiple interactions

ISO

VDAC1 mutant form inhibits the reaction [chromium hexavalent ion results in decreased abundance of Adenosine Triphosphate]

NCBI chr10:37,029,377...37,060,542
Ensembl chr10:37,023,145...37,060,541

G

X-ray repair cross complementing 1

multiple interactions
increases abundance
decreases abundance

ISO

Acetylcysteine inhibits the reaction [XRCC1 gene mutant form results in decreased abundance of Adenosine Triphosphate]; Acetylcysteine promotes the reaction [XRCC1 protein results in increased abundance of Adenosine Triphosphate]

NCBI chr 1:89,268,721...89,296,619
Ensembl chr 1:89,268,644...89,296,613

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

lysine acetyltransferase 2B

affects binding

ISO

butyryl-coenzyme A binds to KAT2B protein

NCBI chr 9:6,799,101...6,903,616
Ensembl chr 9:6,799,145...6,903,616

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

coagulation factor III, tissue factor

multiple interactions

ISO

cangrelor results in decreased expression of and results in decreased activity of F3 protein; Indomethacin promotes the reaction [cangrelor results in decreased expression of and results in decreased activity of F3 protein]

NCBI chr 2:212,511,675...212,523,375
Ensembl chr 2:212,511,680...212,523,369

G

G protein-coupled receptor 17

multiple interactions

ISO

cangrelor inhibits the reaction [Uridine Diphosphate results in increased activity of GPR17 protein]

NCBI chr18:23,850,460...23,857,381
Ensembl chr18:23,850,107...23,857,702

G

integrin subunit alpha 2b

multiple interactions

ISO

cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]]

NCBI chr10:87,908,697...87,926,225
Ensembl chr10:87,908,697...87,925,833

G

integrin subunit beta 3

multiple interactions

ISO

cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]]

NCBI chr10:90,009,927...90,067,787
Ensembl chr10:90,009,900...90,067,800

G

purinergic receptor P2Y12

multiple interactions
decreases activity
affects response to substance

ISO

[cangrelor binds to and results in decreased activity of P2RY12 protein] which results in decreased abundance of phosphatidylinositol 3,4,5-triphosphate; [cangrelor binds to and results in decreased activity of P2RY12 protein] which results in decreased phosphorylation of SYK protein
cangrelor results in decreased activity of P2RY12 protein
P2RY12 gene polymorphism affects the susceptibility to cangrelor

PMID:12606772 PMID:20126830 PMID:22273509

NCBI chr 2:145,631,487...145,673,194
Ensembl chr 2:145,629,967...145,633,410

G

platelet factor 4

multiple interactions

ISO

cangrelor inhibits the reaction [thrombin receptor-activating peptide SFLLRNPNDKY results in increased secretion of PF4 protein]

NCBI chr14:17,582,477...17,583,392
Ensembl chr14:17,582,477...17,583,392

G

selectin P

multiple interactions

ISO

cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]]

NCBI chr13:79,009,379...79,044,994
Ensembl chr13:79,009,475...79,044,987

G

spleen associated tyrosine kinase

multiple interactions

ISO

[cangrelor binds to and results in decreased activity of P2RY12 protein] which results in decreased phosphorylation of SYK protein

NCBI chr17:12,756,493...12,830,927
Ensembl chr17:12,756,493...12,813,278

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adenylate cyclase 5

increases response to substance
multiple interactions

ISO

ADCY5 protein results in increased susceptibility to 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine
ADCY5 protein results in increased susceptibility to [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine co-treated with Quinpirole]

NCBI chr11:78,976,861...79,123,343
Ensembl chr11:78,976,861...79,123,343

G

adenosine A2a receptor

increases response to substance
multiple interactions

ISO
EXP

ADORA2A protein results in increased susceptibility to 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine binds to and results in increased activity of ADORA2A protein; 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA2A mRNA]; 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA2A protein]; 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine promotes the reaction [Oxygen deficiency results in increased expression of ADORA2A mRNA]; 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine promotes the reaction [Oxygen deficiency results in increased expression of ADORA2A protein]; 8-(3-chlorostyryl)caffeine inhibits the reaction [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA2A mRNA]]; 8-(3-chlorostyryl)caffeine inhibits the reaction [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA2A protein]]; PRKCZ protein affects the reaction [[2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine binds to and results in increased activity of ADORA2A protein] which results in decreased expression of VEGFA mRNA]
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine binds to and results in increased activity of ADORA2A protein; 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in decreased expression of ADORA2A mRNA]; 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in decreased expression of ADORA2A protein]

PMID:11172060 PMID:12590138 PMID:15452191 PMID:19749167 PMID:19966059 More...

NCBI chr20:13,315,270...13,332,802
Ensembl chr20:13,315,270...13,332,802

G

brain-derived neurotrophic factor

multiple interactions

EXP

2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in decreased expression of BDNF mRNA]; 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in decreased expression of BDNF protein]

NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:116,619,633...116,670,657

G

beclin 1

multiple interactions

ISO

2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in increased expression of BECN1 protein]

NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,731,650...86,747,002

G

basic helix-loop-helix ARNT like 1

increases expression
multiple interactions

ISO

2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in increased expression of BMAL1 mRNA
[2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine co-treated with TNF protein] results in increased expression of BMAL1 mRNA

NCBI chr 1:176,766,222...176,864,741
Ensembl chr 1:176,829,305...176,864,739

G

cyclin-dependent kinase inhibitor 1A

multiple interactions

ISO

2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased expression of CDKN1A protein]]

NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969

G

clock circadian regulator

increases expression

ISO

2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in increased expression of CLOCK mRNA

NCBI chr14:32,262,747...32,346,872
Ensembl chr14:32,262,750...32,346,872

G

collagen type III alpha 1 chain

increases expression
multiple interactions

ISO

2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in increased expression of COL3A1 protein
CTNNB1 protein affects the reaction [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in increased expression of COL3A1 protein]

NCBI chr 9:54,866,646...54,902,578
Ensembl chr 9:54,866,632...54,903,232

G

cAMP responsive element binding protein 1

multiple interactions

EXP

2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in decreased expression of CREB1 mRNA]

NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:73,397,306...73,466,339

G

catenin beta 1

affects localization
multiple interactions

ISO

2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine affects the localization of CTNNB1 protein modified form
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in increased expression of and affects the phosphorylation of CTNNB1 protein; CTNNB1 protein affects the reaction [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in increased expression of COL3A1 protein]

NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:129,517,545...129,544,662

G

cytochrome P450, family 27, subfamily a, polypeptide 1

multiple interactions

ISO

2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of CYP27A1 mRNA]; 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of CYP27A1 protein]

NCBI chr 9:83,712,402...83,743,222
Ensembl chr 9:83,713,293...83,743,215

G

endothelin 1

multiple interactions

ISO

2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [[Phosphorus, Dietary co-treated with Cisplatin] results in increased expression of EDN1 protein]

NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,660,799...22,666,687

G

endothelin receptor type A

multiple interactions

ISO

2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [[Phosphorus, Dietary co-treated with Cisplatin] results in increased expression of EDNRA protein]

NCBI chr19:47,137,360...47,207,961
Ensembl chr19:47,137,771...47,201,284

G

endothelin receptor type B

multiple interactions

ISO

[Phosphorus, Dietary co-treated with Cisplatin co-treated with 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine] results in increased expression of EDNRB protein

NCBI chr15:87,055,490...87,086,765
Ensembl chr15:87,057,691...87,086,765

G

epoxide hydrolase 2

multiple interactions
increases response to substance
decreases response to substance

ISO

12-(3-adamantan-1-ylureido)dodecanoic acid inhibits the reaction [EPHX2 gene results in decreased susceptibility to 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine]; 14,15-eicosa-5-enoic acid inhibits the reaction [EPHX2 gene mutant form results in increased susceptibility to 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine]; 4-(4-(3-adamantan-1-ylureido)cyclohexyloxy)benzoic acid inhibits the reaction [EPHX2 gene results in decreased susceptibility to 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine]; T 0070907 inhibits the reaction [EPHX2 gene mutant form results in increased susceptibility to 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine]

NCBI chr15:44,465,447...44,503,157
Ensembl chr15:44,465,448...44,503,160

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

EXP

2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of FOS mRNA]

NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598

G

hepatitis A virus cellular receptor 1

multiple interactions

ISO

2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [[Phosphorus, Dietary co-treated with Cisplatin] results in increased expression of HAVCR1 protein]

NCBI chr10:31,619,914...31,652,955
Ensembl chr10:31,619,897...31,653,268

G

3-hydroxy-3-methylglutaryl-CoA reductase

multiple interactions

ISO

2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in increased expression of HMGCR mRNA]

NCBI chr 2:29,732,163...29,754,276
Ensembl chr 2:29,720,553...29,754,533

G

3-hydroxy-3-methylglutaryl-CoA synthase 1

multiple interactions

ISO

2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in increased expression of HMGCS1 mRNA]

NCBI chr 2:53,379,457...53,399,807
Ensembl chr 2:53,382,643...53,399,802

G

interleukin 10

multiple interactions

ISO

2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine promotes the reaction [TNF protein results in increased expression of IL10 mRNA]

NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580

G

interleukin 12A

multiple interactions

ISO

[2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine co-treated with TNF protein] results in decreased expression of IL12A mRNA

NCBI chr 2:155,275,734...155,282,997
Ensembl chr 2:155,275,625...155,282,997

G

leptin

multiple interactions

ISO

2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in decreased expression of LEP mRNA]

NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:58,626,523...58,640,661

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions

ISO

2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in increased cleavage of MAP1LC3B protein]

NCBI chr19:66,571,631...66,582,270
Ensembl chr19:66,574,407...66,584,358
Ensembl chr16:66,574,407...66,584,358

G

matrix metallopeptidase 14

decreases activity

ISO

2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in decreased activity of MMP14 protein

NCBI chr15:31,857,824...31,867,049
Ensembl chr15:31,857,546...31,869,893

G

matrix metallopeptidase 2

decreases activity

ISO

2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in decreased activity of MMP2 protein

NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856

G

matrix metallopeptidase 9

decreases activity
decreases expression

ISO

2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in decreased activity of MMP9 protein
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in decreased expression of MMP9 mRNA

NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442

G

nitric oxide synthase 2

multiple interactions

ISO

2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [[Phosphorus, Dietary co-treated with Cisplatin] results in increased expression of NOS2 protein]

NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880

G

nitric oxide synthase 3

multiple interactions

ISO

2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [[Phosphorus, Dietary co-treated with Cisplatin] results in decreased expression of NOS3 protein]

NCBI chr 4:11,686,088...11,706,604
Ensembl chr 4:11,686,268...11,706,664

G

natriuretic peptide A

multiple interactions

EXP

2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]; Caffeine analog inhibits the reaction [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]]

PMID:15452191 PMID:19966059

NCBI chr 5:163,712,184...163,713,493
Ensembl chr 5:163,712,184...163,713,493

G

nuclear receptor subfamily 1, group D, member 1

increases expression

ISO

2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in increased expression of NR1D1 mRNA

NCBI chr10:84,224,599...84,231,812
Ensembl chr10:84,224,540...84,231,812

G

neurotrophic receptor tyrosine kinase 2

multiple interactions
increases expression

EXP

2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in decreased expression of NTRK2 mRNA]
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in increased expression of NTRK2 mRNA

NCBI chr17:5,560,558...5,875,899
Ensembl chr17:5,564,570...5,874,628

G

period circadian regulator 2

decreases expression

ISO

2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in decreased expression of PER2 mRNA

NCBI chr 9:99,454,828...99,497,069
Ensembl chr 9:99,454,830...99,496,993

G

protein kinase C, epsilon

multiple interactions

EXP

2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine affects the localization of and results in increased activity of PRKCE protein

NCBI chr 6:13,718,050...14,204,931
Ensembl chr 6:13,718,050...14,204,288

G

protein kinase C, zeta

multiple interactions

EXP

2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine affects the localization of and results in increased activity of PRKCZ protein; PRKCZ protein affects the reaction [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in decreased expression of VEGFA mRNA]; PRKCZ protein affects the reaction [[2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine binds to and results in increased activity of ADORA2A protein] which results in decreased expression of VEGFA mRNA]

NCBI chr 5:171,101,774...171,212,694
Ensembl chr 5:171,101,774...171,212,674

G

renin

multiple interactions
increases expression

EXP

Atenolol inhibits the reaction [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in increased expression of REN protein]

NCBI chr13:47,348,312...47,359,539
Ensembl chr13:47,348,143...47,359,543

G

regulator of G-protein signaling 2

multiple interactions

EXP

2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of RGS2 mRNA]

NCBI chr13:58,350,063...58,352,666
Ensembl chr13:58,349,163...58,352,697

G

sirtuin 1

multiple interactions

ISO

2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in decreased expression of SIRT1 mRNA]

NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,305,476...25,328,000

G

sirtuin 3

multiple interactions

ISO

2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in decreased expression of SIRT3 protein]]

NCBI chr 1:205,371,703...205,394,145
Ensembl chr 1:205,371,710...205,394,076

G

solute carrier family 9 member A1

multiple interactions

EXP

2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of SLC9A1 protein]

NCBI chr 5:150,859,412...150,913,525
Ensembl chr 5:150,860,228...150,913,517

G

SMAD family member 3

multiple interactions

EXP

8-(4-methoxyphenyl)-4-oxo-4,6,7,8-tetrahydroimidazo(2,1-c)(1,2,4)triazine-3-carbohydrazide inhibits the reaction [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine binds to and results in increased activity of SMAD3 protein]

NCBI chr 8:73,022,204...73,132,324
Ensembl chr 8:73,024,760...73,132,324

G

suppressor of cytokine signaling 3

multiple interactions

EXP

2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine promotes the reaction [Oxygen deficiency results in increased expression of SOCS3 mRNA]; 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine promotes the reaction [Oxygen deficiency results in increased expression of SOCS3 protein]

NCBI chr10:103,692,579...103,695,975
Ensembl chr10:103,690,976...103,704,825

G

sterol regulatory element binding transcription factor 2

multiple interactions

ISO

2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in increased expression of SREBF2 mRNA]

NCBI chr 7:115,542,774...115,600,945
Ensembl chr 7:115,543,290...115,600,943

G

transforming growth factor, beta 1

multiple interactions

ISO

2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [[Phosphorus, Dietary co-treated with Cisplatin] results in increased expression of TGFB1 protein]

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899

G

tumor necrosis factor

multiple interactions

ISO

2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]; 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine promotes the reaction [TNF protein results in increased expression of IL10 mRNA]; [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine co-treated with TNF protein] results in decreased expression of IL12A mRNA; [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine co-treated with TNF protein] results in increased expression of BMAL1 mRNA
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [[Phosphorus, Dietary co-treated with Cisplatin] results in increased expression of TNF protein]

PMID:21538184 PMID:22923002 PMID:39332792

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

tumor protein p53

multiple interactions

ISO

2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased phosphorylation of TP53 protein]]

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299

G

vascular endothelial growth factor A

increases secretion
decreases expression
multiple interactions

ISO
EXP

2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in increased secretion of VEGFA protein
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in decreased expression of VEGFA mRNA
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [cobaltous chloride results in increased expression of VEGFA mRNA]; PRKCZ protein affects the reaction [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in decreased expression of VEGFA mRNA]; PRKCZ protein affects the reaction [[2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine binds to and results in increased activity of ADORA2A protein] which results in decreased expression of VEGFA mRNA]

PMID:12590138 PMID:20067761

NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acyl-CoA thioesterase 8

affects hydrolysis

ISO

ACOT8 protein affects the hydrolysis of Coenzyme A analog

NCBI chr 3:173,950,530...173,962,188
Ensembl chr 3:173,950,531...173,962,570

G

lysine acetyltransferase 2B

affects binding

ISO

Coenzyme A binds to KAT2B protein

NCBI chr 9:6,799,101...6,903,616
Ensembl chr 9:6,799,145...6,903,616

cyclic ADP-beta-D-ribose

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

CD38 molecule

decreases abundance

ISO

CD38 gene mutant form results in decreased abundance of Cyclic ADP-Ribose

NCBI chr14:71,384,532...71,424,794
Ensembl chr14:71,384,532...71,424,505

G

homer scaffold protein 1

multiple interactions

EXP

HOMER1 protein alternative form inhibits the reaction [Cyclic ADP-Ribose promotes the reaction [RYR2 protein results in increased secretion of Calcium]]

NCBI chr 2:26,279,012...26,388,279
Ensembl chr 2:26,278,105...26,381,657

G

ryanodine receptor 2

multiple interactions

EXP

HOMER1 protein alternative form inhibits the reaction [Cyclic ADP-Ribose promotes the reaction [RYR2 protein results in increased secretion of Calcium]]

NCBI chr17:63,081,527...63,667,141
Ensembl chr17:63,081,527...63,666,705

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

advanced glycosylation end product-specific receptor

multiple interactions
increases expression

ISO

[Ribose co-treated with Glucose] results in increased expression of AGER protein; AGER protein affects the reaction [Ribose promotes the reaction [Glucose results in increased phosphorylation of RELA protein]]
Ribose results in increased expression of AGER protein

NCBI chr20:4,152,758...4,155,956
Ensembl chr20:4,151,965...4,155,685

G

beta-2 microglobulin

increases glycation

ISO

Ribose results in increased glycation of B2M protein

NCBI chr 3:129,549,236...129,555,354
Ensembl chr 3:129,549,318...129,555,356

G

caspase 3

multiple interactions

EXP

[Creatine co-treated with Ribose] results in decreased activity of CASP3 protein

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

component of inhibitor of nuclear factor kappa B kinase complex

increases phosphorylation

ISO

Ribose results in increased phosphorylation of CHUK protein

NCBI chr 1:252,908,748...252,944,273
Ensembl chr 1:252,908,749...252,944,273

G

inhibitor of nuclear factor kappa B kinase subunit beta

increases phosphorylation

ISO

Ribose results in increased phosphorylation of IKBKB protein

NCBI chr16:76,021,968...76,075,717
Ensembl chr16:76,022,008...76,081,911

G

insulin 1

increases secretion

ISO

Ribose results in increased secretion of INS1 protein

NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:261,186,119...261,186,682

G

NFKB inhibitor alpha

increases phosphorylation
multiple interactions

ISO

Ribose results in increased phosphorylation of NFKBIA protein
[Ribose co-treated with Glucose] results in increased phosphorylation of NFKBIA protein

NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072

G

ornithine aminotransferase

multiple interactions

EXP

Ribose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]

NCBI chr 1:196,777,973...196,797,754
Ensembl chr 1:196,777,975...196,797,754

G

RELA proto-oncogene, NF-kB subunit

multiple interactions
increases phosphorylation

ISO

[Ribose co-treated with Glucose] affects the localization of RELA protein; AGER protein affects the reaction [Ribose promotes the reaction [Glucose results in increased phosphorylation of RELA protein]]; Ribose promotes the reaction [Glucose results in increased phosphorylation of RELA protein]
Ribose results in increased phosphorylation of RELA protein

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

D-ribofuranose 5-phosphate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

transaldolase 1

increases abundance

ISO

TALDO1 gene mutant form results in increased abundance of ribose-5-phosphate

NCBI chr 1:205,923,196...205,933,526
Ensembl chr 1:205,923,165...205,933,535

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

hydroxysteroid dehydrogenase like 2

multiple interactions

ISO

[decanoyl-coenzyme A co-treated with NADP] binds to HSDL2 protein

NCBI chr 5:79,238,881...79,274,051
Ensembl chr 5:79,212,525...79,274,798

G

peroxisomal trans-2-enoyl-CoA reductase

multiple interactions

ISO

[decanoyl-coenzyme A co-treated with NADP] binds to PECR protein

NCBI chr 9:81,347,170...81,375,809
Ensembl chr 9:81,347,173...81,375,806

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acyl-CoA thioesterase 4

affects hydrolysis

ISO

ACOT4 protein affects the hydrolysis of glutaryl-coenzyme A

NCBI chr 6:109,399,032...109,405,138
Ensembl chr 6:109,399,578...109,405,138

G

acyl-CoA thioesterase 8

affects hydrolysis

ISO

ACOT8 protein affects the hydrolysis of glutaryl-coenzyme A

NCBI chr 3:173,950,530...173,962,188
Ensembl chr 3:173,950,531...173,962,570

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

caspase 3

multiple interactions

EXP

Guanosine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased activity of CASP3 protein]

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

eukaryotic translation initiation factor 4E

affects binding
multiple interactions

ISO

Guanosine analog binds to EIF4E protein
Guanosine analog inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]; Guanosine analog inhibits the reaction [RNA Caps binds to EIF4E protein]

NCBI chr 2:229,736,309...229,772,628
Ensembl chr 2:229,739,897...229,774,105

G

glutamate-ammonia ligase

multiple interactions

ISO

[Guanosine co-treated with Ketamine] results in increased activity of GLUL protein

NCBI chr13:68,519,500...68,585,554
Ensembl chr13:68,576,067...68,585,520

G

H2A.X variant histone

multiple interactions

ISO

Guanosine inhibits the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]

NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079

G

inosine monophosphate dehydrogenase 2

decreases expression

EXP

Guanosine results in decreased expression of IMPDH2 mRNA

NCBI chr 8:118,135,204...118,139,892
Ensembl chr 8:118,135,262...118,139,873

G

KRAS proto-oncogene, GTPase

multiple interactions

ISO

Guanosine inhibits the reaction [tiazofurin results in decreased expression of KRAS]

NCBI chr 4:179,916,255...179,949,613
Ensembl chr 4:179,919,802...179,949,320

G

mitogen activated protein kinase 1

multiple interactions

ISO

Guanosine results in increased phosphorylation of and results in increased activity of MAPK1 protein

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 3

multiple interactions

ISO

Guanosine results in increased phosphorylation of and results in increased activity of MAPK3 protein

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

MYC proto-oncogene, bHLH transcription factor

multiple interactions

ISO

Guanosine inhibits the reaction [tiazofurin results in decreased expression of MYC]

NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028

G

solute carrier family 1 member 2

multiple interactions

ISO

[Guanosine co-treated with Ketamine] results in increased expression of SLC1A2 protein

NCBI chr 3:109,460,109...109,590,445
Ensembl chr 3:109,459,630...109,605,249

G

solute carrier family 29 member 1

multiple interactions

ISO
EXP

Guanosine inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine]

PMID:9353301 PMID:11085929

NCBI chr 9:22,897,099...22,911,640
Ensembl chr 9:22,902,471...22,914,620

G

solute carrier family 29 member 2

multiple interactions

ISO

Guanosine inhibits the reaction [SLC29A2 protein results in increased uptake of Uridine]

NCBI chr 1:211,756,588...211,764,561
Ensembl chr 1:211,757,000...211,764,560

G

solute carrier family 29 member 3

affects transport

ISO

SLC29A3 protein affects the transport of Guanosine

NCBI chr20:29,191,086...29,228,299
Ensembl chr20:29,191,127...29,228,299

G

tumor protein p53 binding protein 1

multiple interactions

ISO

Guanosine inhibits the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]

NCBI chr 3:128,620,320...128,724,716
Ensembl chr 3:128,620,322...128,696,747

G

uridine phosphorylase 1

increases metabolic processing

ISO

UPP1 protein results in increased metabolism of Guanosine

NCBI chr14:88,023,155...88,043,036
Ensembl chr14:88,023,351...88,043,034

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

peroxisomal trans-2-enoyl-CoA reductase

multiple interactions

ISO

[hexanoyl-coenzyme A co-treated with NADP] binds to PECR protein

NCBI chr 9:81,347,170...81,375,809
Ensembl chr 9:81,347,173...81,375,806

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adenosine deaminase

decreases abundance
increases abundance

ISO

ADA alternative form results in decreased abundance of Inosine
ADA protein results in increased abundance of Inosine

NCBI chr 3:172,818,174...172,842,283
Ensembl chr 3:172,818,176...172,842,293

G

amyloid beta precursor protein

multiple interactions

ISO

[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Inosine; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Inosine]

NCBI chr11:37,506,207...37,724,351
Ensembl chr11:37,506,408...37,722,971

G

Fas ligand

increases expression

ISO

Inosine results in increased expression of FASLG protein

NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503

G

H2A.X variant histone

multiple interactions

ISO

Inosine inhibits the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]

NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079

G

presenilin 1

multiple interactions

ISO

[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Inosine; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Inosine]

NCBI chr 6:109,054,160...109,106,191
Ensembl chr 6:109,060,352...109,106,189

G

solute carrier family 29 member 1

multiple interactions

ISO
EXP

Inosine inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine]

PMID:9353301 PMID:11085929

NCBI chr 9:22,897,099...22,911,640
Ensembl chr 9:22,902,471...22,914,620

G

solute carrier family 29 member 2

multiple interactions

ISO

Inosine inhibits the reaction [SLC29A2 protein results in increased uptake of Uridine]

NCBI chr 1:211,756,588...211,764,561
Ensembl chr 1:211,757,000...211,764,560

G

tumor protein p53 binding protein 1

multiple interactions

ISO

Inosine inhibits the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]

NCBI chr 3:128,620,320...128,724,716
Ensembl chr 3:128,620,322...128,696,747

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

lysine acetyltransferase 2B

affects binding

ISO

isobutyryl-coenzyme A binds to KAT2B protein

NCBI chr 9:6,799,101...6,903,616
Ensembl chr 9:6,799,145...6,903,616

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

glutathione S-transferase alpha 1

multiple interactions

ISO

lauroyl-coenzyme A binds to and results in decreased activity of GSTA1 protein

NCBI chr 9:31,199,887...31,216,606
Ensembl chr 9:31,199,888...31,211,528

G

hydroxysteroid dehydrogenase like 2

multiple interactions

ISO

[lauroyl-coenzyme A co-treated with NADP] binds to HSDL2 protein

NCBI chr 5:79,238,881...79,274,051
Ensembl chr 5:79,212,525...79,274,798

G

peroxisomal trans-2-enoyl-CoA reductase

multiple interactions

ISO

[lauroyl-coenzyme A co-treated with NADP] binds to PECR protein

NCBI chr 9:81,347,170...81,375,809
Ensembl chr 9:81,347,173...81,375,806

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

malonyl-CoA decarboxylase

multiple interactions

ISO

PPARA protein promotes the reaction [MLYCD protein results in decreased abundance of Malonyl Coenzyme A]

NCBI chr19:64,356,582...64,372,447
Ensembl chr19:64,356,223...64,372,446

G

peroxisome proliferator activated receptor alpha

multiple interactions

ISO

PPARA protein promotes the reaction [MLYCD protein results in decreased abundance of Malonyl Coenzyme A]

NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714

methacrylyl-CoA

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

enoyl-CoA hydratase, short chain 1

increases abundance

ISO

ECHS1 gene mutant form results in increased abundance of methacrylyl-coenzyme A

NCBI chr 1:204,324,679...204,333,506
Ensembl chr 1:204,324,682...204,333,506

G

3-hydroxyisobutyryl-CoA hydrolase

increases abundance

ISO

HIBCH gene mutant form results in increased abundance of methacrylyl-coenzyme A

NCBI chr 9:56,082,082...56,161,796
Ensembl chr 9:56,082,091...56,161,886

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

diazepam binding inhibitor

affects binding

ISO

S-tetradecanoyl-coenzyme A binds to DBI protein

NCBI chr13:33,794,231...33,802,632
Ensembl chr13:33,759,845...33,821,450

G

glutathione S-transferase alpha 1

multiple interactions

ISO

S-tetradecanoyl-coenzyme A binds to and results in decreased activity of GSTA1 protein

NCBI chr 9:31,199,887...31,216,606
Ensembl chr 9:31,199,888...31,211,528

G

peroxisome proliferator activated receptor alpha

multiple interactions

ISO

S-tetradecanoyl-coenzyme A binds to and results in increased activity of PPARA protein

NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714

N(6),N(6)-dimethyladenosine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ADAM metallopeptidase domain 17

decreases expression
multiple interactions

ISO

N(6),N(6)-dimethyladenosine results in decreased expression of ADAM17 protein
N(6),N(6)-dimethyladenosine inhibits the reaction [Cycloheximide results in decreased stability of ADAM17 protein]

NCBI chr 6:46,601,583...46,663,690
Ensembl chr 6:46,601,583...46,649,344

G

basigin

decreases expression

ISO

N(6),N(6)-dimethyladenosine results in decreased expression of BSG protein

NCBI chr 7:10,643,788...10,651,005
Ensembl chr 7:10,643,789...10,651,005

N-ethyl-5'-carboxamidoadenosine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adenosine A2B receptor

affects response to substance

ISO

ADORA2B protein affects the susceptibility to Adenosine-5'-(N-ethylcarboxamide)

NCBI chr10:47,439,712...47,456,092
Ensembl chr10:47,439,701...47,456,091

G

adenosine A3 receptor

affects binding

ISO

Adenosine-5'-(N-ethylcarboxamide) binds to ADORA3 protein

NCBI chr 2:196,077,042...196,080,686
Ensembl chr 2:196,077,042...196,080,686

G

caspase 1

increases activity

EXP

Adenosine-5'-(N-ethylcarboxamide) results in increased activity of CASP1 mRNA; Adenosine-5'-(N-ethylcarboxamide) results in increased activity of CASP1 protein

NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:10,746,333...10,882,275

G

C-C motif chemokine ligand 2

increases secretion

ISO

Adenosine-5'-(N-ethylcarboxamide) results in increased secretion of CCL2 protein

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875

G

epoxide hydrolase 2

increases response to substance

ISO

EPHX2 gene mutant form results in increased susceptibility to Adenosine-5'-(N-ethylcarboxamide)

NCBI chr15:44,465,447...44,503,157
Ensembl chr15:44,465,448...44,503,160

G

G protein subunit alpha 11

decreases expression
multiple interactions

EXP

Adenosine-5'-(N-ethylcarboxamide) results in decreased expression of GNA11 protein
Adenosine-5'-(N-ethylcarboxamide) inhibits the reaction [Fluoxetine results in decreased expression of GNA11 protein]

NCBI chr 7:8,814,285...8,828,628
Ensembl chr 7:8,814,327...8,830,558

G

G protein subunit alpha q

decreases expression
multiple interactions

EXP

Adenosine-5'-(N-ethylcarboxamide) results in decreased expression of GNAQ protein
Adenosine-5'-(N-ethylcarboxamide) inhibits the reaction [Fluoxetine results in decreased expression of GNAQ protein]

NCBI chr 1:222,852,453...223,098,754
Ensembl chr 1:222,852,097...223,126,742

G

interleukin 13

increases secretion

ISO

Adenosine-5'-(N-ethylcarboxamide) results in increased secretion of IL13 protein

NCBI chr10:38,290,926...38,293,483
Ensembl chr10:38,290,926...38,293,483

G

surfactant protein B

increases secretion
multiple interactions

EXP
ISO

Adenosine-5'-(N-ethylcarboxamide) results in increased secretion of SFTPB protein
Ro 31-8220 inhibits the reaction [Adenosine-5'-(N-ethylcarboxamide) results in increased secretion of SFTPB protein]

PMID:11704537 PMID:14565945

NCBI chr 4:105,917,495...105,926,631
Ensembl chr 4:105,917,578...105,927,646

G

surfactant protein C

increases secretion
multiple interactions

ISO
EXP

Adenosine-5'-(N-ethylcarboxamide) results in increased secretion of SFTPC protein
Ro 31-8220 inhibits the reaction [Adenosine-5'-(N-ethylcarboxamide) results in increased secretion of SFTPC protein]

PMID:11704537 PMID:14565945

NCBI chr15:52,006,274...52,009,324
Ensembl chr15:52,006,283...52,009,475

G

tumor necrosis factor

multiple interactions

ISO

5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine inhibits the reaction [Adenosine-5'-(N-ethylcarboxamide) inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]]; Adenosine-5'-(N-ethylcarboxamide) inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]; ZM 241385 inhibits the reaction [Adenosine-5'-(N-ethylcarboxamide) inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]]

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

TNF superfamily member 11

increases expression

EXP

Adenosine-5'-(N-ethylcarboxamide) results in increased expression of TNFSF11 mRNA; Adenosine-5'-(N-ethylcarboxamide) results in increased expression of TNFSF11 protein

NCBI chr15:60,083,008...60,114,479
Ensembl chr15:60,083,008...60,114,479

G

thioredoxin interacting protein

increases activity

EXP

Adenosine-5'-(N-ethylcarboxamide) results in increased activity of TXNIP mRNA

NCBI chr 2:186,781,933...186,785,736
Ensembl chr 2:186,781,163...186,785,731

G

vascular endothelial growth factor A

multiple interactions

ISO

Adenosine-5'-(N-ethylcarboxamide) inhibits the reaction [Cyclosporine results in decreased expression of VEGFA mRNA]; Adenosine-5'-(N-ethylcarboxamide) inhibits the reaction [Cyclosporine results in decreased expression of VEGFA protein]; N-(4-cyanophenyl)-2-(4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)-phenoxy)acetamide inhibits the reaction [Adenosine-5'-(N-ethylcarboxamide) inhibits the reaction [Cyclosporine results in decreased expression of VEGFA mRNA]]; N-(4-cyanophenyl)-2-(4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)-phenoxy)acetamide inhibits the reaction [Adenosine-5'-(N-ethylcarboxamide) inhibits the reaction [Cyclosporine results in decreased expression of VEGFA protein]]

NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

glutathione S-transferase alpha 1

multiple interactions

ISO

oleoyl-coenzyme A binds to and results in decreased activity of GSTA1 protein

NCBI chr 9:31,199,887...31,216,606
Ensembl chr 9:31,199,888...31,211,528

G

peroxisome proliferator activated receptor alpha

multiple interactions

ISO

oleoyl-coenzyme A binds to and results in increased activity of PPARA protein

NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714

G

peroxisome proliferator-activated receptor gamma

multiple interactions

ISO

oleoyl-coenzyme A binds to and results in increased activity of PPARG protein

NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104

P(1),P(4)-bis(5'-adenosyl) tetraphosphate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

caspase 3

multiple interactions

EXP

diadenosine tetraphosphate inhibits the reaction [Methamphetamine results in increased cleavage of CASP3 protein]

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

nudix hydrolase 2

increases hydrolysis

ISO

NUDT2 protein results in increased hydrolysis of diadenosine tetraphosphate

NCBI chr 5:61,424,176...61,439,018
Ensembl chr 5:61,424,053...61,439,015

G

tyrosine hydroxylase

multiple interactions

EXP

diadenosine tetraphosphate inhibits the reaction [Methamphetamine results in decreased expression of TH protein]

NCBI chr 1:207,500,959...207,508,276
Ensembl chr 1:207,500,962...207,557,227

P(1),P(5)-bis(5'-adenosyl) pentaphosphate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

CF transmembrane conductance regulator

multiple interactions

ISO

P(1),P(5)-di(adenosine-5'-)pentaphosphate inhibits the reaction [Adenosine Diphosphate binds to and results in decreased activity of CFTR protein]

NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:47,526,735...47,694,643

G

nudix hydrolase 11

multiple interactions
increases metabolic processing

ISO

[NUDT11 protein results in increased metabolism of P(1),P(5)-di(adenosine-5'-)pentaphosphate] which results in increased chemical synthesis of adenosine 5'-tetraphosphate; [NUDT11 protein results in increased metabolism of P(1),P(5)-di(adenosine-5'-)pentaphosphate] which results in increased chemical synthesis of Adenosine Monophosphate; manganese chloride promotes the reaction [NUDT11 protein results in increased metabolism of P(1),P(5)-di(adenosine-5'-)pentaphosphate]

NCBI chr X:18,998,587...19,005,208
Ensembl chr X:18,998,461...19,005,208

G

sirtuin 1

multiple interactions

EXP

P(1),P(5)-di(adenosine-5'-)pentaphosphate analog inhibits the reaction [[Nitrites co-treated with Oxygen deficiency] results in increased expression of SIRT1 mRNA]

NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,305,476...25,328,000

P(1),P(6)-bis(5'-adenosyl)hexaphosphate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

nudix hydrolase 11

multiple interactions
increases metabolic processing

ISO

[NUDT11 protein results in increased metabolism of diadenosine 5',5''''-P1,P6-hexaphosphate] which results in increased chemical synthesis of adenosine 5'-pentaphosphate; [NUDT11 protein results in increased metabolism of diadenosine 5',5''''-P1,P6-hexaphosphate] which results in increased chemical synthesis of Adenosine Monophosphate

NCBI chr X:18,998,587...19,005,208
Ensembl chr X:18,998,461...19,005,208

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acyl-CoA oxidase 1

increases metabolic processing
multiple interactions

ISO

ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A
[ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide; benz(a)anthracene promotes the reaction [[ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide]; Dehydroepiandrosterone promotes the reaction [[ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide]; Tetrachlorodibenzodioxin promotes the reaction [[ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide]

NCBI chr10:101,905,083...101,930,136
Ensembl chr10:101,905,083...101,930,136

G

carboxylesterase 1D

increases hydrolysis

EXP

CES1 protein results in increased hydrolysis of Palmitoyl Coenzyme A

NCBI chr19:30,046,494...30,085,039
Ensembl chr19:30,046,449...30,085,449

G

carnitine palmitoyltransferase 1A

multiple interactions

EXP

valproyl-coenzyme A inhibits the reaction [CPT1A protein results in increased metabolism of Palmitoyl Coenzyme A]

NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:209,993,875...210,056,326

G

diacylglycerol O-acyltransferase 1

multiple interactions

ISO

DGAT1 protein results in increased metabolism of [Palmitoyl Coenzyme A co-treated with Vitamin A]

NCBI chr 7:110,104,514...110,119,091
Ensembl chr 7:110,098,906...110,115,016

G

glutathione S-transferase alpha 1

multiple interactions

ISO

Palmitoyl Coenzyme A binds to and results in decreased activity of GSTA1 protein

NCBI chr 9:31,199,887...31,216,606
Ensembl chr 9:31,199,888...31,211,528

G

hepatocyte nuclear factor 4, alpha

decreases expression

ISO

Palmitoyl Coenzyme A results in decreased expression of HNF4A mRNA; Palmitoyl Coenzyme A results in decreased expression of HNF4A protein

NCBI chr 3:172,606,220...172,667,758
Ensembl chr 3:172,606,220...172,667,758

G

peroxisome proliferator activated receptor alpha

multiple interactions

ISO

Palmitoyl Coenzyme A binds to and results in increased activity of PPARA protein
Acetylglucosamine inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Atorvastatin promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Atropine inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Budesonide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Enalapril inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Fenofibrate promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; gamma-Aminobutyric Acid inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; gedunin inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]; Pravastatin promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Pyrazinamide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Saccharin inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; salicylamide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Tolazoline inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Tolmetin inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]

PMID:11139385 PMID:18812576

NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714

G

peroxisome proliferator-activated receptor gamma

multiple interactions

ISO

Palmitoyl Coenzyme A binds to and results in increased activity of PPARG protein

NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104

G

sex hormone binding globulin

decreases expression

ISO

Palmitoyl Coenzyme A results in decreased expression of SHBG mRNA; Palmitoyl Coenzyme A results in decreased expression of SHBG protein

NCBI chr10:54,831,716...54,849,162
Ensembl chr10:54,831,718...54,838,760

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

glutathione S-transferase alpha 1

multiple interactions

ISO

stearoyl-coenzyme A binds to and results in decreased activity of GSTA1 protein

NCBI chr 9:31,199,887...31,216,606
Ensembl chr 9:31,199,888...31,211,528

G

peroxisome proliferator activated receptor alpha

multiple interactions

ISO

stearoyl-coenzyme A binds to and results in increased activity of PPARA protein

NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714

G

peroxisome proliferator-activated receptor gamma

multiple interactions

ISO

stearoyl-coenzyme A binds to and results in increased activity of PPARG protein

NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acyl-CoA thioesterase 4

affects hydrolysis

ISO

ACOT4 protein affects the hydrolysis of succinyl-coenzyme A

NCBI chr 6:109,399,032...109,405,138
Ensembl chr 6:109,399,578...109,405,138

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

KRAS proto-oncogene, GTPase

multiple interactions
decreases expression

ISO

Guanosine inhibits the reaction [tiazofurin results in decreased expression of KRAS]

NCBI chr 4:179,916,255...179,949,613
Ensembl chr 4:179,919,802...179,949,320

G

MYC proto-oncogene, bHLH transcription factor

decreases expression
multiple interactions

ISO

tiazofurin results in decreased expression of MYC
Guanosine inhibits the reaction [tiazofurin results in decreased expression of MYC]

NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

purinergic receptor P2X 1

affects binding

EXP

TNP-ATP binds to P2rx1 protein

RGD

NCBI chr10:58,117,107...58,132,167
Ensembl chr10:58,117,088...58,132,164

G

purinergic receptor P2X 2

multiple interactions

EXP

TNP-ATP binds to P2rx2 protein; TNP-ATP inhibits the reaction [ATP binds to P2rx2 protein] in transfected glial cells

RGD

NCBI chr12:51,999,107...52,002,627
Ensembl chr12:51,999,372...52,002,627

G

purinergic receptor P2X 5

affects transport

EXP

TNP-ATP affects transport ion flux of P2rx5 receptor

RGD

NCBI chr10:58,276,329...58,291,108
Ensembl chr10:58,276,257...58,287,935

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

multiple interactions

EXP

xanthosine inhibits the reaction [Palmitates results in decreased phosphorylation of AKT1 protein]

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

forkhead box O1

multiple interactions

EXP

xanthosine inhibits the reaction [Palmitates results in decreased phosphorylation of FOXO1 protein]

NCBI chr 2:138,462,974...138,541,420
Ensembl chr 2:138,462,697...138,541,419

G

glucose-6-phosphatase catalytic subunit 1

multiple interactions

EXP

xanthosine inhibits the reaction [Palmitates results in increased expression of G6PC1 protein]

NCBI chr10:86,807,659...86,819,023
Ensembl chr10:86,757,899...86,818,033

G

glycogen synthase kinase 3 beta

multiple interactions

EXP

xanthosine inhibits the reaction [Palmitates results in decreased phosphorylation of GSK3B protein]

NCBI chr11:76,004,502...76,154,665
Ensembl chr11:76,009,507...76,153,249

G

glycogen synthase 1

multiple interactions

EXP

xanthosine inhibits the reaction [Palmitates results in increased phosphorylation of GYS1 protein]

NCBI chr 1:105,051,916...105,071,763
Ensembl chr 1:105,051,961...105,072,419

G

phosphoenolpyruvate carboxykinase 2 (mitochondrial)

multiple interactions

EXP

xanthosine inhibits the reaction [Palmitates results in increased expression of PCK2 protein]

NCBI chr15:32,997,853...33,006,691
Ensembl chr15:32,997,834...33,016,864

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	20862
role	20820
biological role	20818
biochemical role	20264
metabolite	20245
fundamental metabolite	14805
D-ribose	772
2-deoxy-D-ribofuranose 5-phosphate +	0
2-deoxy-D-ribose +	0
2-deoxy-D-ribose 1,5-bisphosphate	0
2-deoxy-D-ribose 5-phosphate +	0
5-deoxy-D-ribose	0
D-hamamelose +	0
D-ribofuranose +	772
D-ribofuranose-2,5-bisphosphate	0
D-ribopyranose +	0
D-ribose 1,5-bisphosphate +	0
D-ribose 1-diphosphate +	0
D-ribose 1-phosphate +	0
D-ribose 5-diphosphate	0
D-ribose 5-phosphate +	1
D-ribose 5-triphosphate +	0
S-methyl-5-thio-D-ribofuranose +	0
S-methyl-5-thio-D-ribose	0
S-methyl-5-thio-alpha-D-ribose 1-phosphate	0
aldehydo-D-ribose +	9
Path 2
Term	Annotations
CHEBI ontology	20862
subatomic particle	20860
composite particle	20860
hadron	20860
baryon	20860
nucleon	20860
atomic nucleus	20860
atom	20860
main group element atom	20781
p-block element atom	20781
carbon group element atom	20715
carbon atom	20710
organic molecular entity	20710
heteroorganic entity	20219
organochalcogen compound	19904
organooxygen compound	19806
carbohydrates and carbohydrate derivatives	15487
carbohydrate	15487
monosaccharide	5123
aldose	3497
aldopentose	776
ribose	774
D-ribose	772
2-deoxy-D-ribofuranose 5-phosphate +	0
2-deoxy-D-ribose +	0
2-deoxy-D-ribose 1,5-bisphosphate	0
2-deoxy-D-ribose 5-phosphate +	0
5-deoxy-D-ribose	0
D-hamamelose +	0
D-ribofuranose +	772
D-ribofuranose-2,5-bisphosphate	0
D-ribopyranose +	0
D-ribose 1,5-bisphosphate +	0
D-ribose 1-diphosphate +	0
D-ribose 1-phosphate +	0
D-ribose 5-diphosphate	0
D-ribose 5-phosphate +	1
D-ribose 5-triphosphate +	0
S-methyl-5-thio-D-ribofuranose +	0
S-methyl-5-thio-D-ribose	0
S-methyl-5-thio-alpha-D-ribose 1-phosphate	0
aldehydo-D-ribose +	9

paths to the root